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2 Summary: 
SUMMARY: 
Glucocorticoid therapy for threatened preterm birth and in preterm infants has become 
common practice in the last 40 years.  This treatment is based on the pioneering work of 
Liggins who discovered that development of fetal tissues was dependent upon the pre-
partum surge in fetal cortisol.  Therefore, exposure to synthetic glucocorticoids in premature 
offspring could accelerate pulmonary maturation, reducing risk of respiratory complications. 
Ante- and post-natal glucocorticoid therapy has since been demonstrated to significantly 
reduce morbidity and mortality in the preterm infant. However, several aspects of this 
therapy are not optimised, including drug choice or drug formulation. There is increasing 
animal and human data that suggest exposure to synthetic glucocorticoids may have a 
detrimental effect on the developing cardiovascular system. Therefore, there is an urgent 
need to understand possible adverse direct effects of current clinical therapy.  The chicken 
embryo model was used to isolate the direct effects of glucocorticoids used in human clinical 
practise on the developing cardiovascular system, without confounding influences on the 
maternal or placental physiology. Specifically, this work compared the effects between 
Dexamethasone phosphate (Dex) Betamethasone phosphate (Phos), acetate (Ace) or 
combined (Beta). Treatment with 0.1mgkg-1 glucocorticoid at 60-70% of incubation resulted 
in significant growth restriction at term, which was more severe following Beta treatment due 
to the acetate formulation. Cardiac function was impaired by all treatments, again with Beta 
having a more severe effect. Dex treatment resulted in enhanced peripheral vasoconstrictor 
reactivity, cardiomyocyte hypertrophy and induced oxidative stress, caspase 3-mediated 
apoptosis, with p38-mediated reduced proliferation. In contrast, Beta treatments impaired 
peripheral vasodilator reactivity, reduced total cardiomyocyte number, promoted excessive 
GR activation due to loss of negative feedback, and led to p53-mediated apoptosis with 
reduced cardiomyocyte proliferation. Beta acetate shared the loss of GR negative feedback 
and enhanced p53 expression, whereas Beta phosphate did not. Therefore, combined, the 
data in this thesis support direct and divergent adverse effects of glucocorticoids used in 
human clinical practise on the developing cardiovascular system.  The work offers insight into 
mechanisms underlying detrimental effects, providing a platform to modify current clinical 
antenatal glucocorticoid therapy and make it safer for the treatment of the preterm baby. 
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‘We are at the very beginning of time for the human race. It is not unreasonable that we 
grapple with problems. But there are tens of thousands of years in the future. Our 
responsibility is to do what we can, learn what we can, improve the solutions, and pass them 
on. It is our responsibility to leave the people of the future a free hand... 
 
…It is our responsibility as scientists, knowing the great progress which comes from a 
satisfactory philosophy of ignorance, the great progress which is the fruit of freedom of 
thought, to proclaim the value of this freedom; to teach how doubt is not to be feared but 
welcomed and discussed; and to demand this freedom as our duty to all coming 
generations.’ 
Richard Feynman, 1988 
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16 Chapter 1: General Introduction 
CHAPTER 1: GENERAL INTRODUCTION 
1.1 PATHO-PHYSIOLOGY OF PRETERM BIRTH 
 
Healthy human pregnancy lasts an average of 40 weeks, with labour typically occurring 
between 37- and 42-weeks of gestation. If a neonate is born prior to 37 weeks of gestational 
age, then the birth is considered preterm (Purisch, 2017). A preterm birth can be the result of 
iatrogenic intervention due to maternal or fetal pathology such as pre-eclampsia, or other 
types of abnormal placentation. However the majority of preterm births are idiopathic and 
occur spontaneously (Goldenberg et al., 2008). Preterm birth is the greatest cause of neonatal 
morbidity and mortality in the UK (NICE, 2015), with preterm infants carrying a greater risk of 
immediate health complications to their respiratory, immunological, nervous, gastrointestinal 
and other systems as well as long-term negative health implications (Harrison & Goldenberg, 
2016). The associated psychological and economic burden to the families of preterm infants 
is significant, and more widely the economic burden on societies is huge (Behrman, 2007). 
There are currently limited preventative or even predictive strategies to address preterm 
birth (Purisch, 2017). As such, advances in understanding the aetiology, outcomes and 
treatment of premature birth are essential to improve the health of children of all nations. 
 
The Office of National Statistics in the UK lists 53,887 births occurring at <37 weeks gestational 
age in England and Wales in 2017, accounting for 8% of live births for which gestational age 
was recorded. This rate has remained relatively unchanged over the past decade, despite 
improvements in obstetric care (Fig.1.1). A similar percentage is recorded in the United States 
at 9.93% in 2017, again with no observable decrease in recent years. There is substantial 
 17 
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heterogeneity in preterm birth rate between different countries; for example, within Europe 
the rate varies from as low as 5% up to 11% (Fig.1.1). 
 
Current understanding for the epidemiological variance in preterm birth rate and 
predisposing factors continues to be poor. Groups at higher risk include black, African-
American and Afro-Caribbean mothers, those with low educational or socioeconomic status, 
women with a short cervix, and very young or old mothers (Goldenberg et al., 2008). Multiple 
pregnancies also carry a much greater risk than singleton pregnancies. Certain environmental 
factors have been associated with preterm birth risk, such as lead exposure (Andrews et al., 
1994), air pollution (Stieb et al., 2012), and tobacco smoke (Behrman, 2007). Environmental 
or psychological stressors may also have an impact; instances of violence and discrimination 
have a positive correlation with pre-term birth rates (Hill et al., 2016; Mendez et al., 2014), as 
well as maternal depressive illness (Orr et al., 2002). 
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Figure 1.1 Preterm birth rates. A., US and England/Wales preterm birth rates from 2007-2017, B. preterm birth 
rates reported in 2008 for various European countries. Data from ONS (UK), CDC (US), and Zeitlin et al. (2013). 
 
 
Understanding the physiological aetiology of preterm parturition and how the myriad of 
associated factors increasing its likelihood is key to identifying at risk women and developing 
preventative treatments. An overarching thesis explaining preterm birth is that several 
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different physiological changes activate a common central pathway resulting in increased 
uterine contractility, premature rupture of membranes and accelerated cervical maturation, 
resulting in preterm labour (Di Renzo et al., 2018). The premature induction of myometrial 
contractility is associated with altered inflammatory signalling in the decidua, resulting in 
expression of specific interleukins (IL-1, -6, -8), and contraction related proteins, including 
connexin-43 and prostaglandin receptors (Wadhwa et al., 2001). Further changes in 
proteases, and breakdown of fibronectin lead to separation of the decidua and 
chorioamniotic membranes, and eventually membrane rupture, again secondary to changes 
in immunological signalling. Cervical dilatation is induced by alterations in extracellular 
membrane proteins such as collagen, which decreases cervical tensile strength (Di Renzo et 
al., 2018). Our overall understanding of the mechanisms of parturition suggests immune 
signalling in the decidua acts as an essential switch towards activation of the uterus and 
cervix. Indeed, intra-amniotic infection has been reported in up to 50% of spontaneous 
preterm births, suggesting that dysregulated immune signalling can affect the decidual clock 
(Gonçalves et al., 2002). Therefore, infection or any other factor that may prime the maternal 
immune system, leading to an exaggerated immunological response to a subsequent insult 
may prematurely initiate the inflammatory changes associated with labour (Norwitz et al., 
2015). Similarly, in women with vaginal bleeding or placental lesions, there is a shift towards 
a pro-inflammatory response and an increased likelihood of preterm labour (Di Renzo et al., 
2018). 
 
Current treatment options available for preventing or stalling preterm labour largely focus on 
the management of risk factors; identifying at risk women, treating infections, and monitoring 
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fetal wellbeing (Harrison & Goldenberg, 2016). Lifestyle interventions, such as advising 
women to quit smoking prior to pregnancy can also help to eliminate certain risk factors 
(McCowan et al., 2009). Women who present with a short cervix during pregnancy may be 
offered several treatments, including cervical cerclage (use of sutures to strengthen and close 
the cervix) or progesterone administration as a pessary (a silicone device) placed at the 
cervical opening, or vaginally (Koullali et al., 2016). These interventions have had mixed 
results in different populations varying from ineffective use of cerclage (Berghella et al., 2010) 
to a significant reduction in preterm birth when vaginal progesterone was administered.  A 
meta-analysis demonstrated a relative risk of preterm birth <35 weeks gestation as 0.69 
compared to placebo treatment (Romero et al., 2012). However, even when preventative 
treatment may be of benefit, detailed obstetric history as well as evaluation of pregnancy-
related symptoms is vital, which may not be available in all healthcare settings. 
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1.2 OFFSPRING OUTCOMES FOLLOWING PRETERM BIRTH 
 
In terms of health outcomes for the preterm infant, the most immediate and significant 
consideration is of course neonatal survival. Despite the consistency in preterm birth rate in 
recent years, the percentage of survival of the preterm infant has increased over the past ten 
years, due to improvements in neonatal care (Patel, 2016). For instance, survival rate in 
Taiwan between 2007 and 2012 improved from 72% to 78% (Su et al., 2015), whilst in the US 
survival improved from 85.7% in 2000 to 87.5% in 2009 (Horbar et al., 2012). There is a 
negative correlation between survival rate and gestational age at birth, for example those 
born at 22 weeks have <40% survival rate (Patel, 2016). The majority of deaths of preterm 
neonates are listed as being due to prematurity or complications associated with preterm 
birth, making it difficult to dissect the exact pathological mechanisms involved. For deaths in 
which a specific cause is listed, the condition described as respiratory distress syndrome 
(RDS), immaturity of the neonatal lungs and therefore inability to ventilate, is the greatest 
contributor, but this has seen significant reductions as neonatal care has improved. In the UK 
respiratory causes of neonatal death have reduced from contributing to 64% of deaths 
between 1988-1994 to 49% between 2002-2008 (Berrington et al., 2012). Over the same time 
period deaths due to necrotising enterocolitis (NEC) have increased from 4% to 11%, making 
this the second largest cause of infant death.  
 
The most common short-term sequalae of preterm birth are associated with respiratory 
dysfunction. RDS can be immediately treated via administration of surfactant and providing 
continuous positive airway pressure, thus allow ventilation of the lungs. Estimates of 
incidence of Respiratory Distress Syndrome (RDS) vary by country but have been estimated 
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at around 1.72% of all live births, and as high as 57.14% for those born at 32 weeks of 
gestation (Ghafoor et al., 2003). Following RDS, further respiratory issues may develop. Babies 
born pre-term are at a high risk of developing Broncho-Pulmonary Dysplasia (BPD) – a chronic 
lung disease affecting both the airways and parenchyma, that is defined by the need for 
oxygen supplementation for babies >36 weeks post-menstrual age (Ryan, 2006). BPD was 
initially defined by Northway in 1967, following investigation into the potential sequalae 
following respiratory distress syndrome (Northway et al., 1967). High levels of inflammation 
are seen in the lungs of neonates suffering from BPD, and it may lead to scarring and cellular 
abnormalities. BPD is also very predictive of future neurological impairment, and long-term 
respiratory dysfunction (Kobaly et al., 2008; Gough et al., 2014). Patent ductus arteriosus is 
also very common in preterm neonates and is associated itself with risk of RDS (Schena et al., 
2015). Respiratory difficulties lead to inability to fully oxygenate the blood, which can lead to 
wide ranging damage in the body if oxygen delivery is compromised. 
 
Several other serious short-term outcomes are secondary to immaturity of the neonatal 
circulatory system. Haemorrhage in the new-born brain is a common and serious finding in 
premature neonates. Intraventricular haemorrhage (IVH) occurs at a very high rate in 
extremely premature infants (45% of neonates) and occurrence rates remain relatively 
unchanged (Wilson-Costello et al., 2005; Jain et al., 2009). IVH is secondary to a number of 
factors, including immaturity of the germinal matrix vasculature in the brain, alterations in 
cerebral perfusion such as hypo- and hypertension, and alterations to the blood coagulation 
system (Ballabh, 2010). Hypotension is itself a common issue in premature neonates, who 
struggle to regulate and maintain arterial blood pressure (Fanaroff & Fanaroff, 2006). IVH is 
 23 
 
23 Chapter 1: General Introduction 
associated with increased risk of several adverse neurological outcomes (Payne et al., 2013). 
Another outcome associated with an immature circulatory system is retinopathy of 
prematurity (ROP) leading to blindness due to reduced retinal vascular growth. Excessive 
supplementation with oxygen can worsen ROP by further affecting vascular endothelial 
growth factor (VEGF) levels in the retina (Chen & Smith, 2007). 
 
The main metabolic morbidity present in preterm neonates is NEC in which portions of the 
bowel die leading to feeding intolerance, which may progress to intestinal perforation and 
peritonitis. NEC affects up to 10% of preterm infants, and a large proportion of very low birth 
weight neonates with NEC will die (20-30%; Patel & Denning, 2015). Again, the 
pathophysiology is multifactorial and complex, but it is thought that prematurity of the 
gastro-intestinal system may predispose to NEC due to insufficient immune defences and a 
propensity towards inflammatory responses (Nanthakumar et al., 2000), as well as decreased 
intestinal barrier function (Sharma et al., 2007). It is also thought that a lack of the normal 
commensal microbiota in the intestines may contribute (Patel & Denning, 2015).  
 
Neurodevelopmental outcomes can also be seriously affected by preterm birth, with a 
spectrum of dysfunction listed in the literature. Cerebral Palsy represents a permanent 
movement disorder secondary to a brain injury that occurs at high rates in preterm infants 
(Patel, 2016). The gross motor function classification system (GMFCS) is typically used to 
describe cerebral palsy ranging from level 1 where speed, balance, and coordination are 
affected but children can walk and run, to level 5 where children are permanently wheelchair 
bound and have a limited ability to control head and trunk movement (Graham et al., 2016). 
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As with many other outcomes of preterm birth, the risk of cerebral palsy increases with 
decreasing gestational age. The pathogenesis of the brain injury that results in cerebral palsy 
is thought to be secondary to hypoxia or ischaemia, which are more common when 
respiratory difficulties are present (Graham et al., 2016).  
 
As more infants are surviving preterm birth and the associated immediate jeopardies, the 
number of children with long-term health implications is increasing. A prospective study in 
the East Midlands estimated the difference in societal cost of healthcare between a single 
term born infant and a single preterm infant over the first 24 months of life to be £4657 (Khan 
et al., 2015). Clinical follow up of preterm born children have demonstrated increased risk of 
various adverse neurological outcomes. Rates of both deafness and blindness are higher in 
survivors of extreme prematurity (Doyle & Anderson, 2010). Developmental delay is also 
more common in survivors of preterm birth as are rates of major neurological disability 
diagnosed in early childhood (Msall & Tremont, 2002). Cognitive disability in the first 3 years 
of life has been reported in various studies following preterm birth, with rates as high as 42% 
of preterm children affected (Hack et al., 2000). At 6 years of age, cognitive impairment was 
reported in 21% of children born extremely preterm in the UK (Marlow et al., 2005). A meta-
analysis of preterm born children assessed after 5 years of age also demonstrated increased 
risk of lower cognitive test scores in children born preterm, with more severe effects on those 
born at a lower gestational age (Bhutta et al., 2002). Follow up studies at adolescence have 
demonstrated increased instances of grade-repetition and special education measures in 
preterm born teenagers in Ontario (Saigal et al., 2000). Clearly, a spectrum of 
neurodevelopmental disorders is associated with preterm birth, even the least severe of 
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which can cause substantial negative effects on individuals. This is also not accounting for 
those with serious disability, such as cerebral palsy due to neonatal brain damage, which are 
diagnosed much earlier in life. 
 
Long-term respiratory illness is also common in individuals born preterm. Asthma rates have 
been shown to be increased in some but not all studies (Doyle & Anderson, 2010). In terms 
of pulmonary function, there is evidence for decreased forced expiratory volume (FEV) and 
increased bronchial hyper-responsiveness in adolescents born extremely preterm (Halvorsen 
et al., 2004). In the same study there was also an increased likelihood of pneumonia or asthma 
reported during childhood. At 21 years of age, survivors of preterm birth are more likely to 
self-report occurrence of respiratory symptoms including asthma, coughing or wheezing 
(Narang et al., 2008). At adulthood, reduced total alveoli numbers have been demonstrated, 
as well as bronchiole hyper-reactivity, both of which can impair lung function by reducing the 
surface area for gas exchange (O’Reilly et al., 2013). Further exposure to environmental 
factors, such as tobacco smoke or air pollution may exasperate these conditions leading to 
outright respiratory disease. As those populations at higher risk of preterm birth are also 
often at higher risk of being exposed to negative environmental factors such as air pollution, 
this is concerning (Stieb et al., 2012). 
 
Preterm birth is also highly associated with later cardio-metabolic dysregulation, which in 
many instances is associated with adult-onset hypertension and diabetes – two of the main 
components of the metabolic syndrome. At 30 years of age, individuals born preterm have a 
significantly increased systolic blood pressure (3.5mmHg greater than control group), and 
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insulin resistance (Dalziel et al., 2007). A similar increase in blood pressure has been 
demonstrated in other cohorts of young adults born preterm (Hovi et al., 2016). Whilst these 
blood pressure increases are not particularly large, a small increase in early adulthood is 
highly associated with increased risk of cardiovascular disease in later life (Chen & Wang, 
2008). Cardiac structure is also known to be altered in preterm individuals, specifically an 
increase in left ventricular mass and reductions in functional cardiac parameters 
(Lewandowski et al., 2013a). Increased left ventricular mass is a risk factor for heart failure, 
and there is some evidence linking preterm birth with increased risk of heart failure (Carr et 
al., 2017). As well as insulin resistance, an increase in plasma low-density lipoprotein (LDL) 
level has been reported in ex-preterm adults (Parkinson et al., 2013), which is itself associated 
with atherosclerosis. Higher fasting insulin levels, and increased instance of gestational 
diabetes and type-2 diabetes have also been demonstrated in survivors of prematurity (Luu 
et al., 2017). In a world in which many consider us to be amidst an epidemic of non-
communicable diseases including diabetes and heart disease, large numbers of children being 
born with a predisposition to develop these conditions is again concerning (Murray et al., 
2012).  A summary of the reported short- and long-term effects of preterm birth on an 
individual’s health is shown in Table 1.1. 
 
When the World Health Organisation (WHO) released their ‘Global Action Report on Preterm 
Birth’ in 2012, they estimated that around 1 million children globally every year die due to 
complications of prematurity. In 2015 this number remained unchanged despite advances in 
neonatal care (Liu et al., 2016). Even with reductions in preterm associated mortality in 
economically developed countries, such as in England and Wales, the estimated cost to the 
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public sector remains huge, with an estimated cost of £2.946 billion per year (Mangham et 
al., 2009). Clearly, it continues to be vital to increase our understanding of the 
pathophysiology leading to preterm birth as well as to improve its treatment to further reduce 
both mortality and morbidity associated with prematurity. 
 
Physiological 
System 
Short-term Outcomes Long-term Outcomes 
Respiratory • Broncho-pulmonary 
Dysplasia 
• Patent Ductus 
Arteriosus 
• Asthma 
• Airway Hyperreactivity 
• Reduced Alveoli Number 
Circulatory • Intra-ventricular 
haemorrhage 
• Peri-ventricular 
haemorrhage 
• Hypotension 
• Retinopathy of 
Prematurity 
• Increased Systolic Blood 
Pressure 
• Increased Diastolic Blood 
Pressure 
• Increased Left Ventricular 
Mass 
• Increased Risk of Heart Failure 
Neurological • Cerebral Palsy & Motor 
Impairment 
• Major Neurological Disability 
• Reduced IQ Score 
• Deafness 
• Blindness 
• Special Education Measures 
Metabolic • Necrotizing 
Enterocolitis 
• Increased Fasting Insulin 
• Increased Insulin Resistance 
• Increased Plasma LDL levels 
• Increased Risk of Gestational 
and Type-2 Diabetes 
 
Table 1.1 Overview of main short- and long-term outcomes on offspring of preterm birth. 
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1.3 DEVELOPMENTAL EFFECTS OF GLUCOCORTICOIDS IN THE PERINATAL PERIOD 
 
It has been established for many years, that in almost all animal species studied, there is a 
prepartum surge in fetal plasma levels of glucocorticoids (Silver, 1988; Fig.1.1). This pre-
partum surge is intricately linked with maturation of various physiological systems such that 
the neonatal transition can occur (Fowden & Forhead, 2015). It is also characterised by a 
switch away from tissue accretion, and towards distinct cellular maturational changes (Silver, 
1988). As such, endogenous glucocorticoids in many ways act as the indispensable 
orchestrator of fetal maturation, either directly inducing tissue maturation or acting via other 
endocrine systems. 
 
 
 
 
 
 
 
 
 
Figure 1.2 Ontological rise of fetal plasma cortisol, in the 30 days prior to term, in various species. Reproduced 
from Fowden & Forehead, 2015. Length of pregnancy: pig 115 d (filled circles), sheep 145 d (open circles), 
humans 280 d (filled triangle), cow 280 d (filled squares), and horses (pony) 335 d (open triangles). 
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During pregnancy in the human, the majority of cortisol present in the fetal circulation is of 
maternal origin as it can pass directly into fetal blood via the placenta (Fowden et al., 2016). 
The placenta contains relatively high levels of inactivating enzyme 11-βHSD2, which converts 
active cortisol into comparatively bio-inactive cortisone, however around 20% of maternal 
cortisol passes through without becoming inactivated (Mastorakos & Ilias, 2003). Maternal 
cortisol production rises during pregnancy as the maternal adrenal glands become 
hypertrophic. However, in late gestation the fetal hypothalamo-pituitary-adrenal (HPA) axis 
is also active (Fig.1.2). In sheep, it has been shown that the pre-partum cortisol surge is 
predominantly fetal in origin (Mastorakos & Ilias, 2006). There is also some evidence that in 
primates, CRH may be of placental origin with trophic effects on the fetal pituitary-adrenal 
axis (MacLean et al., 1995). Parturition in humans is thought to be triggered primarily by fetal 
androgens (DHEAS predominantly), arising from the fetal adrenal gland (Nathanielz et al., 
1998). 
 
Glucocorticoids may act directly to alter gene expression via the MR (Mineralocorticoid 
receptor) or the GR (Glucocorticoid receptor), which once activated can bind to 
Glucocorticoid Response Elements (GREs) in the promoters of specific genes with or without 
other transcription factors to alter transcription (Oakley & Cidlowski, 2013; Fig.1.3.). This is 
thought to reflect the main pathway for glucocorticoids to directly alter cellular maturation. 
The transcriptional effects are clearly dependent on tissue receptor expression but also on 
local glucocorticoid availability which may be altered by inactivating enzymes such as 11β-
HSD2 which is prominently expressed for example in the developing brain and the placenta 
(Wyrwoll et al., 2011; Fowden et al., 2016). The response will also be tissue specific, 
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depending on the developmental trajectory and thus epigenetic state of the cells receiving 
the glucocorticoid signal. Hence, the timing of exposure is also critical.  
 
 
 
 
Figure 1.3 Sources of fetal plasma cortisol. Maternal hypothalamus produces CRH, stimulating ACTH production 
from the anterior pituitary gland, which induces cortisol release from the adrenal. Maternal cortisol may cross 
the placenta into the fetal circulation or become inactivated by placental 11β-HSD2. Fetal cortisol may originate 
from the fetal HPA axis, or from the maternal circulation. Both the maternal and fetal HPA axes can be stimulated 
by placental origin CRH. 
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Figure 1.4 Simplified Glucocorticoid Receptor (GR) pathway. Canonical GR signalling to induce genomic effects 
occurs via binding of ligand to cytosolic GR (with accessory proteins), leading to translocation of the ligand-
receptor complex into the nucleus. A. positive transcriptional regulation can occur via; direct binding of GR dimer 
to a glucocorticoid response element (GRE), concerted binding of GR with a secondary transcription factor (TF), 
binding of GR onto a TF either directly or indirectly. B. Negative regulation of gene expression can occur via; GR 
dimer binding to a negative-regulator GRE (nGRE), competitive binding with an overlapping TF site, binding of 
GR onto a TF, TF sequestration. C. ligand bound GR can also induce genomic effects in mitochondria when bound 
to mtDNA. Image adapted from (Scheschowitsch, Leite and Assreuy, 2017). 
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Glucocorticoids are known to have additional rapid cellular effects (termed the non-canonical 
pathway), mediated by cytoplasmic receptors. The nature and functional consequences of 
this mode of signalling are less well understood, particularly in relation to fetal maturation, 
but various cellular kinases have been implicated (Oakley & Cidlowski, 2013). It is also known 
that the GR may activate a non-canonical signalling pathway which is cytoplasmic and may 
induce rapid changes, although the exact role of this pathway is unknown (Stahn & Buttgereit, 
2008). Fetal maturation is also known to be secondary to changes in the functionality and set 
points of other hormonal systems including the thyroid hormones (Forhead et al., 2006), the 
insulin-like growth factors (IGFs; Fowden, 2003),  leptin (De Blasio et al., 2015), and insulin 
signalling (Jellyman et al., 2012).  Cortisol is also known to mature the adrenal gland, leading 
to increased sensitivity and magnitude of catecholamine release in response to stress, which 
is vital during parturition and neonatal life (Liggins, 1994; Fletcher et al., 2006). The effects of 
a plethora of hormonal changes are diverse and distinct changes are seen throughout the 
fetal body, both directly and indirectly in response to the pre-partum cortisol surge (Fig.1.5). 
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The Maturational effects of glucocorticoids have perhaps been most studied in the fetal lung. 
The fetal lungs are fluid filled, and relatively inelastic (Harding & Hooper, 1996). However, the 
neonate must be able to inflate the lungs to begin respiration immediately after birth. As 
development progresses to term, levels of surfactant proteins increase and histologically 
surfactant granules can be seen in type II pneumocytes (DiFiore & Wilson, 1994). Lung liquid 
also begins to be removed (Jain & Eaton, 2006), and elastin levels increase (Liggins, 1994). 
These changes have been shown in vivo and in vitro, to rely on the surge in circulating levels 
of glucocorticoids (Gonzales et al., 1986; Liley et al., 1987; Banks et al., 1999; Bird et al., 2015). 
Antioxidant defences in the lung are also up-regulated prior to term, including pulmonary 
superoxide dismutase (SOD) and paraoxanase-3, again these changes are thought to be 
secondary to the increased plasma glucocorticoid levels (Walther et al., 1991; Belteki et al., 
2010; Erenberg et al., 1982). 
 
Similarly, glucocorticoid dependent changes are seen in other systems essential for neonatal 
survival. Fetal metabolism switches towards a gluconeogenic state, and production of 
digestive enzymes is initiated (Fowden et al., 1998; Fowden et al., 2006). Pancreatic 
development is also stimulated (Fowden et al., 2005). The fetal circulation likewise changes 
substantially towards term. Fetal arterial blood pressure increases with increasing gestational 
age (Forhead et al., 2000; Shinozuka et al., 2000; Giussani et al., 2005). This change can be 
experimentally stimulated by exogenous administration of synthetic glucocorticoids (Fletcher 
et al., 2002). The fetal baroreflex has different responsiveness depending on gestational age 
(O’Connor et al., 2006; Blanco et al., 1988).  In sheep, the set-point increases towards term to 
allow a greater resting arterial blood pressure, again in a manner which can be replicated by 
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administering exogenous glucocorticoids (Fletcher et al., 2002). There are also significant 
maturational effects of glucocorticoids on the fetal heart. They stimulate cardiomyocyte 
maturation; specifically hypertrophy and bi-nucleation, and induce a switch away from 
hyperplasia (Rog-Zielinska et al., 2014a). The electrical conduction system in the heart is 
matured in preparation for the increased cardiac workload at birth (Davies et al., 1996). Left 
ventricular developed pressure also increases towards term, and a switch towards 
parasympathetic cardiac dominance occurs, although it is not clear what role glucocorticoids 
play in this maturation (Fletcher et al., 2005). During acute stress, for example a period of 
fetal hypoxia, the fetal cardiovascular system typically redistributes blood flow to vital 
circulations, such as the brain – the so called fetal brain sparing effect (Giussani, 2016). The 
extent of this response increases with advancing gestational age (Fletcher et al. 2006) and this 
maturation can be accelerated in the preterm fetus by maternal (Jellyman et al., 2005) or fetal 
(Fletcher et al. 2003) treatment with Dexamethasone. The fetal HPA axis is vital for acute 
stress responses by means of a rapid rise in blood cortisol levels (Newby et al., 2015). The 
sensitivity of the HPA axis to an acute stressor increases with gestational age, secondary to 
changes in production of POMC hormones in the pituitary (Yang et al., 1991), and increased 
sensitivity of the adrenal itself to ACTH (Fraser et al., 2001).  There is also evidence to support 
that exposure of the preterm fetus to synthetic glucocorticoids accelerates the maturation of 
the fetal adrenal gland, for instance by increasing adrenocortical sensitivity to ACTH during a 
period of acute hypoxic stress (Fletcher et al., 2004). 
 
During fetal life the kidneys do not act as the main osmoregulatory organ, that role is 
distributed to the placenta, however they do produce large volumes of relatively hypo-
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osmotic urine which enters the amniotic fluid (Wlodek et al., 1992). The fetal kidneys are poor 
at retaining sodium and consequently have a large fractional excretion of sodium (FENa). This 
allows for the excretion of the large amounts of fluid that cross the placenta and must be lost 
from the fetal circulation (Holtbäck & Aperia, 2003). As gestational age increases, FENa is 
reduced as transporters increase in number and activity in the nephron (Holtbäck & Aperia, 
2003), this can be induced experimentally by glucocorticoids (Aperia et al., 1981). This 
prepares the kidneys for sodium retention upon birth to maintain blood volume. For example, 
in the sheep fetus FENa decreases from around 15% at 0.75 of gestation to 5% at term (Segar 
et al., 1992), and continues to decrease during early neonatal life (Smith & Lumbers, 1989). 
In human babies, FENa also decreases during neonatal life (Benson, 2008).  Glomerular 
filtration rate (GFR) in the fetal kidneys is also low. Again, this increases towards term, in part 
due to an increased cardiac output and renal blood flow (Chang et al., 2003) which increases 
from around 3% to 25% in the neonate (Holtbäck & Aperia, 2003). Maturation of the kidney 
is also essential for several endocrine systems. The renin-angiotensin system (RAS) is vital for 
sodium homeostasis and long-term control of blood pressure. Renin production increases 
with gestational age (Robillard & Nakamura, 1988), concomitant with changes in expression 
of AT-1 and AT-2 receptors in various target organs (Shanmugam & Sandberg, 1996). 
Aldosterone production has also been shown to increases before birth (Robillard et al., 1992), 
and whilst the fetal kidneys are relatively insensitive (Martinerie et al., 2009), the neonate 
has an active responsiveness. The period of nephrogenesis occurs in sheep (Moritz et al., 
2003) and humans (Hinchliffe et al., 1992) predominantly during late gestation (in humans no 
nephrogenesis occurs after 36 weeks). The pre-term glucocorticoid surge is involved in a 
decrease in nephrogenesis in exchange for cellular changes within the tubules themselves 
(Moritz et al., 2003). 
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The need for the neonate to have various neurological functions at birth is clear – homeostatic 
regulatory mechanisms must become active to ensure survival. The relationship between the 
pre-partum cortisol surge and neurological development is complex, and different cell 
populations and brain regions are affected differently. Neurogenesis occurs predominantly 
during early gestation, and by late gestation the principal events occurring are: multiplication 
of glia and astrocytes and their subsequent migration, programmed cell death, neuronal 
migration, synapse formation, pruning, and myelination (Knuesel et al., 2014). 
Glucocorticoids are thought to be highly involved in regulating these processes. Specifically, 
activation of the canonical GR pathway is thought to be vital in stabilising vascular endothelial 
cells in the brain (thus reducing the risk of haemorrhage), and in regulating proliferation of 
neural stem/progenitor cells (NSPCs; Vinukonda et al., 2010; Peffer et al., 2014). 
Administration of synthetic glucocorticoids has been demonstrated to alter cell number and 
size within specific cellular populations, and to cause long-term alterations in synaptic 
function (Kreider et al., 2006). Glucocorticoids have been implicated in balancing apoptosis in 
the developing brain (Almeida et al., 2000). Neuronal maturation of several endocrine axes 
has also been related to glucocorticoids, e.g. the HPA axis (Davis et al., 2006), and the renin-
angiotensin system (RAS; Dodic et al., 2002).  
 
A brief look at the myriad of effects of the prepartum glucocorticoid surge highlight the 
potential difficulties if a neonate is born prior to exposure to this surge, and hence is not 
sufficiently matured for survival in the extra-uterine environment. 
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1.4 CLINICAL BENEFITS OF GLUCOCORTICOIDS IN PERINATAL LIFE 
 
The first steps towards clinical use of glucocorticoids to treat pre-term birth occurred with 
Liggins’ serendipitous observation that synthetic glucocorticoid injection into the pregnant 
ewe triggered fetal lung maturation (Liggins, 1969). He correctly inferred that glucocorticoids 
must be critical for fetal maturation, and immediately saw the clinical potential. Together with 
obstetrician Howie an initial clinical trial using AGT when women presented at hospital with 
threatened pre-term labour was completed in 1972, with clear positive results – incidence of 
respiratory distress syndrome (RDS) in the neonate was reduced from 25.8% in the control 
group to 9% in the glucocorticoid treated group, whilst perinatal death was reduced from 18% 
to 6.4% (Liggins & Howie, 1972). Several other clinical trials then followed (Roberts & Dalziel, 
2006), demonstrating a decrease in various neonatal morbidities following AGT, with the 
positive effects comparable for older and more recent studies (in which other advances in 
neonatal care were also available). Initially, the obstetrics community was reluctant to adopt 
AGT as standard. However, in 1994 the NIH released a consensus statement (NIH, 1994) which 
purported that:  
‘‘Antenatal corticosteroid therapy is indicated for women at risk of premature 
delivery with few exceptions and will result in a substantial decrease in neonatal 
morbidity and mortality, as well as substantial savings in health care costs.”  
 
In the years since then AGT has become almost universally implemented for threatened pre-
term birth. Four Cochrane systematic reviews have been conducted on AGT, concluding that 
there is an associated decrease in several neonatal morbidities including respiratory distress 
syndrome (RDS), and an associated decreased risk of perinatal death (Sotiriadis et al., 2009; 
Brownfoot et al., 2013; Crowther et al., 2015; Roberts et al., 2017) with the latest update 
cementing the drastic benefits of AGT (Roberts et al., 2017). Consequently, AGT is now 
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considered to be an indispensable treatment by most health organisations. The World Health 
Organisation lists antenatal glucocorticoids for preterm labour as an essential medicine (Lawn 
& Althabe, 2013) and AGT is recommended by the Royal College of Obstetricians and 
Gynaecologists for all pregnancies at risk of preterm birth between 26-34 weeks (Royal 
College of Obstetricians & Gynaecologists, 2010).  
 
The positive effects of AGT on neonatal respiratory outcomes are mainly due to direct effects 
on the fetal lungs leading to accelerated maturation (Ballard, 2000). AGT has been shown in 
animal models to induce structural changes leading to greater alveolar volume (Willet et al., 
1999), drastically increased lung volume (Jobe et al., 1993), and increased surfactant 
production (Ballard, 2000). These changes lead to improvements in lung compliance and 
ventilation efficiency (Ikegami et al., 1997). In clinical trials, AGT results in a significant 
reduction in RDS, moderate/severe RDS, and the need for mechanical ventilation, whilst not 
having an effect on instance of chronic lung disease (Roberts & Dalziel, 2006). These beneficial 
effects on the lungs are also independent of post-natal surfactant therapy (Martin & Fanaroff, 
2013). 
 
As well as improved respiratory outcomes for preterm babies, AGT significantly reduces other 
associated morbidities. Rates of IVH are significantly reduced in AGT treated neonates 
(Roberts et al., 2017). This may be due to maturation of the cardiovascular system, for 
example these neonates have a higher mean blood pressure (and are less likely to suffer from 
hypotension; Dempsey, 2017), and the brain microvasculature itself is likely directly affected 
(Garton et al., 2017). There is also a significant decrease in NEC following AGT treatment. This 
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may be secondary to decreased bacterial translocation across the intestinal barrier, 
decreased colonisation with aerobic bacteria, and/or increased activity of enzymes including 
lactase, sucrase, and the Na+/K+ ATPase in intestinal epithelial cells (Lin et al., 2014).  
 
AGT coverage of women at risk of preterm birth, between 24 and 34 weeks of gestation, has 
a target of 85% in the UK (the other 15% being comprised of women with contraindications; 
Royal College of Paediatrics and Child Health, 2015), however global coverage does in fact 
vary drastically. Those countries with the most developed health care systems typically have 
coverage at or approaching the 85% mark. However, developing countries often have far 
poorer coverage. For example, Afghanistan and the Democratic Republic of Congo had 
reported coverage between 2010 and 2011 of only 16% in pregnancies 26-34 weeks (Vogel et 
al., 2015). Few of the clinical trials have been conducted in low-income countries and so 
efficacy in these settings is yet to be made entirely clear. Exposure to AGT is also not limited 
to these groups, in fact many women who are exposed to AGT will go on to deliver after 35 
weeks, or up to a week after drug administration (Makhija et al., 2016; Razaz et al., 2015), 
especially in those developed countries with high coverage. Clearly, with the number of 
fetuses at risk of preterm birth and the expected coverage with AGT, vast numbers of 
individuals have been and will go on to be exposed to this treatment  
 
As well as AGT, it is also relevant that synthetic glucocorticoids may be administered to the 
new-born infant in the immediate post-natal period, predominantly to treat BPD, provide 
blood pressure support and ameliorate sepsis. Steroids such as Dexamethasone administered 
in this period have also been shown to successfully decrease inflammation and allow 
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extubation of the infant (Farstad et al., 2011). The use of steroids for this purpose rose during 
the 1990’s, with predominantly Dexamethasone being utilised (Kobaly et al., 2008; Mammel 
et al., 1983). However, it was soon observed that those children who had received post-natal 
glucocorticoids demonstrated both severe immediate and long-term adverse side effects 
from this treatment, including gastrointestinal bleeding, hypertension, and neurological 
impairment. In 2002, the American Academy of Pediatrics released a consensus statement 
advising against the use of steroids for treatment of BPD (American Academy of Paediatrics, 
2010). The result was a rapid decrease in use of this therapy, except in the most severe cases 
of BPD, despite lack of large controlled trial data (DeMauro et al., 2014). Since then, the DART 
study indicated no strong association with long term consequences when low-dose 
Dexamethasone treatment was trialled (Doyle et al., 2007). The rates of BPD in very low birth 
weight, and very low gestational age neonates has not changed since the early 2000s 
(remaining at just over 50%). In Finland, of babies born preterm between 22-25 weeks, the 
incidence of BPD was 67.3%, and between 26-30 weeks this decreased to 36.6% (Farstad et 
al., 2011).  Whilst the rate of neonatal steroid use has decreased since the early 2000s, it still 
affects around 8% of neonates in this category. What’s more, the rate of antenatal steroid 
use in this group is high.   A retrospective analysis in North America estimated antenatal 
steroid coverage of this group of new born children at 61-75% (Walsh et al., 2006), meaning 
that many preterm individuals are exposed to both antenatal and postnatal steroid therapy.  
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1.5 ADVERSE EFFECTS OF GLUCOCORTICOIDS IN THE PERINATAL PERIOD 
 
Despite the clear life-saving benefits of AGT, there is mounting concern about adverse effects 
of exposure to high levels of synthetic glucocorticoids on organ systems other than the lungs. 
Adverse changes to physiological systems in the fetal and neonatal period may result in 
permanent dysfunction than increases risk of disease in the adult; what is termed 
developmental programming of adult disease (DoHaD; Barker, 2007). Our understanding of 
these detrimental effects of synthetic steroids is compounded by the use of multiple animal 
models, timings of glucocorticoid exposure, glucocorticoid dose, and timing of outcome 
measurements throughout the literature. The human data are also difficult to interpret as the 
majority of children exposed to AGT experienced a sub-optimal pregnancy and hence it is not 
possible to disentangle the effects between multiple factors. 
 
 Despite these difficulties, there is significant evidence that exposure to glucocorticoids in 
early life impairs growth. In animal studies both single and repeat doses of antenatal 
glucocorticoids lead to growth restriction (Newnham et al., 1999; Jobe et al., 1998). Antenatal 
glucocorticoids are also associated with decreased placental weight (Newnham & Moss, 
2001), alterations in placental blood flow (Jellyman et al., 2004), and amino acid transport 
(Audette et al., 2014) – all factors associated with impaired fetal growth. Studies in non-
human primates also observe a growth restriction following one or multiple antenatal doses 
(Doyle et al., 2014). However in humans, in the Cochrane reviews of single AGT, there is no 
significant difference in birth weight between treatment and placebo groups, suggesting that 
in humans a single course may not be sufficient for serious growth impairment (Roberts et 
al., 2017).  
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Exposure to excess glucocorticoids during early life can also have several effects on the fetal 
and adult cardiovascular system. There are a number of rapid alterations to fetal 
haemodynamics and movement (Koenen et al., 2002; Mulder et al., 2009; Fletcher et al., 
2002), primarily a transient hypertension and a decrease in fetal movements. Exposure to low 
levels leads to a shift in set-point of the fetal baroreflex and hypertension up to 48-hours after 
the initial injection (Fletcher et al., 2002). In the neonate and adult, the most commonly 
reported long term effect is dysregulation of blood pressure (Lindsay et al., 1996). Sheep 
exposed in utero have been reported to have elevated blood pressure at 6 months of age, 
and an attenuated baroreflex (Shaltout et al., 2012; Davis et al., 2006). In human clinical 
follow-up studies, both systolic and diastolic blood pressure in exposed individuals at 14 years 
of age is increased (Cheong et al., 2014). In both humans and animal models, there are several 
reported changes directly to the vasculature, such as endothelial dysfunction (a well-known 
harbinger of future cardiovascular disease), changes in aortic arch stiffness, and blood flow 
pulsatility (Docherty et al., 2001; Pulgar & Figueroa, 2006; Kelly et al., 2012). Direct cardiac 
effects have been shown including transient hypertrophy, altered autonomic responses, 
impaired Starling mechanism, systolic dysfunction, and increased end diastolic volume and 
pressure (Yunis et al., 1999; Dodic et al., 2001; Niu et al., 2013). Many of these changes are 
seen in cardiovascular disease and heart failure.  
 
The renal system is also of great importance when discussing cardiovascular and metabolic 
disease. The kidney, as a key regulator of blood pressure, is a central thespian in hypertension. 
Chronic kidney disease (CKD) is also highly associated with diabetes, and levels are rising at a 
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serious rate (Webster et al., 2016). Given the costs and detriment to wellbeing of treatments 
for CKD, this rise is worrying. Several studies have demonstrated that antenatal glucocorticoid 
exposure can reduce nephron number (Figueroa et al., 2005; Ortiz et al., 2001; Moritz et al., 
2011) and can lead to reduced glomerular filtration rate (GFR) in the adult (Finken et al., 
2008). This has been proposed to result in adult hypertension via a positive feedback 
mechanism of glomerular damage.  This is summarise by the Brenner hypothesis that states 
that increased load of filtrate per nephron leads to an increased glomerular pressure, this 
causes glomerular damage leading to further loss of GFR and hypertension, hypertension 
causes more glomerular damage (Brenner et al., 1988). However, the hypertension observed 
after antenatal glucocorticoid exposure is not proportional to nephron number, hence other 
factors are also contributing (Zhang et al., 2010). A reduction in nephron number may also 
impair the response to a later renal insult. In male sheep treated antenatally with 
betamethasone, exposure to Angiotensin II significantly increased markers of oxidative stress 
and increased protein excretion (Bi et al., 2014). Glucocorticoids may also alter the developing 
renal RAS (Connors et al., 2010; Contag et al., 2010; Forhead et al., 2015). Alterations in the 
set-point of this system again may contribute towards hypertension. 
 
There are several known links between antenatal glucocorticoids and future metabolic 
disease. In the fetus, exposure to glucocorticoids can alter pancreatic development leading to 
a decrease in beta cell endowment in the islets. Several studies have observed dysfunction in 
insulin sensitivity (Blanco et al., 2014), and glucose tolerance at adulthood (Nyirenda et al., 
1998). Exposure to antenatal glucocorticoids may also increase risk for obesity and abnormal 
fat deposition (Drake et al., 2010; Finken et al., 2011). Alterations in the leptin axis have also 
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been reported (Sugden et al., 2001). These parameters are risk factors for type-II diabetes, 
which itself increases risk of both CKD and cardiovascular disease. Being exposed to an altered 
maternal metabolic profile in utero (e.g. pregnancy with maternal diabetes or obesity) may 
itself programme future metabolic dysfunction in the offspring (Fernandez-Twinn & Ozanne, 
2006). 
 
Several animal studies have also suggested a reduction in brain weight following antenatal or 
postnatal glucocorticoid exposure. Specifically, this appears to be associated with a decrease 
in volumes of cortical and deep grey matter, and hippocampal neuronal soma volume (Uno 
et al., 1990; Tijsseling et al., 2013; Camm et al., 2011). This decrease in brain volumes may be 
transient or persistent (Noorlander et al., 2014). Cellular alterations include delayed 
myelination (Antonow-Schlorke et al., 2009), alterations in gap junction proteins (Sadowska 
& Stonestreet, 2014), and specific changes in gene expression (Labaune et al., 2002; Pascual 
et al., 2014). Functionally, it seems that these changes may lead to impaired performance in 
various neurological tests and altered behaviour in the adult (van der Voorn et al., 2015). 
There are also reports of altered stress and anxiety responses (Oliveira et al., 2006, 2012; 
Alexander et al., 2012). This may be secondary to alterations in the HPA axis (Shaltout et al., 
2011; Li et al., 2013). Follow-up studies of school children exposed to post-natal 
glucocorticoids suggest a decrease in IQ (Hitzert et al., 2014). Adolescents at age 14-17 who 
have been exposed to postnatal Dexamethasone have adverse motor function, impaired 
neuropsychological test scores, and the females were more likely to need special education 
measures (ter Wolbeek et al., 2013). This group also displays decreased brain volumes, 
specifically of the white matter, thalami, and basal ganglia, with a potential dose-dependent 
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relationship (Cheong et al., 2014), and altered HPA axis function (Ter Wolbeek et al., 2015). 
There is human evidence of altered stress responses following antenatal glucocorticoid 
exposure, for example increased cortisol response to stress tests in adolescents (Moisiadis & 
Matthews, 2014a). In primates there is also an increase in HPA activity in juveniles, and 
alterations in hippocampal mRNA129 have been observed in sheep models. The implications 
of neurological effects of antenatal glucocorticoids for clinical treatment are great. Clearly, 
there is a scale of neurological impairment, and whilst follow-up studies may focus on 
manifest neurological diseases, such as cerebral palsy, even modest changes in neural 
function can significantly impact future health and wellbeing. 
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1.6 MECHANISMS OF DYSFUNCTION INDUCED BY GLUCOCORTICOIDS 
 
The missing piece in preventing the lifelong unwanted implications of AGT, and more broadly 
of fetal and/or neonatal exposure to elevated levels of glucocorticoids, is a lack of clear 
understanding of the mechanisms underlying these adverse effects. Because of the 
pleiotropic nature of glucocorticoids in different tissues and at different gestational ages, it is 
very difficult to isolate specific causes. However, the changes observed in different studies 
throughout the literature can be summarised into several categories of potential mechanistic 
changes in the aetiology of the dysfunctional adult phenotype (Fig.1.6.). 
 
 
 
Figure 1.6 Mechanisms of antenatal glucocorticoid induced dysfunction. 
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One of the main effects of glucocorticoids in the fetus is a switch away from tissue accretion 
towards maturation (Newnham & Moss, 2001; Fowden et al., 2016). Prematurely exposing 
the fetus to high levels of synthetic glucocorticoids may therefore induce this switch earlier, 
resulting in a decrease in growth. Decreased body growth, or of specific organs has been 
demonstrated in many animal models. For certain organs in which the endowment of 
particular cell types is set during prenatal development, this premature switch could lead to 
a life-long impairment. For example, in many animals, cardiomyocyte number is established 
in late gestation, and the pre-partum cortisol surge is known to cause a shift from cell division 
to cellular hypertrophy (Thornburg et al., 2011; Gay et al., 2015). Therefore, antenatal 
exposure to glucocorticoids at levels inappropriate for the stage of gestation can prematurely 
reduce cardiomyocyte number, potentially leading to impaired contractility, excessive 
hypertrophy, and cardiac dysfunction in adulthood (Gay et al., 2015). Similarly, as we have 
discussed, a decrease in nephron number may pre-dispose someone to hypertension and 
kidney disease in adulthood (Brenner et al., 1988). Equally, early exposure to glucocorticoids 
may alter the ratio of different cell types in a particular tissue. Exposure to Dexamethasone 
has been shown to reduce the proportion of beta cells in the pancreas (Dumortier et al., 
2011). This could in turn lead to insufficiency of insulin production, with potential 
downstream changes in the sensitivity of insulin target organs, such as adipose tissues, 
leading eventually to an increased risk of insulin resistance (Dumortier et al., 2011).  Brain 
weight can be reduced by antenatal glucocorticoid exposure, and loss of cell number is 
specific brain areas may be in part responsible for the neurological deficits described 
(Tijsseling et al., 2013). 
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In adults, there is a clear link between glucocorticoids and oxidative stress, and further this 
oxidative stress is associated with cardiovascular and metabolic dysfunction (Wu et al., 2014;  
Aboelwafa and Yousef, 2015; Takeshita et al., 2015). Indeed, in vitro, it seems that 
glucocorticoid administration in high doses can increase cellular oxidative stress, and a meta-
analysis of the link between glucocorticoids and oxidative stress in adult animals suggests that 
there is a significant effect, which is larger in long term studies (Costantini et al., 2011; Tang 
et al., 2013). In the fetus, this relationship is less clear, with some organs appearing to have a 
reduction in oxidative stress following antenatal exposure (Walther et al., 1998). However, it 
is probable that in some tissues an induction of cellular oxidative stress may be responsible 
for some of the observed dysfunction. Endogenous cortisol matures fetal mitochondria, 
leading to an increase in oxidative capacity by up-regulation of specific electron transport 
chain components (Lee et al., 2013). A mismatch between substrate availability and 
mitochondrial activity could lead to an increase in generation of oxidative stress. Free radicals, 
most notably reactive oxygen species (ROS), may subsequently damage cellular components, 
affect signalling pathways, and alter oxidant tone of the vasculature by decreasing NO 
availability (Keaney & Chen, 2004). There is evidence of oxidative stress in the heart and brain 
in animal models of AGT (Wallwork et al., 2003; Zhang et al., 2004, 2005; Adler et al., 2010; 
Camm et al., 2011; Tijsseling et al., 2013). A study in which HUVECs (Human Umbilical Vein 
Endothelial Cells) were treated with Dexamethasone also demonstrated an increase in 
hydrogen peroxide production and decreases in cellular NO, secondary to ROS production via 
NAD(P)H Oxidase, Xanthine Oxidase, and the Mitochondrial electron transport chain (Iuchi et 
al., 2003). In humans, there is evidence that Betamethasone may cause an acute repression 
of Glutathione peroxidase 3 (GPx3; Verhaeghe et al., 2009). 
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Glucocorticoids alter mitochondrial biogenesis, oxidative phosphorylation, and substrate 
preference, either directly or via changes in nuclear genes (Lee et al., 2013). In late gestation, 
there is a switch towards increased numbers of mitochondria and towards metabolism of 
fatty acids in energy demanding tissues such as the heart (Rog-Zielinska et al., 2014a). A 
premature transition to this state may lead to ROS build-up within the mitochondria, 
potentially damaging mitochondrial proteins and DNA. Excessive glucocorticoid levels may 
thus result in mitochondrial dysfunction, which may persist into adulthood, as mitochondria 
are not generated de novo, but by replication of the existing organelles. Mitochondrial 
dysfunction is a hallmark of many diseases including diabetes, atherosclerosis and heart 
failure (Ma et al., 2012; Yu & Bennett, 2014; Goldenthal, 2016). For example, it is thought that 
mitochondrial dysfunction may lead to a build-up of intermediates of lipid metabolism, which 
may cause lipotoxicity and contribute towards development of insulin resistance (Bakar et al., 
2015). There is relatively little research into the role of mitochondria in programming by 
antenatal glucocorticoids, but it is known to exist in other models of developmental 
programming, e.g. in maternal under-nutrition programming of diabetes (Reusens & 
Remacle, 2006).  
 
As well as discrete changes in gene expression, which may alter organ and tissue growth, 
glucocorticoids can also act via epigenetic mechanisms resulting in persistent long-term 
changes in gene expression. Epigenetics refers to trans acting mechanisms that alter gene 
expression without altering the underlying genetic code. The most common mechanisms of 
this type of control include alterations in DNA methylation, histone modifications, and 
changes induced via miRNAs (Moisiadis & Matthews, 2014b; Sales et al., 2017). Cytosine 
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residues in DNA can be reversibly methylated, leading to recruitment or prevention of binding 
of other regulatory factors. Methylation of gene promoter or enhancer regions may lead to 
either up or down-regulation of expression. Histone modifications, including acetylation and 
methylation, can alter histone-DNA interactions leading to compaction or loosening of 
chromatin, or can also recruit further effector proteins. miRNAs act via a post-transcriptional 
mechanism to reduce gene expression – complementary miRNA regions target specific gene 
transcripts for degradation via the DICER complex. Glucocorticoids may act either directly via 
the GRE, or secondarily by changing levels of epigenetic regulators or other hormones to alter 
these systems. Overall, this leads to an incredibly complex network of gene regulatory 
mechanisms that can be either transient or persist throughout the life course. Persistent 
modifications in gene expression could lead to fundamental alterations in parameters of 
homeostatic systems, especially in the fetus where the epigenome is relatively plastic (Jang & 
Serra, 2014). It has been shown that antenatal dexamethasone treatment leads to changes in 
DNA methylation in the guinea pig hippocampus, in a gene specific manner (Crudo et al., 
2012), and alters mRNA levels of imprinted genes in the rat potentially secondary to 
methylation changes (Drake et al., 2011). Gay et al. (2015) demonstrated that the reduction 
in cardiomyocyte proliferation following dexamethasone treatment in rat pups was 
secondary to changes in DNA methylation and down-regulation of cyclin D272. This may be 
most pertinent in systems that are heavily controlled by epigenetic mechanisms, for example 
key HPA axis regulatory genes NR3C1, NR3C2, CRH, POMC, and 11HSD2 (Moisiadis & 
Matthews, 2014b). In other models of developmental programming there is also increasing 
evidence for the contribution of epigenetic changes (Pham et al., 2003; Bogdarina et al., 2007; 
Aagaard-Tillery et al., 2008; Dudley et al., 2011; Lie et al., 2014). A further implication of 
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epigenetic mechanisms of programming is that changes may persist for multiple generations, 
if the changes are resistant to embryonic epigenetic reprogramming (Yao et al., 2014). 
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1.7 A WAY FORWARD? UNKNOWNS AND CONSIDERATIONS 
 
The lifesaving benefits of AGT mean this treatment is unlikely to become out of favour with 
obstetricians, despite the growing evidence for negative effects on the developing heart, 
brain and other organs and systems. However, it is clear that more basic research is needed 
to improve understanding of the effects of AGT, and to tailor current clinical practise to 
minimise the detrimental effects whilst maintaining the clinical benefits. Current estimates 
suggest that the number needed to treat with AGT to prevent one neonatal death is 798 at 
34 weeks gestational age (Travers et al., 2017), hence there is still much room for 
improvement. 
 
The current dose regimen used in clinical practise is based largely on the original clinical trials 
and is not adjusted for any maternal or fetal factors (e.g. maternal weight, age, twinning; 
Ballard, 1995). Further, if a mother threatened with pre-term labour does not deliver within 
7 days of receiving AGT, a repeat course may be given (FIGO committee report, 2019). There 
is no clear consensus on how many repeat courses should be given to maintain beneficial 
effects of AGT (Bonanno et al., 2007), and as early as 1996, 58% of responders to a US based 
survey answered they would give 6 or more courses if pre-term labour had still not occurred 
(Planer et al., 1996). RDS instance is slightly reduced by multiple courses (Crowther et al., 
2015), and a rescue course has been shown to reduce neonatal morbidity (Garite et al., 2009). 
However, there is growing concern about the more severe negative effects of repeat doses 
(Romejko-Wolniewicz et al., 2014). So much so, that in 2003, a second NIH Consensus panel 
advised against the use of repeated courses of AGT (Crane et al., 2003). There is also evidence 
from animal studies that significantly lower equivalent doses than those used in clinical 
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practise can achieve similar levels of lung maturation (Jobe et al., 2009). However, some 
clinical evidence of incomplete course of AGT have shown smaller benefits in preventing RDS 
when compared to neonates who completed a full course, although the partial course was 
still effective in reducing IVH and neonatal death (Chien et al., 2002). Further research is 
therefore clearly needed into the optimal dose, whether it should be adjusted for maternal 
factors, and how many courses could be given before the potential future detrimental effects 
outweigh the benefits. 
 
There are also unanswered questions surrounding the correct method of drug administration. 
Administering glucocorticoids to the mother rather than directly to the fetus has been 
reported to cause a more significant growth retardation (Jobe et al., 1998), likely as a result 
of additional detrimental effects of AGT on placental blood flow and function (Jellyman et al., 
2004). However, fetal administration with synthetic glucocorticoids produced smaller 
improvements in postnatal lung function than with maternal administration despite higher 
fetal plasma glucocorticoid levels (Jobe & Soll, 2004). Intra-amniotic administration has been 
shown to be successful in maturing fetal lungs in the sheep and the monkey (Gilbert et al., 
2001), but has a high associated morbidity making it potentially unsuitable for clinical use 
(Moss et al., 2003). Any potential route of fetal administration needs to be investigated 
thoroughly prior to introduction to clinical practise. It may also be unfeasible in low-income 
populations, or where obstetric care is less available. Another possibility for route of drug 
administration is to give AGT orally to the mother. The only clinical trial to use oral 
dexamethasone as an alternative to standard intra-muscular treatment was ceased after IVH 
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levels were found to be significantly increased in the oral compared to the intra-muscular 
administration group (Egerman et al., 1998). 
 
Another impending unanswered question as to the optimum clinical treatment is the choice 
of glucocorticoid for AGT. The synthetic glucocorticoids that are mostly used are 
Dexamethasone and Betamethasone (Table.1.2; Jobe & Soll, 2004). Both drugs are synthetic 
analogues of endogenous cortisol, which can readily cross the placenta, with a substantially 
increased affinity for the GR. They also will not interact with the MR, or with inactivating 
enzyme 11βHSD2 (Buttgereit et al., 1999). Betamethasone was initially used by Liggins and 
Howie for the first clinical trials because the acetate formulation of the drug was thought to 
have a long plasma half-life (Liggins & Howie, 1972). Since then many trials have been 
conducted using either Dexamethasone or Betamethasone, with few directly comparing the 
two steroids. A comparison of meta-analyses by Jobe suggests that Betamethasone may be 
more effective in reducing IVH and death than Dexamethasone (Jobe & Soll, 2004), however 
this is only based on a small number of studies. Animal studies have also demonstrated that 
the acetate formulation of Betamethasone may be as effective at stimulating lung maturation 
as the combined phosphate and acetate formulation used in clinical practise (Jobe et al., 2009; 
Schmidt et al., 2019). There clearly needs to be more research into the drug of choice, and 
formulation of that drug. The WHO currently only lists Dexamethasone as an essential 
medicine, largely due to it being both cheaper and more widely available than Betamethasone 
(WHO, 2015). However, the WHO highlighted this as an area in need of further research in 
their 2015 report on preterm birth outcomes, stating: 
‘There is no conclusive evidence on the comparative efficacy of dexamethasone and 
betamethasone that would support a recommendation of one over the other.’ 
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Table 1.2 Comparison of Dexamethasone and Betamethasone dosing regimens for AGT (WHO, 2012). 
 
 
The lack of a clear consensus surrounding so many aspects of the clinical use of AGT has been 
reported by several public health bodies. The World Health Organisation (WHO) in 2015 
(WHO, 2015) identified the following questions as priority research directions: 
• What are the long-term outcomes of all infants exposed to antenatal corticosteroids 
(including term infants)? 
• What are the effects of antenatal corticosteroid at different gestational ages at birth? 
• What is the minimum effective dose of corticosteroids to achieve fetal lung 
maturation and other improved outcomes? 
• What is the minimum dose required for repeat courses of antenatal corticosteroids? 
• What are the most effective regimen and dose for antenatal corticosteroids? 
Drug 
 
Dexamethasone Betamethasone 
Formulation Phosphate 
 
50:50 Phosphate/Acetate 
Route of 
Administration 
Maternal intra-muscular 
injection 
 
Maternal intra-muscular 
injection 
Clinical Administration 4x6mg doses,  
12hrs apart 
2x12mg doses, 
24hrs apart 
 
Total Dose 24mg 
 
24mg  
MSP   
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1.8 ISOLATING EFFECTS OF GLUCOCORTICOIDS IN THE PERINATAL PERIOD 
 
Part of the difficulty in improving our understanding of how AGT can affect fetal physiological 
systems differentially, is the impossibility in isolating effects of AGT on the mother, the 
placenta and the fetus in human clinical studies or in basic science studies using mammalian 
animal models.  In this regard, studies in avian species circumvent these problems, allowing 
us to research the direct effects of a clinically relevant treatment of glucocorticoid on the 
fetus, without additional confounding influences on the mother and the placenta, as the avian 
embryo develops in isolation within the egg. In addition, in the chicken, the temporal 
developmental milestones for cardiac maturation are much more similar to the human in 
terms of the % of development at which specific events occur, in contrast with rats and mice, 
which are born highly immature and maturation of the cardiovascular system extends well 
into the postnatal period (Sissman, 1970; Marcela et al., 2012; Itani et al., 2018). Due to these 
similarities, an insult applied at a similar time of development to the chick embryo can be 
expected to have similar effects on cardiovascular development as an insult applied at that 
time to a human fetus (Itani et al., 2018)( Fig.1.7).  
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Figure 1.7 Cardiac developmental milestones in various species. (Taken from Itani et al., 2018). 
 
 
 
In addition to a similar course of cardiovascular development, it is vital to find a model in 
which a comparable role and timing of the glucocorticoid surge is seen. In the chicken embryo 
it has been demonstrated that the HPA axis is active from as early as 5 days of incubation 
(total incubation time in the chicken is 21 days; Siegel & Gould, 1976). There are two distinct 
periods in which an increase in plasma glucocorticoid levels are observed; between 
embryonic days 14-16 there are increases in both circulating corticosterone and cortisol 
(Kalliecharan & Hall, 1974), whilst immediately prior to hatching there is a drastic rise in 
circulating corticosterone (Scott et al., 1981; Tanabe et al., 1986; Fig.1.8) – the latter being 
the primary endogenous glucocorticoid in most birds. It is thought that this pre-hatching rise 
is secondary to increased sensitivity of adrenal cells to ACTH, as well as increased CRH and 
ACTH production in the hypothalamus and pituitary (Carsia et al., 1987). This secondary 
increase in corticosterone is qualitatively similar to the pre-partum cortisol rise in the human 
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fetus (Jenkins & Porter, 2004). Other favoured animal models do not necessarily have an 
analogous glucocorticoid profile. Rodents are well known to have a delayed glucocorticoid 
surge that happens in the post-natal period, with peak corticosterone levels in the rat 
occurring approximately at post-natal day 20 (Pignatelli et al., 2006). 
 
More importantly, this glucocorticoid rise in birds has been demonstrated to have a similar 
maturational role as human cortisol. In the chicken embryo lung administration of 
glucocorticoids results in increased surfactant production (Sullivan & Orgeig, 2001). 
Glucocorticoids have also been demonstrated to alter neuronal division and maturation in a 
manner similar to that seen in the mammalian brain (Austdal et al., 2016; Aden et al., 2011). 
 
Studies in our laboratory have previously demonstrated that it is possible to dose the chicken 
embryo directly via application of a solution onto the chorioallantoic membrane, and that 
drugs applied in this manner are readily taken up into the fetal circulation and tissues (Itani 
et al., 2015).  
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Figure 1.8 Ante-natal glucocorticoid surge, in chicken egg allantoic cavity and human fetal plasma. Data 
compiled from (Murphy 1978; Tona et al. 2003; Woods et al. 1970).  
 
The chicken embryo has the final advantage of being reasonably large, having an average 
weight at day 19 is ca.25g (Itani et al., 2015), compared with  the term rat fetus, which weighs 
ca.4g (Camm et al., 2011).  Hence, the chicken embryo is amenable to cardiovascular 
functional tests, including assessment of cardiac function via the Langendorff preparation, 
and of peripheral vascular function via small vessel wire myography (Itani et al., 2018) in 
addition to studies at the cellular and molecular levels. 
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1.9 AIMS AND OBJECTIVES OF THIS THESIS 
 
Therefore, using the chicken embryo model system, the main aims of this thesis were:  
A. To determine the direct effect on the developing cardiovascular system of a human 
clinically relevant dose of Dexamethasone;  
B. To compare the direct effects on the developing cardiovascular system of human 
clinically relevant doses of Dexamethasone versus Betamethasone; and 
C. To isolate the direct effects on the developing cardiovascular system of human 
clinically relevant doses of Betamethasone using different drug formulations.  
 
Within each aim, there were 5 specific objectives: 
1. To determine direct effects on embryonic survival and growth; 
2. To determine direct effects on the cardiac structure and function; 
3. To determine direct effects of vascular function; 
4. To determine molecular pathways mediating direct effects; 
5. To determine direct effects on lung maturation. 
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CHAPTER 2: GENERAL METHODS 
All procedures were performed under the UK Animals (Scientific Procedures) Act 1986 and 
approved by the University of Cambridge Ethical Review Board. 
 
2.1 EGG INCUBATION AND DRUG ADMINISTRATION 
Fertilised Bovans Brown eggs (Medeggs, Henry Stewart & Co., UK) were delivered weekly and 
further stored at 14°C in a cooler (Bosch KTW18V80GB, Robert Bosch Limited, UK) to arrest 
development, as standard (Fasenko, 2007). Eggs were also manually rotated daily during 
storage to prevent fusion of the embryo and the chorioallantoic membranes (Tazawa, 1980). 
After one to five days of storage, the eggs were weighed and placed in an incubator under 
normoxic (21 % O2) optimal conditions (37.9 °C, 45 % humidity, 12:12 hour light: dark cycle, 
automatic rotation every hour, incubator Mod.75-A and Mod.M-240, Masalles, Spain; Fig. 
1.1.). This was termed as day 1 and the start of the incubation period. Eggs were candled daily 
from day 13 onwards and any displaying no evidence of fetal development, indicated by a 
clear air cell at one end of the egg, were discarded. 
 
A dose of 0.1mg.kg-1 was administered on day 14 of the 21-day incubation period. This dose 
was selected initially as it is lower than the clinical dose experienced by a human fetus, yet 
lead to significant growth effects in preliminary studies. Glucocorticoid in the chicken embryo 
was administered at 66% of the incubation period, as this is equivalent to ca. 26/27 weeks of 
human gestation, which reflects an early time point at which antenatal glucocorticoid therapy 
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(AGT) is administered clinically, and at which this treatment has been shown to be effective 
in improving neonatal outcomes (Roberts et al., 2017). The dosing regimen and experimental 
timeline is shown in Fig.1.2. Outcome measurements were taken at day 19 of incubation, 
which is equivalent to term in a human pregnancy. This time point was chosen as throughout 
days 21-23 of incubation chicken embryos will begin to ‘pip’ through the chorioallantoic 
membrane and switch to air breathing. Thus to characterise effects on the embryo prior to 
any neonatal transition occurring, day 19 was chosen. In preliminary studies we noted a 
significant impairment in hatching rate of glucocorticoid treated embryos, making it 
practically unfeasible to measure outcomes in the newly hatched chick which would be more 
relatable to the human neonate. 
 
To dose the eggs, candling reveals the air space, which can then be accessed via drilling of a 
small hole through the shell. Drug administration can then be made through this hole topically 
onto the chorioallantoic membrane with substances being absorbed by the chorioallantoic 
circulation. Previous studies in this laboratory have established this as an effective and non-
invasive method of egg dosing (Itani et al., 2015). 
 
In this thesis 4 cohorts of chicken embryos were utilised to achieve an n number of 8-10 for 
each outcome described below, for control and treatment groups. Cohort 1 was used for 
biometry and snap freezing of tissues. Cohort 2 was used for Langendorff and small vessel 
wire myography. Cohort 3 was used for perfusion fixation. Cohort 4 was used for molecular 
digestion of the embryonic heart to isolate individual cardiomyocytes. 
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Figure 2.1 Egg incubation and dosing procedures. A. Eggs were incubated in an incubator with automatic 
rotation, controlled humidity of 45% and temperature of 37.9°C, B. Eggs were candled to locate air cell, as this 
both provides evidence for embryonic growth and demonstrates location of the chorioallantoic membrane for 
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drug administration, C. Drugs were administered via a small hole drilled through the shell, directly onto the 
chorioallantoic membrane (shown in red), where they are readily taken up by the chorioallantoic vasculature. 
 
 
 
 
 
 
Figure 2.2 Dosing scheme for both control and glucocorticoid treatments. Eggs are dosed with 100µL of either 
sterile water or aqueous glucocorticoid (to give a total dose of 0.1mgkg-1) on day 14 of incubation.  
 
2.2 ASSESSMENT OF EMBRYONIC GROWTH 
 
On Day 19 of incubation, embryos were removed from their eggshells and euthanized by 
spinal cord transection. Embryo mass (g) and mass of the eggshell, yolk, non-embryonic 
tissues, and any remaining fluid was measured and recorded. Measurements of fetal size 
were made using an electronic calliper (Mitutoyo 500-181- 20, Japan). Crown Rump Length 
(CRL) was taken as length between the crown of the skull, and base of the back. Head 
diameter (HD) was measured just behind the eyes (Fig. 1.3.). Animals were further dissected 
such that heart and brain mass could also be recorded. 
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Figure 2.3. Biometry on the day 19 chicken embryo. 
 
2.3 ASSESSMENT OF EX VIVO CARDIAC FUNCTION 
 
On day 19, embryos were removed from their eggshells and euthanized by spinal cord 
transection. The hearts were then rapidly excised and placed into ice-cold Krebs Buffer 
solution (NaCl 120mM, KCl 4.7mM, MgSO2.7H2O 1.2mM, KH2PO4 1.2mM, NaHCO3 25mM, 
glucose 10mM, CaCl2.2H2O 1.3mM, all reagents from Sigma, UK). The glucose concentration 
utilised was based on evidence of embryonic chicken plasma glucose levels (Latour et al., 
1996; Sunny & Bequette, 2014; Shi et al., 2014). Excess tissue was removed, and upon 
identification, the aorta was cannulated onto a 19-gauge blunt needle thereby mounting the 
heart onto the Langendorff apparatus (Fig.1.4). In this set up, the heart is perfused via the 
coronary arteries by oxygenated Krebs Buffer (95% O2, 5% CO2) at 40°C, at a pressure of 
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40cmH2O (systolic pressure at day 19 of incubation; Tazawa, 2004). The buffer was 
continuously re-circulated around the apparatus and cleaned with a nitro-cellulose filter 
(8.0μm SCWP, Merck Millipore, USA). The heart was then allowed to stabilise for several 
minutes, before an incision was made into the top of the left atrium.  A small non-flexible 
balloon, made of cling film and attached to a cannula and a pressure transducer (Argon 
Medical Devices, UK), was then inserted to the base of the left ventricle. The balloon was filled 
using a Hamilton syringe by incrementally introducing 5µL of water into the cannula, until a 
final volume of ca. 30µL and a stable optimal pressure reading of between 5-10mHg LVEDP 
were reached (Giussani et al., 2012). The final filling volume of the syringe was established 
during preliminary experiments and use of the same volume throughout ensured any changes 
seen were due to changes in ventricular pressure. The heart was further allowed to stabilise 
for a minimum of 10 minutes. Data were acquired from the pressure transducer via the M-
PAQ data acquisition system and IDEEQ software (Maastricht Programable AcQuisition 
System, Maastricht, NL). 
 
Analysis of the Langendorff experiments was conducted on the LabChart software (Version 7, 
ADInstruments), following export of the IDEEQ files to a text document.  Baseline readings of 
several variables were taken (left ventricle end diastolic pressure LVEDP; left ventricle 
developed pressure, LVDP; maximal rate of contraction, dP/dt max; Cycle Duration; Diastolic 
and Systolic Cycle Duration; Tau, τ; Contractility Index; Fig.1.5). In addition, coronary Flow 
Rate (CFR) was measured gravimetrically by timing collection of 2mL of perfusate. In vitro 
responses to the sympathetic 1-adrenergic receptor agonist Isoprenaline (Sigma, UK, in the 
range 10-9 – 10-7M) and the parasympathetic cholinergic agonist Carbachol (Sigma, UK, in the 
range 10-8 – 10-6M) were then assessed by diluting these drugs into Krebs Buffer, warming 
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them, and administering them in increasing doses to the heart via the perfusing cannula, with 
care taken to match perfusion rate to coronary flow rate. To assess drug responses a 
representative baseline and response section of the trace were highlighted and used to derive 
measurements of heart rate (HR) and LVDP, which were then calculated as percentage 
changes from baseline. The heart was given time to return to baseline measurements 
between each incremental dose. 
 
 
 
 
 
Figure 2.4 Langendorff apparatus. Blue arrows indicate direction of flow. Krebs solution is pumped from the 
reservoir through an oxygenator and then to the heart via the compliance chamber. Perfusion of the heart occurs 
via the coronary arteries, and drainage via the pulmonary artery. A non-distensible balloon is inserted into the 
left ventricle and connected to a pressure transducer. All glassware is heated to maintain the heart at ca. 38°C 
(chicken body temperature). 
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. 
 
Figure 2.5. Calculation of cardiac parameters. LVDP is calculated as amplitude of contraction, LVEDP is the 
lowest pressure reached during diastole, cycle duration is calculated as time taken between the peak of each 
contraction, systolic duration is the time from the lowest pressure to the peak of the contraction curve, diastolic 
duration is time taken from the peak to reach the lowest pressure, τ is the time taken for the ventricle to relax 
by (1-1/e)%, contractility index is calculated as dP/dT max divided by maximum pressure generated.  
 
2.4 ASSESSMENT OF EX VIVO PERIPHERAL VASCULAR FUNCTION 
 
At day 19 of incubation, embryos were removed from their eggshells and euthanized by spinal 
cord transection. A 2nd order branch of the femoral artery (diameter ca. 300µm) was dissected 
into cold Krebs buffer (118.5mM NaCl, 25mM NaHCO3, 4.7mM KCl, 1.2mM MgSO4.7H2O, 
1.2mM KH2PO4, 2.5mM CaCl2, 2.8mM D-glucose; all reagents Sigma, UK). Two platinum wires 
of 40µm diameter were fed through a vessel section of ca. 2mm in length and used for 
mounting onto the jaws of each channel of a small vessel wire myograph (Multi-wire 
Myograph System 610M and 620M, DMT, Fig.1.6). Vessels were warmed to 37°C and bubbled 
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with 95%O2/5%CO2. After warming, vessels were normalized to the internal circumference 
needed to generate a pressure of k x 2.66kPa (mean blood pressure of the chicken embryo at 
day 19; Altimiras & Crossley, 2000), where  k=0.9. Preliminary results from our laboratory 
suggest that the k=0.9 normalisation factor used gives the maximum difference between 
passive and active tension in these vessels, and is a widely used normalisation value (Ping et 
al., 2014). Vessels then underwent a ‘wake-up’ procedure in which they were exposed to 
120mM KCl for 3 minutes, then responses to Norepinephrine (NE) 10-4 and Acetylcholine 
(ACh) 10-4 were assessed to check for endothelial and vascular smooth muscle integrity. To 
assess vasoconstrictor responsiveness, vessels were exposed to increasing doses of NE, 
Serotonin (5-HT), Phenylephrine (PE), and Endothelin-1 (ET-1; all from Sigma, UK) at 2min 
intervals (Fig.1.5). To assess vasodilator function vessels were pre-constricted with 64mM KCl 
to induce a sub-maximal constriction, then exposed to increasing doses of ACh to determine 
endothelium-dependent relaxation, or Sodium-nitroprusside (SNP) to determine vascular 
smooth muscle-dependent relaxation (Fig 1.6). To further assess the nitric oxide (NO) 
dependent component of the Ach response, vessels were treated with 5µm of the NOS 
inhibitor N(G)-Nitro-L-arginine methyl ester (L-NAME; Sigma, UK). Vessels were allowed to re-
establish baseline during 20 minutes between each dosing curve and washed repeatedly with 
Krebs solution after each dose-response curve to remove any residual drug from the bathing 
solution. 
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Figure 2.6 Small vessel wire myography apparatus. A. DMT 620M wire mygoraph with four separate channels 
for vessels, B. Individual channel; 2mm segment of vessel is attached via two 40µm platinum wires to the jaws, 
one side leads to a micrometer so diameter between the jaws can be adjusted to stretch/relax the vessel, the 
other side leads to a force transducer which records tension generated by the vessel in mN, C. Example of dose 
response curves.  Vessels are preconstricted with 64mM KCl then exposed to increasing doses of SNP and the 
%relaxation is calculated, similarly, vessels are exposed to increasing doses of PE and the total constriction at 
each dose is measured. 
 
To analyse vascular responses, a baseline was set at the start of each dosing curve, and then 
the ΔmN between baseline and the maximal response at each dose was measured. Dose-
response curves were plotted on GraphPad Prism 7. A best-fit curve was then fitted to the 
data, and the GraphPad program was used to generate a maximal response value, and area 
under or above the curve. The area above the curve for the Ach response curves for each 
vessel both before and after L-NAME treatment were calculated. The area above the post L-
NAME curve was taken as the NO-independent component of the Ach response, whilst the 
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area above the pre-L-NAME curve minus the area above the post L-NAME curve was taken as 
the NO-dependant component. 
 
2.5 ASSESSMENT OF EMBRYONIC CARDIAC STEREOLOGY 
 
Embryos were removed from their eggshells and anaesthetised with sodium pentobarbital 
(intraperitoneal 0.3mL of Pentoject, Animalcare Ltd., UK). The heart was exposed via the chest 
cavity and the right atrium cut.   A 27 gauge needle was inserted through the left ventricle 
and heparinized saline (Sigma, UK) followed by 4% paraformaldehyde (PFA; Sigma, UK) were 
flushed through this system via spontaneous contraction of the heart for approximately 15 
minutes at 40cmH2O (Tazawa, 2004). The hearts were dissected into PFA, and after 24 hours 
placed in Phosphate Buffered Saline (PBS, Sigma, UK), in which they were stored in at 4°C until 
assessment.  
 
Fixed hearts were sectioned into 1mm slices (Acrylic mouse heart slicer matrix with coronal 
section intervals; Zivic Instruments, UK). The slices were arranged in ascending order (apex 
side down) and photographed (Nikon camera). Images were analysed using the ImageJ 
software (version 1.46, National Institute of Health, USA). Gridlines of 0.5mm intervals were 
imposed on the images, and a mid-cardiac section was then chosen to analyse. Width 
measurements were made at points where the outer edges crossed the gridlines. To measure 
areas, a cross grid of 1mm2 was superimposed onto the images and crosses within each 
compartment (left ventricle, LV; left lumen, LL; right ventricle, RV; right lumen RL) were scored 
if the centre of the cross was on the compartment (Fig.1.7). Compartment areas were 
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assessed in all heart sections. Areas were then calculated according to the Cavalieri principle 
(Gundersen et al., 1988), whereby:  
Area (mm2) = A(ρ) ∗ ∑ P 
Volume (mm3) =  area ∗ section thickness ∗ no. of sections 
Where A(ρ) is the area associated with each point, and ΣP is the number of points in each 
compartment. 
 
The initial 5mm of the descending aorta was also dissected from the top of each fixed heart 
and processed in paraffin using a tissue processing machine (TP1020, Leica Biosystems, UK). 
The section of the aorta was then embedded into a paraffin block and sectioned at 5µm 
(RM2235 Vibratome, Leica Microsystems, UK). Consecutive sections (10) for each aorta 
segment were arranged onto a microscope slide, deparaffinised with xylene (Sigma, UK), and 
then stained with Gill’s Haemotoxylin (Sigma, UK). Slides were subsequently dehydrated by 
processing through 70%, 80%, and 100% ethanol (Sigma, UK). Aortic slices were quantified 
using NewCast software 2.0 (Computer Assisted Stereological Toolbox, Integrator software 
version 4.6.3.857, Visiopharm, UK) attached to a microscope (Leica DMI 6000B, UK).   Gridlines 
of 100µm were imposed on the images and measurements were made at gridline 
intersections with the outside of the blood vessels. To quantify area, a grid of points was 
placed over the image and values calculated using the Cavalieri principle, as described for the 
heart chambers above. 
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Figure 2.7 Cardiac Stereology. A. Perfusion fixed hearts were sliced into 1mm sections, and imaged.  Width 
measurements were made where a superimposed grid line met the outer edge of either ventricle; points falling 
on tissue were assigned a count of 1mm2, B. Isolated cardiomyocyte stained with Methyl Blue, width is measure 
across the nucleus, length is from furthest apart edges. 
 
To quantify cardiomyocyte nuclear density, two mid cardiac sections were selected from each 
fixed heart and dissected into ca. 1mm3 pieces. These tissues were transferred to histological 
cassettes and soaked in 100% ethanol overnight. The following day the tissues were exposed 
to 2 x 1-hour incubations in 100% ethanol, then soaked overnight in 100% butanol. On the 
third day the tissues were soaked in Technovit 7100 resin (Hereus Kulzer, DL), for 4 hours and 
then overnight. On the fourth day, the tissues were transferred to moulds and embedded in 
Technovit 7100 resin plus hardener and left at 40°C to set for several days. Tissues were then 
sectioned using a glass blade microtome (2050 Microtome, Reichart-Jung, DL) at a thickness 
of 30µm, then stained with Haematoxylin (Sigma, UK) for 15 minutes, agitated with water for 
30 minutes, stained with 0.15% basic fuchsine (Sigma, UK) for one minute, and dipped three 
times in tap water.  
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NewCast software 2.0 (Computer Assisted Stereological Toolbox, Visiopharm Integrator, 
software version 4.6.3.857) attached to a Leica DMI 6000B microscope, was again used to 
assess nuclear density. On 10x magnification, each tissue piece was traced to define a region 
of interest. The software was then used to set up a meander sampling of approximately 40 
counting frames of 400µm2. For this sampling, the central 10µm of each 30µm thick section 
was assessed. Using the counting frame, nuclei within the frame or touching the top or right 
lines were counted, whilst those outside the frame or touching the bottom or left lines were 
excluded. The top right and bottom left corners were used to count tissue area.  If the corner 
fell on cardiac tissue, then it was assigned a count of 200 µm2 (half of the counting frame).  If 
it did not fall on tissue, then no count was assigned. This process was repeated until at least 
100 nuclei were counted per heart. These results could then be used to determine numerical 
density of cardiomyocyte nuclei for each heart using the following equation: 
nuclear density (μm−3) =  
∑ nuclei
10 ∗ 200 ∗ ∑ P
 
Where nuclei is the nuclei counted in that heart, and P is the ventricular tissue points assigned 
in the heart (10 µm is the height of the optical dissector, whilst 200 µm2 is the area associated 
with each point of ventricular tissue). These results can then further be used to estimate total 
number of nuclei in the left ventricle by multiplying nuclear density (µm-3) by total left 
ventricular volume (mm3). 
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2.6 ASSESSMENT OF ISOLATED CARDIOMYOCYTES 
 
On day 19 of incubation embryos were euthanised by spinal cord transection, and the heart 
was subsequently exposed in the thoracic cavity.   Heparinised saline (0.4mL; Sigma, UK), 
followed by saturated KCl solution (0.2mL; Sigma, UK) were injected into the heart via a 24-
gauge needle into the aorta to flush any remaining blood clots and ensure the cardiomyocytes 
are all in diastole. Hearts were then excised and mounted onto a modified Langendorff 
preparation. In this set up the heart was also cannulated via the aorta, and initially perfused 
with Tyrode’s buffer (140mM NaCl, 5nM KCl, 1mM MgCl2, 10mM Glucose, 10mM HEPES, pH 
adjusted to 7.35, all reagents Sigma, UK) until bleaching of the ventricles occurred, 
demonstrating that the majority of blood had been flushed from the heart. After 10 minutes 
of perfusing the heart with Tyrode’s, the solution was switched to Tyrode’s containing 
160Uml-1 of type-II collagenase (Gibco, UK) and 0.78Uml-1 of type-XIV protease (Sigma, UK). 
This enzymatic solution was allowed to perfuse the heart for 12-15 minutes, until digestion 
of the heart was apparent, but it still had enough integrity to remain attached to the perfusing 
cannula. The heart was then perfused further with Krebs buffer (as per Section 1.3) for 10 
minutes to wash out any remaining active enzymes. Once this had been completed, the heart 
was removed from the cannula and placed into a Falcon tube containing 5mL of Krebs buffer 
and gently inverted several times to dislodge the dissociated cardiomyocytes. PFA was then 
added to make the solution up to a final concentration of 4% PFA, then stored at room 
temperature. 
 
To assess both nuclearity and cardiomyocyte length or width of, solutions were stained with 
50% Methyl Blue stain (Sigma, UK) and visualised under a light microscope (Leica DMI 
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6000B, UK). The NewCast software (Computer Assisted Stereological Toolbox, Visiopharm 
Integrator system version 4.6.3.857) was used to randomly search each 15µL solution 
sample to measure 50 randomly chosen cardiomyocytes per heart. Cardiomyocytes were 
assessed for nuclearity and both thickness (as defined as the central point through the 
mononucleated nucleus, or directly between the binucleated nuclei), and length (Fig.1.7.B). 
Estimated cardiomyocyte volumes were then calculated as per Österman et al.(2015) using 
the mathematical approximation of two cones with cone base width equal to cardiomyocyte 
width, and cone length equal to half of the cardiomyocyte length:  
volume =  
2
3
π
lw
4
2
 
 
2.7 ASSESSMENT OF CARDIO-PULMONARY MOLECULAR PATHWAYS  
 
2.7.1 Protein Extraction 
 
To freeze tissues for molecular analysis, organs were dissected immediately following 
euthanasia of the animal via spinal cord transection, then weighed and snap frozen in liquid 
nitrogen. The samples were then stored at -80°C. For samples of frozen cardiac tissue, only 
the ventricles were frozen. For lung, liver, and brain samples the entire organ was frozen. 
 
Prior to molecular extraction, frozen tissue was sectioned on dry ice using a razor blade. The 
tissue was then aliquoted into roughly 50mg portions in Eppendorf tubes and again stored at 
-80°C.  Extraction of protein was conducted using cell lysis buffer (10x solution, Cell Signalling, 
UK) with addition of a protease inhibitor cocktail (cOmplete Mini, EDTA-free, Roche 
Diagnostics, Dl). One aliquot from each animal was transferred to a lysing matrix tube (Lysing 
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Matrix A, MP Biomedicals, UK) and 500µL of lysis buffer was added.  These samples were then 
homogenised using a tissue homogeniser (MagNA Lyser, Roche Diagnostics, Dl) for 20 
seconds, they were then placed in ice for 2 minutes before being homogenised for a further 
20 seconds. Samples were then centrifuged at 4°C, 13000rpm, for 5 minutes (Thermo 
Scientific, Dual rotor, UK). The supernatants were collected into new Eppendorf tubes and 
assayed for protein content. 
 
A BCA assay was conducted to assess protein levels in extractions. Neat protein samples were 
diluted to a concentration of 1 in 25, and then 25µL of each sample was loaded in duplicate 
into a 96 well plate, along with a series of Bovine Serum Albumin (BSA; Sigma, UK) standards. 
Assay solution (200µL of) was then added to each well. Assay solution was prepared by mixing 
Bichorionic acid (Sigma, UK) and Copper Sulphate (Sigma, UK) in a 50:1 ratio. The plate was 
allowed to incubate at room temperature for 10 minutes before being read at 562nm on an 
automatic plate reader (ELx800, BioTek, UK). The standard curve was then used to extrapolate 
concentrations in the diluted, and thus in the neat samples. 
 
2.7.2 Western Blots 
 
Western blotting was used to assess levels of proteins of interest in these samples. The 
reagents used to dilute the protein samples, make the acrylamide gels, running and transfer 
buffers are all listed in Table 1.1 (all reagents from Sigma, UK). Gels were set between two 
glass plates, with a 21-space plastic comb being inserted into the stacking gel prior to setting. 
Once set, the gels were placed into an electrophoresis chamber (ATTO AE6500, JP), which was 
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subsequently filled with running buffer. Protein samples in SDS buffer (Table 1.1) were boiled 
at 90°C for 10 minutes then allowed to cool. Samples were then loaded into the gel wells at a 
total protein amount of 15µg per well, and a molecular marker ladder (Page-Ruler Plus, 10-
250KDa, Thermo-Scientific, UK) was added to the first and final wells. Gels were run at 110V, 
12mA for 4 hours. 
 
Samples were then transferred from the agarose gel to a membrane (Polyvinyl difluoride 
Immobilin-P membrane, Millipore, USA), using a semi-dry transfer apparatus (Bio-Rad semi-
dry transfer pack, Bio-Rad Laboratories, UK). Three pieces of filter paper soaked in transfer 
buffer (Table 1.1) were placed onto the transfer apparatus. The membrane was activated in 
methanol for 1 minute, then placed on top of the filter paper stack. The gel was removed 
from the glass plates and placed on top of the transfer membrane, followed by three further 
transfer buffer-soaked pieces of filter paper. A roller was used to ensure no air bubbles were 
left between the membrane and the gel. The transfer apparatus was run for 90 minutes at a 
current of 200mA. Once this was completed the membrane was removed, stained with 
Ponceau S solution (Sigma, UK) for 5 minutes, and an image was taken. Subsequently, the 
membrane was washed in TBST (Table 1.1), then soaked for 1 hour in blocking buffer (Table 
1.1) at room temperature prior to antibody staining. Primary antibodies were diluted in either 
5% BSA, or 5% milk powder (Marvel Original, Premier Foods, UK) and the membrane was 
incubated overnight at 4°C. Secondary antibody incubation was performed at room 
temperature for 1 hour. TBST was used to wash the membranes between blocking, primary 
and the secondary incubation steps. Antibodies were detected by using West Pico 
chemiluminescent substrate (Thermo Scientific, UK), then exposing the membranes to a 
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photo-sensitive film (GE Healthcare Amersham Hyperfilm ECL, Fisher Scientific, UK). The 
intensity of the bands was assessed using ImageJ software (version 1.46, National Institute of 
Health, USA), and normalised to the total protein expression determined by the Ponceau 
stain. Antibodies used are listed in Table 1.2. 
 
Buffer/Gel Components 
SDS Gel Loading Buffer 200mM Tris-Base (pH adjusted with HCl to pH 6.8) 
400mM Dithiothreitol 
8% Sodium dodecyl sulphate (SDS) 
40% Glycerol 
a few crystals of Bromophenol blue. 
Stacking Gel 1.5M Tris-Base (pH 6.8) 12.5mM 
30% Acrylamide/Bis (19:1 ratio) 5% 
10% SDS 1% 
10% Tetramethylethylemediamine (TEMED) 0.005% 
10% Ammonion Persulfate (APS) 0.05% 
Running Gel 1.5M Tris-Base (pH 8.8) 37.5mM 
30% Acrylamide/Bis (19:1 ratio) 10.05% 
10% SDS 1% 
10% TEMED 0.005% 
10% APS 0.05% 
Running Buffer 25mM Tris-Base 
250mM Glycine 
0.5% SDS 
Transfer Buffer 39mM Glycine 
48mM Tris-Base 
0.037% SDS 
20% Methanol 
TBS-T Wash Buffer 20mM Tris-Base 
0.15M Sodium Chloride 
pH adjusted with HCl 
0.1% Tween-20 
 
Table 2.1 Western blot buffer and gel reagents. 
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Target Dilution Antibody 
ERK1/2 1:1000 Cell Signalling Technology 9102 
Phosphorylated ERK1/2 1:1000 Cell Signalling Technology 9101S 
SAPK/JNK 1:1000 Cell Signalling Technology 2402S 
Phosphorylated SAPK/JNK 1:1000 Cell Signalling Technology 99251S 
Hsp27 1:1000 Cell Signalling Technology 2402S 
Hsp70 1:2000 Cell Signalling Technology 4872 
PDI 1:1000 Abcam ab3672 
Hsp60 1:2000 Abcam ab46798 
Cleaved caspase-3 1:1000 BD Biosciences 610539 
Caspase-3 1:1000 Abcam ab90437 
DNPH 1:200 Chemicon Oxyblot 
GR 1:1000 Santa Cruz Biotechnology, Inc. sc-393232 
 
Table 2.2 Antibodies used for western blot. 
 
2.7.3 RNA Extraction 
 
A second aliquot of frozen cardiac ventricular tissue was used to extract RNA for gene 
expression analysis. Extraction was completed using Qiagen RNeasy Mini Kit (Qiagen, UK). 
Tissue was disrupted using an electrical homogeniser (Polytron PT1200, Kinematica, UK) and 
RLT Buffer from the Qiagen kit (600µL buffer to 30mg tissue). The lysate was centrifuged for 
3 minutes at 12,000g and the supernatant was moved to fresh Eppendorf tubes. Ethanol 
(70%) was added to the supernatant and mixed by pipetting, and then 700µL of the sample 
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was transferred to a RNeasy Mini spin column in a collection tube. Tubes were centrifuged 
for 15 seconds at 8,000g and the flow through was discarded. Then, 700µL RW1 was added 
to the spin column and the centrifuge step was repeated, again with flow-through discarded. 
This was further repeated with 500µL Buffer RPE, and then a further 500µL Buffer RPE. The 
spin column was then transferred to a new collection tube, 50µL of RNase-free water was 
added directly to the spin column membrane, and then the tubes were centrifuged at 1 
minute for 8000g to elute the RNA. This final step was repeated due to large amounts of tissue 
being used. Once extracted, the RNA samples were kept on ice and for RNA concentration, 
and quality of extracted RNA using a NanoDrop spectrophotometer (Thermo Fisher Scientific, 
UK). 
 
The synthesis of cDNA for real-time quantitative PCR (RT-QPCR) was achieved using a First 
Strand cDNA Synthesis Kit (Thermo Fisher Scientific, UK). RNA samples were diluted to give a 
total amount of 20ng, 1µL random primer, 4µL of 5x Reaction Buffer, 1µL of RiboLock RNase 
Inhibitor, 2µL 10mM dNTP Mix, and 1µL RevertAid M-MulVRT were added and then total 
volume was adjusted to give a 20µL reaction volume in a PCR tube. Tubes were then gently 
mixed. The synthesis reaction was carried out in a thermocycler (S1000, BioRad, UK).  Samples 
were heated to 25°C for 5 minutes then 42°C for 60 minutes, and finally heated to 70°C for 5 
minutes to terminate the reaction. cDNA was stored at -20°C. 
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2.7.4 Real-time Quantitative PCR 
 
Q-PCR primers were designed using Primer3 software (National Institutes of Health, USA), 
based on the Gallus gallus reference genome, then ordered from the Sigma Simple Primer 
ordering system. Primers were diluted to 100µM combined forwards and reverse pair stock 
solutions. The RNA primers used are listed in Table 1.3. Prior to running with experimental 
samples, primers were tested on control cDNA to ensure there was an amplification efficiency 
of 90-110%, and that a single amplification product was present (Fig. 1.8). SYBR Green PCR 
master mix (Thermo Fisher Scientific, UK) was added to template cDNA, 30µL RNA primers 
(forward and reverse pair), and made up to a 6µL total of reaction volume. All samples were 
run in duplicate, and a minimum of two house-keeper genes were run for each sample. A 
QuantStudio 7 Flex (Applied Biosystems, UK) Q-PCR machine was used to run the reaction, 
completing a hold stage of 2 minutes at 50°C then 10 minutes at 95°C, followed by 40 cycles 
of 15 seconds at 95°C then 1 minute at 60°C.  Finally, a melt curve was produced from the 
reaction products by heating to 95°C for 15 seconds, allowing to cool to 60°C for 1 minute, 
then a further 15 seconds at 95°C. Threshold levels for Ct value determination were set 
manually following the Q-PCR reaction, and automatic analysis was carried out by the Q-PCR 
machine. Samples were discarded from the analysis for a gene if the Ct replicate values had a 
greater than 0.5 standard deviation difference. Other criteria for exclusion from analysis 
included no amplification, multiple peaks in melt curve, or other machine-based errors that 
led to no Ct value being produced. To analyse expression levels the ΔΔCt method was 
employed (Livak & Schmittgen, 2001).   Briefly, the difference between Ct values of the gene 
of interest in a control vs. experimental condition was calculated, and then compared to the 
difference between Ct values in a housekeeper gene between the control and experimental 
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condition to give a ΔΔCt value. A value for expression fold change vs. control can be calculated 
using the following equation: 
fold change(vs. control) =  2(−∆∆Ct) 
 
 
 
Table 2.3 RNA Primers for RT-QPCR. 
 
 
 
Target Gene Forward Primer Reverse Primer 
sdha (housekeeper) TCTGTCCATGGTGCTAATCG TGGTTTAATGGAGGGGACTG 
β-actin (housekeeper) TGCTGTGTTCCCATCTATCG TTGGTGACAATACCGTGTTCA 
gapDH (housekeeper) CCTCTCTGGCAAAGTCCAAG CAACATCAAATGGGCAGATG 
catalase ACTGGTGCTGGCAACCC ACGTGGCCCAACTGTCAT 
GPx TTGTAAACATCAGGGGCAAA TGGGCCAAGATCTTTCTGTAA 
eNOS GGGCTCTGCGGTTCTCTG CACAGAAGGTCTCGCAGGC 
P38 CGAAATGACCGGCTACGTGG CACTTCATCGTAGGTCAGGC 
SOD2 CTTCCTGACCTGCCTTAC CGTCCCTGCTCCTTATT 
MKK3 CTACTTGGTGGACTCGGTGG CGACTTCACGTTGTAGCCCT 
P53 GTGGGCTCTGACTGTACCAC GCCCTCCAGTGTAAGGATG 
P16 TCCTCCTCCTACCAGAGATG TGTACCTGAGGCTCCTTGTC  
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Figure 2.8 PCR primer optimisation. A. Primers were tested using control cDNA to ensure that only one product 
was present in the melt curve. B. Primer efficiency was tested by using various amounts of control cDNA and 
measuring amplification, a threshold was manually set in the linear region of the amplification curve (in red), C. 
Average Ct values from the amplification plot in B. are plotted against log[cDNA] to determine the amplification 
efficiency, D. Primer efficiency can then be calculated from the slope of the Ct vs log[cDNA] graph.   An efficiency 
of 90-110% is required. 
 
2.8 ASSESSMENT OF EMBRYONIC LUNG MATURATION 
 
Following perfusion fixation of the embryo (Section 1.5), upper thoracic embryonic lungs were 
also dissected into 4% PFA, then changed to PBS after 24 hours. Lung tissues were transferred 
to histological cassettes, then soaked in 100% ethanol overnight. The following day, samples 
were transferred to fresh 100% ethanol for 1 hour, then further 100% ethanol for another 
hour, before being soaked in 100% butanol overnight. On the third day, samples were soaked 
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in molten paraffin for 3 hours using a wax-processing machine (Section 1.6). Samples were 
then embedded in paraffin with the posterior side of the lungs at the base of the embedding 
mould. Tissues were then sectioned using an ultramicrotome at a thickness of 8µm, floated 
on warm water (40°C) and then allowed to dry on glass slides. Sectioning began at the 
posterior end of the embedded lungs, 10 tissue sections were taken, with the 7th and 8th 
chosen for analysis. 
 
Once dry, slides were stained and imaged using the same computer software (Section 1.6). 
Using a protocol adapted from Bjørnstad et al. (2014), for each animal, the outlines of the left 
and right lung lobes were traced and the software then produced a random sampling within 
that area. A total of 20 measurements were made for: parabronchial atrial diameter, atrial 
septum thickness, air capillary diameter, and the distance between the air capillary and the 
nearest blood vessel – the diffusion distance (Fig.1.9).  In addition, 5 measurements were 
made of thickness of the gas exchange zone (Fig 1.9).  
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Figure 2.9 Lung Histology Measurements. Diagrammatic representation of gas exchange unit in the avian lung 
next to histological images of stained lung sections; A – bronchiole, B - atrium into air capillaries, C - branching 
air capillaries, D – closely associated vasculature, E – thickness of gas exchange area wherein air capillaries and 
vasculature are in close association. 
 
2.9 POWER CALCULATIONS & STATISTICS 
 
Appropriate power calculations have been established to determine the minimum sample 
size required to achieve statistical significance from previously published data in the chicken 
embryo using similar outcomes and in a similar number of experimental groups. The 
variable which has been found to have the smallest mean value difference between the 
experimental groups is; heart rate for isolated organ work, and cardiac wall:lumen area ratio 
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for cellular techniques. Power calculations were conducted using G*Power software 
(Heinrich Heine Universitӓt, Dusseldorf, DL)(Faul et al., 2007). Calculations comparing these 
variables between 4 animal groups are shown in Table 2.4 below: 
 
 Heart Rate (isolated 
organ) 
Wall:Lumen ratio 
(stereology) 
Difference between means 3.3 2.9 
Standard Deviation 1.5 1.5 
Power (95% confidence when α=0.05) >0.8 >0.8 
Minimum Required Sample Size 8 8 
 
Table 2.4 Power Calculations 
 
Two additional animals were generated where possible per group to compensate for 
experimental failure, such as increased mortality, cardiac arrhythmia for the isolated organ 
work, or provision of sufficient material to run experiments in duplicate for the cellular and 
molecular studies. 
 
The resulting experimental groups and there use in this thesis are show below in Fig.2.10. 
There were 40 eggs in each treatment group, of which 10 each were used for the molecular, 
stereology, biometry & isolated organ, and cardiomyocyte isolation studies. New control 
groups were used on each occasion (Chapters 3, 4 & 5) and new groups for all the other 
experimental treatments except dexamethasone, where results from the original group of 
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40 eggs were used in the later studies (see Fig.2.10). For some experimental groups and 
techniques, an n-number of 8 was not possible due to practical restrictions, for example the 
number of available wells on western blot gel. All n-numbers are listed in figure legends. For 
some experimental groups and techniques, an n-number of 8 was not possible due to 
practical restrictions, for example the number of available wells on western blot gel. All n-
numbers are listed in figure legends. 
 
 
 
 
Figure 2.10 Use of animal groups. A. Each experimental group was generated to give 40 embryos to establish 
all outcomes, B. Use of experimental groups in each chapter, where different colours represent different egg 
cohorts.  
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Due to limitations of incubation equipment and cost, it was not possible to repeat the Dex 
group for chapters 4 & 5. However new control and Beta eggs were generated for chapters 
4 & 5, to ensure no seasonal or temporal effects on embryo growth. As eggs were 
purchased from a research egg supplier, it is not known whether eggs are from the same or 
different chickens throughout the experiments. Throughout the various chicken embryo 
projects conducted in our laboratory we have seen no significant changes over time on 
embryo growth, or isolated organ parameters.  
 
In chapter 3, statistical significance was calculated via use of a parametric t-test, whereby 
significance was set at P=0.05 and denoted by: * P<0.05, ** P<0.01, *** P<0.001, 
****P<0.0001. For isolated organ drug response curves a two-way ANOVA with Tukey post-
hoc test was used, again with P=0.05. If a significant interaction was reported (between 
dose and treatment group) then multiple comparisons were examined and denoted by * 
P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001, directly above the corresponding dose. 
 
In chapters 4 & 5, statistical significance was calculated via a one-way ANOVA with Tukey 
post-hoc test with significance set at P=0.05. If a significant interaction was reported 
(between dose and treatment group) then multiple comparisons were examined and 
denoted using letters to represent statistically different groups (i.e. if a letter is shared 
between any 2 experimental groups, then those groups are not statistically different from 
each other). For isolated organ drug response curves a two-way ANOVA with Tukey post-hoc 
test was used, again with P=0.05. If a significant interaction was reported (between dose 
and treatment group) then multiple comparisons were examined and denoted by * P<0.05 if 
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significantly different to the control value, and † P<0.05 if significantly different to the Dex 
value. 
 
All statistical tests were conducted using GraphPad Prism 7 software (Graphpad Software, 
CA, USA). 
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CHAPTER 3: DEXAMETHASONE IN THE CHICKEN EMBRYO 
3.1 INTRODUCTION 
Since initial clinical trials in 1972, antenatal glucocorticoid therapy (AGT) has become a 
standard treatment for obstetricians, and has significantly reduced neonatal mortality and 
morbidity (Liggins, 1969)(Roberts & Dalziel, 2006). Numerous clinical studies have been 
conducted on AGT, concluding that there is a significant associated decrease in several 
neonatal morbidities including respiratory distress syndrome (RDS), intraventricular 
haemorrhage (IVH) and necrotising peritonitis (NEC) (Sotiriadis et al., 2009; Brownfoot et al., 
2013; Crowther et al., 2015; Roberts et al., 2017).  
 
Dexamethasone (Dex) is one of the most popular glucocorticoids of choice for AGT in the 
majority of countries, primarily due to its wide availability for other medical treatments and 
its low cost per course (Lawn et al., 2012). Dex is a synthetically produced analogue of 
endogenous glucocorticoid cortisol (Fig.3.1). It has an added Fluoride atom at the 9 C position, 
which is thought to enhance its biological activity. Insertion of an additional 1,2 carbon-
carbon double bond selectively augments glucocorticoid over mineralocorticoid activity, 
decreasing the rate of metabolic clearance and increasing the biological half-life of in plasma 
(Buttgereit et al., 1999).  Mineralocorticoid activity is further elisminated by methylation at 
the 16 C position (He et al., 2014). Thus, Dex has a negligible mineralocorticoid activity but a 
glucocorticoid potency approximately 25-fold that of cortisol (Parker & Schimmer, 1996) and 
the half-life for clearance from the plasma of fetal sheep is extended by approximately 6-8 h 
compared to cortisol (Jellyman et al., 2009a).  
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Figure 3.1 Structure and dosing regimen of Dexamethasone phosphate for use in AGT.  
 
 
In addition to AGT, synthetic glucocorticoids, particularly Dex, may be administered to the 
neonate in the immediate post-natal period to treat Broncho-pulmonary dysplasia (BPD; 
Davidson et al., 2017). There is no consensus of dosing regimen for post-natal Dex 
administration. Initially very high doses were used, however these were shown to have 
negative effects and hence were advised against (Mammel et al., 1983; Kobaly et al., 2008; 
American Academy of Pediatrics, 2010). Since then, the DART study indicated no strong 
association with long term consequences when low-dose Dexamethasone treatment was 
trialled delivering 0.89mgkg-1 over a 10-day course (Doyle et al., 2007). This lower dose is the 
most commonly used clinically in the new-born period. 
 
Despite the clear benefits of AGT, there is mounting concern about potential damaging effects 
on the fetal developing cardiovascular system and cardiovascular function in adulthood. In 
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the neonate and adult, the most commonly reported long term cardiovascular effect is 
dysregulation of blood pressure (Lindsay et al., 1996). Sheep exposed in utero have been 
reported to have elevated blood pressure at 6 months of age, and an attenuated baroreflex 
(Shaltout et al., 2012; Davis et al., 2006). In human clinical follow-up studies, both systolic and 
diastolic blood pressure are increased in youths at 14 years of age (Cheong et al., 2014). In 
both animal models and in human clinical studies there are several reported changes directly 
to the vasculature such as endothelial dysfunction (a well-known harbinger of future 
cardiovascular disease), changes in aortic arch stiffness, and blood pulsatility (Docherty et al., 
2001; Pulgar & Figueroa, 2006; Kelly et al., 2012). Direct cardiac effects have been shown 
including transient hypertrophy, altered autonomic responses, impaired Starling mechanism, 
systolic dysfunction, and increased end diastolic volume and pressure (Yunis et al., 1999; 
Dodic et al., 2001; Niu et al., 2013).  
 
 
In order to assess the effects of AGT on the fetus, and to isolate mechanistic changes leading 
to altered cardiovascular function, it was vital to find a suitable model system. The chicken 
embryo model is unique in allowing us to research the direct effects of a clinically relevant 
treatment of Dex on the fetus, without the confounding influence of the mother and placenta, 
as the embryo develops in isolation within the egg. This is important as there is evidence for 
maternal cardiovascular changes in the acute period following dexamethasone 
administration (Elwany et al., 2018), and to changes in placental function (Audette et al., 
2014). Of added value, cardiac maturation is similar in the chicken embryo to that of the 
human fetus (Sissman, 1970; Marcela et al., 2012). Studies in our laboratory have previously 
demonstrated that it is possible to dose the chicken embryo directly via application of 
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aqueous solution to the chorioallantoic membrane, and that drugs applied in this manner are 
readily taken up into the fetal circulation and tissues (Itani et al., 2015). The chicken embryo 
has the final advantage of being reasonably large (average weight is ca. 25g (Itani et al., 2015) 
), and so amenable to various ex vivo cardiovascular tests, including investigation of cardiac 
function via an isolated Langendorff preparation, and assessment of peripheral vascular 
function via small vessel wire myography. 
 
Therefore, in this chapter we have addressed the hypothesis that Dex administration at day 
14 of incubation would result in cardiac and peripheral vascular dysfunction by the end of 
incubation (day 19). To address this hypothesis, there were six objectives: 
1. To develop a clinically relevant model of antenatal Dex treatment in the chicken 
embryo; 
2. To investigate the effects of Dex treatment on embryonic survival and growth of the 
chicken embryo; 
3. To investigate the effects of d Dex treatment on the cardiac function and structure of 
the chicken embryo; 
4. To investigate the effects of Dex treatment on peripheral vascular function in the 
chicken embryo; 
5. To investigate the molecular pathways induced by Dex treatment in the chicken 
embryo; 
6. To investigate the effects of Dex on lung maturation in the chicken embryo. 
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3.2   METHODS 
3.2.1 Experimental Protocol 
 
Details of the methodology are presented in Section 2.  In brief, all procedures were 
performed under the U.K. Animals (Scientific Procedures) Act 1986 and were approved by the 
Ethical Review Board of the University of Cambridge. Fertilised Bovans Brown chicken eggs 
were weighed, irradiated with UV light, and placed into a normoxic incubator at 38°C and 45% 
humidity for 19 days (term is 21 days; see Section 2.1.). Eggs were dosed with dexamethasone 
phosphate in aqueous solution, or water on day 14 of development via injection through a 
small hole in the shell (situated above the air sac) onto the chorioallantoic membrane, as 
previously described (Itani et al., 2015).  
 
The Dexamethasone dose used in this study was 0.1mgkg-1. AGT was administered at two 
thirds of gestation, which is equivalent to 24 weeks in human pregnancy; a relevant, early 
period at which glucocorticoids can realistically be administered in the clinical setting (Ballard 
& Ballard, 1995; Roberts et al., 2017).  
 
3.2.2 Assessment of Embryonic Growth 
 
On Day 19 of incubation, embryonic growth was assessed using a high precision calliper 
(Mitutoyo 500-181-20, U.K.) to determine embryonic lengths. Embryo mass and mass of the 
eggshell, yolk, extra tissues (chorioallantoic membrane and connected blood vessels), and any 
remaining liquid was measured and recorded. The ratio of partitioning of resources was 
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calculated as embryonic tissue mass/extra-embryonic tissue mass. Crown-rump length, head 
diameter were recorded (Section 2.2). Individual organs were also dissected and weighed. 
 
3.2.3 Assessment of Cardiac Structure & Function 
 
At day 19 of the incubation period, 10 embryos per group were anaesthetised with sodium 
pentobarbitate (0.3mL of Pentoject (Animalcare Ltd., York, UK; intraperitoneal), then 
perfusion fixed with paraformaldehyde (Section 2.5) at 2.66kPa (embryonic day 19 blood 
pressure (Altimiras and Crossley, 2000) ) inserted into the left ventricle via a cannula. Fixed 
hearts were sectioned into 1mm slices and photographed. Areas of cardiac compartments in 
each section were counted, and a mid cardiac section was chosen to measure widths. 
Volumes were then calculated as per section 2.5. The initial 5mm of the descending aorta was 
dissected from the top of each fixed heart and processed in paraffin. Consecutive sections 
(n=10) for each aorta were arranged onto a microscope slide, de-paraffinised, and then 
stained with Gill’s Haemotoxylin. Slides were subsequently dehydrated and imaged (Section 
2.5). Thicknesses and areas were then counted. 
 
Cardiomyocytes were also isolated from hearts of a different cohort of day 19 embryos 
(Section 2.6). The coronary vasculature was perfused with collagenase and protease solution. 
After 10 minutes, the hearts were perfused with Kreb’s buffer to remove enzymes, and then 
suspended in buffer for 40 minutes. Cells were stored at 4% PFA. Cardiomyocyte suspensions 
were mixed with 10% methylene blue in a 1/1 ratio and visualised under a light microscope 
(Section 2.6). Cell nuclearity of 300 random cardiomyocytes per heart was assessed, and 
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measurements of length and width were taken from 50 random cardiomyocytes. Cell volumes 
were then calculated. 
 
To assess ex vivo cardiac function, hearts from a different cohort were rapidly excised and 
placed into icy Krebs’ Buffer solution. The aorta was cannulated onto a 19-gauge blunt needle 
and mounted onto the Langendorff apparatus. Pressure recordings were subsequently made 
(Section 2.3). In brief, following a period of normalisation, a small non-distensible balloon 
made from saran wrap and connected to a pressure transducer, was introduced through the 
left atrium into the left ventricle. The balloon was then filled with water in 5µL increments 
until a smooth baseline recording was established. Baseline recordings were made and 
Coronary Flow Rate (CFR) was assessed. In vitro responses to the sympathetic agonist 
Isoprenaline (Sigma-Aldritch, in the range 10-9 – 10-7) and the parasympathetic agonist 
Carbachol (Sigma-Aldrich, in the range 10-8 – 10-6) were then assessed by administering via 
the perfusing cannula. Analysis of the Langendorff experiments was conducted on the 
LabChart software (Version 7, ADInstruments).  
 
3.2.4 Assessment of Peripheral Vascular Function 
 
A 2nd order branch of the femoral artery was dissected into cold Krebs solutions and then 
2mm sections were mounted onto a wire myograph (Section 2.4). Vessels were maintained 
at 38°C in Krebs solution, and were aerated with 95% O2/5% CO2 gas. To assess 
vasoconstrictor responses vessels were exposed to increasing doses of NE, 5-HT, PE, and ET-
1 at 2-minute intervals. To assess vasodilator function vessels were pre-constricted with K+, 
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then exposed to increasing doses of Ach, or SNP. To assess the NO dependent component of 
the Ach response, vessels were treated with 5µM L-NAME.  
 
3.2.5 Assessment of Molecular Pathways in the Heart 
 
Frozen heart tissue was powdered on dry ice, and separated into 50mg aliquots, then stored 
at -80°C. Extraction of proteins was conducted in TK lysis buffer (Section 2.7.1). For Western 
blot analysis, protein extracts were separated on a 10% agarose gel, then stained with primary 
antibody and secondary antibodies (Table 2.2). Gel bands were then quantified as described 
in section 2.7.2. 
 
A further set of frozen tissue aliquots were used to conduct RNA extraction using a Quiagen 
RNEasy mini kit (Section 2.7.3). RNA samples were then converted into cDNA libraries using 
Quiagen Reverse Transcriptase kit. DNA primers to various mRNAs of interest were designed 
and tested.  Only primers that gave a single peak, with a clear dose-dependent relationship 
were used further (table 2.3). mRNA expression analysis was then conducted as per section 
2.7.4.  
 
3.2.6 Assessment of In Vivo Oxidative Stress 
 
In this chapter, further experiments were undertaken to assess in vivo production of 
mitochondria-derived reactive oxygen species using the molecular probe MitoB, kindly 
supplied to us by Professor Michael Murphy of the Mitochondrial Biology Unit, Addenbrookes 
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Hospital, Cambridge.  The probe, MitoB, comprises a triphenyl-phosphonium (TPP) cation 
driving its accumulation within mitochondria, conjugated to an arylboronic acid that reacts 
with H2O2 to form a phenol, MitoP. Quantifying the MitoP/MitoB ratio by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) enables measurement of a 
weighted average of mitochondrial H2O2 that predominantly reports retrospectively on tissue 
mitochondria of the living chicken embryo (Cochemé et al., 2012).   Therefore, on day 19 of 
incubation, a subset of embryos were dosed with 20nmol MitoB in aqueous solution. Precisely 
one hour after treatment, embryos were killed and heart, brain, liver, and skeletal muscle 
were snap frozen in liquid nitrogen. To extract the molecules for analysis by mass 
spectrometry; 50mg of tissue was homogenised in pH 7 Tris buffer (Bullet Blender, Next 
Advance, New York, USA), then 600µL of acetonitrile (ACN, Romil, Cambridge, UK) mixed with 
0.1% formic acid (Sigma, Gillingham, UK). An internal standard was added, then samples were 
centrifuged at 16,000g for 10 minutes and the supernatant collected into fresh Eppendorf 
tubes. A further 500µL of 95%ACN/0.1% formic acid was added to the remaining pellet then 
the previous step repeated, and the two resulting supernatants combined. The tubes were 
left overnight to evaporate in a SpeedVac, and the following day 170µL of 20%ACN/0.1% 
formic acid was added and the centrifugation step repeated. The supernatant was then 
filtered (0.22µm PVDF filters, Millipore, Watford, UK), into mass spectrometry autosampler 
vials (Thermo Fisher Scientific, Loughborough, UK). Simultaneously to the experimental 
sample extraction, standard curves for both MitoB and MitoP were generated by spiking 
control tissue with known amounts of MitoB (0, 10, 25, 100, 250, 1000pmol) or MitoP (0, 1, 
5, 10, 100pmol). The MitoB and MitoP contents of the samples were then analysed on an I-
class Acquity UPLE attached to a Xevo TQ-S triple quadruple mass spec (Waters, Milford, USA). 
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The mass spectrometry and analysis were conducted by Dr. Angela Logan (Mitochondrial 
Biology Unit, Addenbrookes Hospital, Cambridge, UK). 
 
3.2.7 Assessment of embryonic lung maturation 
 
Perfusion fixed lungs were embedded in paraffin, then sectioned into 8µm sections with an 
ultramicrotome (Section 2.8). Slides were stained with haemotoxylin and eosin (Section 2.6), 
then imaged. In tissue isolated from each embryo, 20 measurements of parabronchial atrial 
diameter, atrial septum thickness, air capillary diameter, and distance between air capillary 
and nearest blood vessel (diffusion distance), and 5 measurements of thickness of gas 
exchange zone were taken. 
 
3.2.8 Statistics 
 
All results except for dose-response curves were compared for statistical significance using 
the Student’s t test for unpaired data. Dose-response curves were assessed using a mixed-
model two-way ANOVA with the Tukey post hoc test. Statistical tests were conducted on 
GraphPad Prism 7 (Graphpad Software, CA, USA) software and significance was accepted 
when P<0.05. All significant differences are indicated by: * P<0.05, ** P<0.01, *** P<0.001, 
****P<0.0001. 
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3.3 EFFECTS ON EMBRYONIC GROWTH 
 
Following assignment to treatment groups on day 14 the survival rate for control embryos 
was 100%, whilst for dexamethasone treated embryos it was reduced to 66.7% (P<0.05). At 
day 19, dexamethasone treated embryos had a significantly lower total haemoglobin level, 
and a higher blood glucose concentration (Fig.3.2). 
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Figure 3.2 Day 19 blood parameters. A. total blood haemoglobin levels (g/L), B. blood glucose concentration 
(mM) Control n=12, Dexamethasone n=12. Parametric t-test, * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001. 
 
 
Embryos treated with Dexamethasone had a significant growth restriction at day 19 of 
incubation (Fig.3.3), both in absolute terms, and relative to the day 1 and day 19 egg weights. 
The ratio of partitioning of resources between embryonic and extra-embryonic tissues was 
significantly reduced in dexamethasone treated embryos, and they had a significantly higher 
mass of liquid in the day 19 egg. Relative head diameter and brain weight were increased 
comparative to control embryos, as was relative heart weight, whilst crown-rump length (CRL) 
was significantly reduced. 
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Figure 3.3 Day 19 biometry. A. absolute embryo mass (g), B. relative embryo mass (% d19 egg mass), C. ratio of 
embryonic to extra-embryonic mass, D. liquid mass (g), E. crown-rump length (mm), F. head diameter relative 
to embryo mass (mm/g), G. relative brain mass (% embryo mass), H. relative heart mass (% embryo mass) Control 
n=12, Dexamethasone n=12. Parametric t-test, * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001. 
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3.4 EFFECTS ON CARDIAC STRUCTURE & FUNCTION 
 
The area of the left ventricle wall and septum was unaltered in dexamethasone treated 
embryos relative to controls, whilst the area of the left ventricle lumen was significantly 
increased (Fig.3.4). The same trend was observed when muscle and chamber volumes were 
assessed, with the left ventricle wall having an unchanged volume and the left ventricle lumen 
a significantly increased volume. The ratio of left ventricle lumen to wall was increased in 
terms of both area and volume, suggesting left ventricular dilatation.  The right ventricular 
wall volume and right ventricular lumen volume were increased differentially in 
dexamethasone treated embryos, resulting in a significant increase in the right lumen to wall 
volume ratio, also suggesting right ventricular dilatation. 
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Figure 3.4 Ventricle areas, volumes, and ratios. A. left ventricular lumen area, B. left ventricular lumen volume, 
C. Ratio of left ventricular lumen to wall area, D. ratio of left ventricular lumen to wall volume left ventricle wall 
volume, E. right ventricular volume, F. right ventricular lumen volume, G. ratio of right ventricular lumen to wall 
area, H. ratio of right ventricular lumen to wall volume, I. representative mid-section of control embryo heart, J. 
representative mid-section of Dex treated heart, in control (n=10) and dexamethasone treated (n=10) embryos, 
at day 19 of incubation. Parametric t-test, * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001. 
 
 
Aortic wall thickness was significantly reduced in dexamethasone treated embryos (Fig.3.5), 
whilst aortic lumen diameter was unaltered. 
 
1 cm 
I. J. 
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Figure 3.5 Aortic thickness. A. Aortic wall thickness, B. aortic lumen diameter, in control (n=7) and 
dexamethasone treated (n=10) embryos at day 19 of incubation. Parametric t-test, * P<0.05, ** P<0.01, *** 
P<0.001, ****P<0.0001. 
 
Isolated cardiomyocytes were quantified to assess cellular size and nuclearity. 
Dexamethasone treated animals had a significantly larger cardiomyocyte width, and 
calculated cell volume. There was also a significant reduction in the % of cardiomyocytes that 
were mononucleated (Fig.3.6). Left ventricular cardiomyocyte nuclear density was also 
significantly reduced in dexamethasone treated embryos. 
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Figure 3.6 Cardiomyocyte analysis. A. cardiomyocyte width in um, B. calculated cardiomyocyte volume in mm3, 
C. percentage of all cardiomyocytes counted that were mononucleated, D. number of cardiomyocyte nuclei per 
mm3 of left ventricular tissue, in control (n=6) and dexamethasone treated (n=6) embryos at day 19 of 
incubation. Parametric t-test, * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001 
 
In terms of basal cardiac function, dexamethasone treated animals had a significantly 
increased LVEDP, suggestive of diastolic dysfunction (Fig.3.7). This was accompanied by a 
significant decrease in Tau, which is an index of the speed of left ventricle relaxation. 
Dexamethasone treated animals also displayed systolic dysfunction, with a significantly 
impaired LVDP and contractility index (Fig.3.7). 
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Figure 3.7 Diastolic and systolic function. A. Left ventricular developed pressure, B. contractility Index, C. Left 
ventricular end diastolic pressure, D. Tau, in control (n=10) and dexamethasone treated (n=10) day 19 embryos. 
Parametric t-test, * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001. 
 
 
Coronary flow rate was slightly reduced in dexamethasone treated animals, although this did 
not reach significance. Systolic duration was significantly reduced in dexamethasone treated 
animals, whilst diastolic duration was unaltered (Fig.3.8). 
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Figure 3.8 Coronary flow rate and heart cycle duration. A. Coronary flow rate relative to heart weight, B. Systolic 
and diastolic cycle duration, in control (n=10) and dexamethasone (n=10) treated embryos at day 19. Parametric 
t-test, * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001. 
 
 
In terms of stimulated cardiac function, the developed pressure response of dexamethasone 
treated embryos to the muscarinic agonist carbachol was significantly impaired relative to 
control embryos (Fig.3.9), however the heart rate response, and responses to the adrenergic 
agonist isoprenaline were not altered significantly. 
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Figure 3.9 Cardiac responses to autonomic agonists. A. left ventricular developed pressure response to 
isoprenaline, B. left ventricular developed pressure response to carbachol, C. ratio of the maximum developed 
pressure responses to isoprenaline and carbachol, D. heart rate response to isoprenaline, E. heart rate response 
to carbachol, F. ratio of heart rate response to isoprenaline and carbachol, in control (O n=10) and 
dexamethasone treated (•n=10) embryos at day 19 of incubation. † P<0.05, control vs. Dex, two-way ANOVA.   
 
 
3.5 EFFECTS ON PERIPHERAL VASCULAR FUNCTION 
 
The femoral arteries response to K+-induced constriction was significantly increased in the 
dexamethasone group (Fig.3.10). There was no significant difference in sensitivity of the dose-
dependent response to vasoconstrictor PE between treatment groups (as assessed by pD2), 
and the magnitude of the response, relative to each vessel’s maximum K+-induced response, 
was unchanged (Fig.3.10). The dose-dependent vasoconstriction response to endothelin-1 
(ET-1) was also significantly enhanced in the dexamethasone treated embryos (Fig.3.10). The 
response to serotonin (5-HT) however, was impaired. 
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Figure 3.10 Vasoconstrictor responses. A. tension generated in response to KCl (mM), B. Area under the curve 
of the KCL response (arbitrary units), C. response to PE as a % of maximal KCl response, D. pD2 of PE response, 
E. response to 5-HT as a % of maximal KCl response, F. area under the curve of 5-HT response (arbitrary units), 
H. response to ET-1 as a % of maximal KCl response, H. maximal ET-1 response as a % of maximal KCl response, 
in control (O n=10) and Dex (•n=10) treat embryos, two-way ANOVA with Tukey post-hoc test, A parametric t-
test * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001, † P<0.001, where † represents a main effect, two-way 
ANOVA. 
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There was no significant difference observed between control or dexamethasone treated 
animals in response to the vasodilator Ach (Fig.3.11). The proportion of the Ach-induced 
relaxation attributable to NO-dependant or NO-independent mechanisms was also similar 
between the two groups (Fig.3.11). The response to NO donor SNP was also unchanged in the 
dexamethasone treated embryos relative to the control embryos, suggesting no impaired 
vasorelaxation is present (Fig.3.11). 
 
-9 -8 -7 -6 -5 -4
0
50
100
log[Ach]
%
 R
el
ax
at
io
n
(f
ro
m
 K
C
l-
in
d
u
ce
d
 p
re
co
n
st
ri
ct
io
n
)
-10 -8 -6 -4
0
50
100
log[SNP]
%
 R
el
ax
at
io
n
(f
ro
m
 K
C
l-
in
d
u
ce
d
 p
re
co
n
st
ri
ct
io
n
)
A B
C
Co
nt
ro
l
De
x
0
100
200
300
NO Dependent
NO Independent
A
re
a 
u
n
d
er
 t
h
e 
cu
rv
e
 
 
Figure 3.11 Vascular vasodilator responses. A. vascular relaxation from KCl-induced pre-constriction in response 
to increasing doses of Ach, B. breakdown of the vasodilator response to Ach, by treating vessels with the eNOS 
inhibitor L-NAME, and assessing the area under the Ach dose-response curve, before and after inhibition, the 
area under the curve dependent on eNOS and hence NO can be determined, C. vascular relaxation from KCl-
induced pre-constriction in response to NO donor SNP, in control (O n=10) and dexamethasone treated (•n=10) 
embryos.  
 
 114 
 
114 Chapter 3: Dexamethasone in the chicken embryo 
3.6 EFFECTS ON MOLECULAR PATHWAYS IN THE HEART 
 
Endogenous in vivo H2O2 production, assessed via the molecular probe MitoB, revealed that 
at 5 days post dexamethasone exposure, there was increased H2O2 production in the fetal 
liver (Fig.3.12) Further evidence for oxidative stress was given by a decrease in mRNA 
expression of antioxidants Catalase, and Super-oxide Dismutase (Mn-dependent), and an 
increase in the mRNA expression of the pro-oxidant cp450 2A1. There was also a significant 
increase in protein carbonylation levels the chicken embryo, which is evidence of oxidative 
protein damage.  
 
Dex treated embryonic hearts had a significant up-regulation of cell stress kinases at day 19 
of incubation, specifically the pERK and pSAPk/JNK pathways (Fig.3.13). There was also 
demonstrated to be a significant up-regulation of protein chaperones that are known to be 
up-regulated in the unfolded protein response (UPR). Hsp27 is associated with endoplasmic-
reticulum (ER) unfolded protein stress, whilst hsp70 is associated with cytoplasmic unfolded 
protein stress, and TID-1 and hsp60 are mitochondrial chaperones associated with unfolded 
protein stress. As well as evidence for cellular stress in Dex treated embryos, there was also 
evidence for an increase in cellular apoptosis in the day 19 embryonic heart. There was a 
significant increase in total caspase-3 levels, cleaved caspase-3 levels, and no change in levels 
of the anti-apoptotic protein BCL (Fig.3.13). This suggests a significant increase in levels of 
apoptosis in the day 19 heart. Whilst there was no change in levels of key cell cycle regulator 
p53 mRNA in Dex treated embryos, there was a significant increase in mRNA expression of 
MKK3, p38, and p16 (Fig.3.13). These are all kinases associated with cell dynamics and known 
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to be up-regulated in response to various stresses and induce cellular senescence or 
apoptosis. 
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Figure 3.12 Oxidative stress following Dex exposure. A. MitoP/B ratio in the fetal liver 6 days post Dex 
administration, B. Levels of protein carbonylation detected by western blot, C. mRNA expression of Catalase, 
SOD1 (Zn/Cu), SOD2 (Mn), Glutathione peroxidase (GPx) and cp450 2A1, in control (n=10) and dexamethasone 
(n=10) treated embryos. Each graph assessed by parametric t-test, * P<0.05. 
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Figure 3.13 Cellular stress, apoptosis, and cell cycle markers. A. phosphorylated ERK protein/non-
phosphorylated levels, phosphorylated SAPK/JNk / non-phosphorylated levels, protein expression of chaperones 
HSP27, HSP70, HSP60, and PDI B.. protein levels of caspase-3 cleaved caspase-3, ratio of cleaved caspase-3 to 
total caspase 3, BCL,  C. mRNA levels relative to control of MKK3, p16, p38, p53, in control (n=6) and 
dexamethasone (n=6) treated embryos. Parametric t-test, * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001. 
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3.7 EFFECTS ON LUNG MATURATION 
 
In the day 19 embryonic lung, there was a significant increase in protein expression of the key 
surfactant protein SP-B (Fig.3.15). There was a trend towards an increase in caveolin-1, which 
is a cellular marker of lung maturation, although this increase did not reach significance. 
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Figure 3.14 Protein markers of lung maturation. A. protein levels of caveolin 1, B. protein levels of SP-B, in 
control (n=6) and dexamethasone (n=6) treated embryos. Parametric t-test, * P<0.05. 
 
 
In terms of morphological maturation of the embryonic lungs, there was a significant increase 
in parabronchial atrial diameter, air capillary diameter, and total thickness of the gas 
exchange region adjacent to the parabronchi (Fig.3.16). There was also a significant decrease 
in diffusion distance between air capillaries and the closest blood capillary, for oxygen 
exchange. 
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Figure 3.15 Morphological markers of lung maturation. A. parabronchial atrial diameter (µm), B. air capillary 
diameter (µm), C. diffusion distance (µm), D. thickness of gas exchange region adjacent to parabronchi (µm), in 
control (n=10) and dexamethasone (n=10) treated embryos. Parametric t-test, *** P<0.001. 
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3.8  DISCUSSION 
 
3.8.1 Summary 
 
Dexamethasone treatment did not alter egg mass at any stage of incubation, however it 
resulted in a decrease in embryonic survival from day 14 of incubation. Dexamethasone 
treatment resulted in significant asymmetric growth restriction in the day 19 embryo in terms 
of absolute mass, mass relative to egg mass and head diameter to body mass ratio. Embryonic 
cardiac function was significantly impaired following dexamethasone treatment. Coronary 
flow rate remained unchanged, however systolic duration in the cardiac cycle was 
significantly reduced. Dexamethasone treated embryos had a significant impairment in left 
ventricular developed pressure (LVDP) and in contractility index, as well as increased left 
ventricular end diastolic pressure (LVEDP) and Tau (time taken to reach 67% ventricular 
relaxation). In terms of cardiac structure, there was a significant left ventricular and right 
ventricular dilatation observed in dexamethasone treated embryos. Peripheral vascular 
constriction to KCl was increased and there was an enhanced vascular response to ET-1 and 
5-HT, but no effect on the dilator responses to either SNP, or Ach. 
 
Hearts displayed various indices of oxidative stress, including an increase in protein 
carbonylation, and changes in antioxidant/oxidant related genes, including catalase, Mn-SOD, 
and cp450 2A1. Dex treated embryos demonstrated an activation of cell stress kinases pERK 
and pSAPK/JNK, and upregulation in associated cellular proteins known to be important in the 
UPR response (hsp27, hsp70, hsp60, and PDI). Up-regulation of total and cleaved caspase 3 
suggest an apoptotic phenotype. This was associated with an up-regulation of p53 mRNA 
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expression. Furthermore, both MKK3 and p38 kinases were significantly up-regulated at the 
transcriptional level, as were cell cycle mediators p16 and p38. Dex treated embryos also 
demonstrated a negative feedback effect on the glucocorticoid receptor (GR) in the heart, as 
protein expression levels were decreased relative to controls. 
 
Various markers of lung maturation were up-regulated in the day 19 embryonic lungs from 
Dex treated embryos relative to controls. SP-B expression was up-regulated, and there were 
morphological markers consistent with pulmonary maturation, including parabronchial atrial 
diameter and air capillary diameter. 
 
In this chapter we addressed the hypothesis that Dex exposure in late cardiovascular 
development will result in cardiac and peripheral vascular dysfunction. Therefore, the data 
presented here support this hypothesis. 
 
3.8.2 Effects on Embryonic Growth & Survival 
 
We have demonstrated in this model of embryonic glucocorticoid administration a profound 
growth restriction by the end of development. This is an effect of fetal over-exposure to 
glucocorticoids that has been reported in various animal models including rodents, sheep, 
and non-human primates (Jobe et al., 1998; Newnham & Moss, 2001; Doyle et al., 2014; 
Fowden & Forhead, 2009). Conversely, glucocorticoid deficiency during pregnancy, e.g. 
following adrenalectomy, results in increased fetal mass relative to control animals (Fowden 
and Forhead, 2009a). In systematic reviews of the human data however, there is no clear 
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difference in growth between treatment and placebo groups, although this is compounded 
by difficulties in disentangling the effects of glucocorticoids with those of complicated 
pregnancy (Roberts et al., 2017). The likely cause of this overall growth restriction is the 
glucocorticoid mediated induction of the late development switch away from tissue accretion 
towards maturation (Fowden & Forhead, 2015). The majority of organs display a decrease in 
mass following early glucocorticoid exposure, as well as changes in cell number and function 
(Fowden and Forhead, 2009b). Mechanistically, glucocorticoids have been demonstrated to 
act via the GR pathways to alter; cellular receptors, ion channels and transporters, enzyme 
production, cytoskeletal proteins, and intracellular growth pathways (Fowden and Forhead, 
2009a). 
 
Interestingly in this study we have demonstrated that the growth restriction induced by Dex 
exposure is asymmetric, with the embryonic brain and heart being spared relative to the 
overall body mass. This could be an effect secondary to differential expression of GR in 
different tissues. It may also be secondary to reduced Dex levels in certain tissues due to 
exclusion by drug efflux transporter P-glycoprotein, which is known to be highly expressed in 
the brain (Karssen et al., 2002). This may lead to overall lower activation of the GR pathway 
in the fetal brain. GR however is known to be highly expressed in the fetal heart and so it is 
unlikely that a lower level of receptor is the reason for the sparing of heart growth (Rog-
Zielinska et al., 2014b). Another possibility is that certain organs may be spared due to 
differential effects of Dex on the vasculature. Whilst in the periphery (e.g. the femoral and 
mesenteric circulations) glucocorticoids induce vasoconstriction, thereby reducing delivery of 
oxygen and nutrients (Pulgar & Figueroa, 2006; Lee et al., 2014), this occurs to a lesser extent 
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in vital circulations, such as the heart and brain (Jellyman et al., 2009b). This is a key feature 
of the fetal stress response, which generally acts to protect the fetal brain at the expense of 
other tissues, and is known to be at least partly due to glucocorticoid mediated signalling 
(Giussani, 2016). 
 
In this chapter we also report a significant decrease in embryonic survival at day 19 of 
incubation in Dex treated embryos relative to controls (66.7% vs. 100%). This is clearly not the 
case in the human situation in which survival of the fetus following AGT is not impaired 
(Roberts et al., 2017). This difference could be due to the relative growth trajectory of the 
chicken embryo relative to the human fetus. Between day 14 and day 19 of incubation the 
chicken embryo mass increases from an average of 5.7g to 19g (preliminary studies), an 
increase of 233%. Comparatively the human fetus increases from an average of 1031g at 27 
weeks to 2624 at 36 weeks, an increase of 154% (Salomon et al., 2007). Hence restriction of 
growth during this period may have a greater effect on the chicken embryo, leading to more 
severe growth restriction and decreased survival. The chicken embryo also lacks any maternal 
responses to AGT which may blunt the negative effects on survival. 
 
3.8.3 Effects on Cardiac Structure and Function 
 
Functionally, hearts displayed profound systolic and diastolic dysfunction, showing an 
inability to generate appropriate left ventricular pressure and a slower than normal 
ventricular relaxation. This was associated with a biventricular dilator phenotype. This is 
significant as these are all indices of a failing heart (Tanai & Frantz, 2015).  
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In dexamethasone-treated embryos, there was also a reduced total number of left ventricular 
cardiomyocytes and the myocytes were significantly larger than in control hearts. Typically, 
in late gestation, both systolic and diastolic cardiac function improve as the ventricular walls 
thicken due to hyperplastic growth of cardiomyocytes (Harada et al., 1999; Corrigan et al., 
2010; Oparil et al., 1984; Christoffels et al., 2000). There is also growth of the t-tubular and 
sarcoplasmic reticulum systems, and alterations in ion channel density and identity (Davies et 
al., 1996; Siedner et al., 2003; Fahmi et al., 2004). Finally, there is a profound change in cardiac 
metabolism as the number of mitochondria increases and the fetal heart switches towards 
primarily fatty acid metabolism and increased ATP production (Bartelds et al., 2000; Mizuno 
et al., 2010). Endogenous glucocorticoids are known to be either directly or indirectly involved 
in many of these key maturational processes, and loss of glucocorticoid signalling during 
cardiac development has been shown to lead to a dilated phenotype, with poorly functioning 
cardiomyocytes (Rog-Zielinska et al., 2013; Oakley & Cidlowski, 2015). In our model, it appears 
as though the cardiomyocytes have prematurely switched away from a proliferative 
phenotype towards binucleation and hypertrophic growth, which is normally associated with 
the post-natal heart (Porrello et al., 2008; Pohjoismäki et al., 2013). This has led to both 
hypertrophied cardiomyocytes and an overall decrease in cardiomyocyte number. The 
resulting systolic and diastolic dysfunction could therefore arise from the reduced number of 
cardiomyocytes, impairing the ability of the left ventricle to develop significant pressure, and 
premature maturation of the cardiomyocytes imparting electrical conductance and 
contractility alterations leading to the dysfunctional cycle duration and diastolic relaxation. A 
dilated phenotype in the ventricles is in the adult individual is typically associated with acute 
decompensated heart failure, when neuro-hormonal compensatory changes eventually fail 
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to maintain systolic function, resulting in a volume overload in the left ventricle and a failure 
to pump (Japp et al., 2016; Kurmani & Squire, 2017). Whilst we have no direct measurement 
of blood pressure in these animals, it is plausible that a combination of dexamethasone-
induced reductions in cardiomyocyte number and increased afterload have resulted in an 
inability of the heart to pump sufficiently, leading to a pressure overload and dilated 
cardiomyopathy. 
 
In most animals cardiomyocyte endowment is dependent on myocyte proliferation during 
early development. Chicken cardiomyocytes proliferate throughout incubation with the 
greatest rate occurring in early development (days 3 and 4), however this proliferation also 
continues into post-hatching life (up to 6 weeks of age) (Li et al., 1997; Sedmera & Thompson, 
2011). Therefore, any insult which decreases proliferation during incubation, either by 
inhibiting progression of the cell cycle or stimulating cell cycle exit and terminal 
differentiation, can affect endowment. However, the ability of chicken cardiomyocytes to 
proliferate after hatching means that the decreased numbers of cardiomyocytes shown at 
day 19 may not persist to adulthood. In comparison in mammals there is little to no post-natal 
cardiomyocyte proliferation, meaning endowment is largely established during gestation 
(Thornburg et al., 2011). Glucocorticoids are known to play a role in the switch towards 
binucleation and terminal differentiation, either directly or indirectly (for example via 
stimulation of the thyroid hormone axis) (Porrello et al., 2008; Thornburg et al., 2011). 
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3.8.4 Effects on Peripheral Vascular Function 
 
When peripheral femoral vascular function was assessed ex vivo, no change was seen to the 
vasodilator responses to ACh or SNP, however a significantly increased response to K+, ET-1 
and 5-HT was measured in the Dex treated embryos. The elevated response to vascular 
smooth muscle cell (vSMC) depolarisation, suggests either vSMC hyperplasia or hypertrophy 
resulting in more contractile units in the vascular wall. Glucocorticoids have been shown in 
other studies to induce proliferation and increase contractility of vSMCs directly, in vivo and 
in vitro (Volk et al., 2010; McLellan et al., 1992). This increased contractile capacity of the 
peripheral circulation is likely associated with increased resistance and decreased flow in 
these circulations. This would fit with the apparent restriction in growth in the embryo leg 
length, as a reduction in delivery of oxygen and nutrients will enhance the reduction in tissue 
accretion. Whether this femoral hypercontractile phenotype results in hypertension in the 
fetal circulation is unclear from this experiment but this effect may contribute in the 
asymmetric growth restriction effects of dexamethasone and increased cardiac afterload in 
this model. In other models of antenatal Dex exposure, a subsequent hypertension has been 
reported, often associated with an increase in femoral vascular resistance (Figueroa et al., 
2005; Docherty et al., 2001; Celsi et al., 1998). As blood pressure increases towards term, this 
could be simply a premature switch towards the increased afterload seen with advancing 
gestation in preparation for neotnatal life (Giussani et al., 2005; Forhead et al., 2000). It could 
also be a stress response, as endogenous glucocorticoids are known to mediated responses 
to hypoxia and undernutrition by redistributing blood flow towards vital organs (Anwar et al., 
2016). 
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The significantly increased vascular response to ET-1 in Dex exposed is mirrored in other 
studies (Pulgar & Figueroa, 2006; Kutzler et al., 2003). Dex has been shown in vitro to increase 
both ET-1 production and release from vSMCs, and also to potentiate the contractile effects 
of ET-1 (Kanse et al., 1991; Sato et al., 1992; Rouhert et al., 1993). ET-1 acts on the vasculature 
via way of two separate receptors (Fig.3.17), the ET-A and ET-B receptor. The ET-A receptor is 
present on the vSMCs and induces an intense vasoconstriction, whilst the ET-B receptor is 
present on the vascular endothelium and is known to induce NO production via nitric oxide 
synthase (NOS; Davenport et al., 2016). Thus the balance of ET-A to ET-B receptors in a given 
circulation is important in determining the overall vasomotor response to ET-1. There is 
evidence that antenatal glucocorticoid exposure causes an up-regulation of ET-A, thus shifting 
towards a vasoconstrictor phenotype (Kutzler et al., 2003). As the responses reported here 
are due to direct administration of ET-1 to the vasculature, it is likely the changes seen are 
due to alterations in vascular receptors, or the downstream contractile pathways. However, 
there is no altered response to nor-adrenaline or phenylephrine in this model, which both act 
via α1-adrenergic receptors to induce IP3 production and thus show a convergence with the 
ET-A receptor pathway. This suggests that the downstream pathway is unchanged and rather 
alteration at the level of the ET-1 receptors is favoured. However, other groups have 
demonstrated alterations to downstream vasoconstrictor pathways, such as the cd38/cADPR 
pathway (Lee et al., 2014). Abnormality of the endothelin signalling in the present model is of 
biological and clinical significance, as endothelin dysregulation has been associated with 
various adult cardio-pathologies, and has been shown to be present in pregnancy complicated 
by gestational diabetes and pre-eclampsia (Dieber-Rotheneder et al., 2006, 2012). 
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We also observed an impaired response to 5-HT in the Dex treated embryos, becoming more 
apparent at higher concentrations. 5-HT is known to act via a multitude of receptors and to 
have divergent effects in different vascular system (Watts, 2016). The dose-dependent 
vasoconstriction is thought to mainly be due to action of the 5-HT-2A receptor (Watts, 2005), 
and 5-HT has long been associated with hypertension in the adult (Huzoor-Akbar et al., 1989; 
Watts & Thompson, 2004; Nichols, 2009). Here, we also report a dose-dependent 
vasoconstriction in isolated femoral arteries. The reduced response in Dex exposed embryos 
could be secondary to a variety of factors including distribution and identity of 5-HT receptors 
in the femoral artery. Other studies have demonstrated that glucocorticoids can attenuate 5-
HT mediated vasoconstriction (Angeles et al., 2006; Selli & Tosun, 2016). A further study of 5-
HT receptors sub-types would help elucidate the mechanism behind the altered 5-HT vascular 
constriction reported here. 
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Figure 3.16 Vascular interactions. Interactions of vasodilators Ach which activates nitric-oxide synthase (eNOS), 
cyclo-oxygenase (COX) and endothelium derived hyperpolarising factors (EDHF). Production of NO and 
prostacyclins (PGI2) leads to production of secondary messengers cAMP and cGMP in the vSMCs, which activate 
K+ efflux channels, protein kinase A (PKA), SERCA, and inhibit myosin light-chain kinase (MLCK) and reduced Ca2+ 
sensitivity of sarcomeres. Vasoconstrictors acting on 5-HT2A receptors or thromboxane receptors (TP Rs) on the 
endothelial cells stimulate production of ET-1, thromboxane (TBX2) and PGH2. Activation of 5-HT2A, TP, ET-A, or 
α1-adrenergic receptors leads to production of secondary messenger IP3 and a subsequent increase in cytosolic 
Ca2+. 
 
 
3.8.5 Effects on Molecular Pathways in the Heart 
 
There is significant evidence for activation of cellular stress pathways in the Dex exposed 
embryonic heart, secondary to generation of oxidative stress. Both direct measurements of 
in vivo mitochondria-derived oxidative stress (MitoP/B measurements) and of oxidative 
protein damage (protein carbonylation) show elevated levels in the Dex exposed embryos. 
There was also a significantly down-regulation of mRNA levels of antioxidants catalase and 
(Mn)-SOD. In adult tissues it is well known that Dex can induce oxidative stress (Lv et al., 2018; 
Yazıcı et al., 2018; Costantini et al., 2011). This is likely a combination of down-regulation of 
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antioxidant defences, up-regulation of pre-oxidant pathways, and direct actions on the 
mitochondria (Goodman et al., 1996; Takahashi et al., 2002; Du et al., 2009; Mutsaers & 
Tofighi, 2012). Oxidative stress has also been demonstrated in other models of AGT, and in 
additional organs such as the brain (Camm et al., 2011), whilst antioxidant treatment has been 
shown to protect against some of the glucocorticoid induced dysfunction (Zhang et al., 2004; 
Herrera et al., 2010; Wu et al., 2014). The effects of an increase in cellular oxidative stress 
include direct protein and DNA damage, disturbances to Ca2+ homeostasis, membrane 
potential, and mitochondrial function (Tönnies & Trushina, 2017).  
 
There is evidence for a significant up-regulation of cellular stress pathways, likely secondary 
to the increase in oxidative stress. This includes the pERK, pSAPK, p38, and MKK3 pathways. 
There was also significant up-regulation of downstream markers of the unfolded protein 
reponse (UPR) stress, including hsp27, hsp70, hsp60 and PDI, and of cell cycle regulators p53 
and p16. Likely consequences of activation of these pathways include a decrease in protein 
synthesis in an attempt to reduce protein stress in the ER; if this stress cannot be alleviated 
then the UPR response can lead to induction of apoptosis (Scull & Tabas, 2011) and an 
inflammatory response (Hotamisligil & Davis, 2016). There is evidence for this in our model 
as both total and cleaved caspase-3 protein levels were significantly increased, and there was 
a significant reduction in total nuclei in the left ventricle. Therefore, a combination of reduced 
cardiomyocyte number with impaired contractility and relaxability due to cellular stress in the 
cardiomyocytes is likely to be in part responsible for the systolic and diastolic dysfunction 
shown in this model. The molecular pathways leading to observed cardiac dysfunction are 
shown in Fig.3.18 
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Figure 3.17 Summary of molecular pathways activated in the embryonic heart following Dex administration. 
 
3.8.6    Effects on Lung Maturation 
 
As one of the greatest beneficial effects of AGT in the pre-term neonate is accelerated lung 
maturation and a reduction in respiratory distress (McKinlay et al., 2015), it is pertinent to 
assess the effects of Dex administration in the lungs of our chicken embryo model. However, 
the avian lung is different to the mammalian lung in several key aspects. Mammalian lungs 
consist of highly compliant lobular gas exchange regions containing millions of alveoli, 
attached to a tubular conducting pathway which allows for bi-directional flow of gas into and 
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out of the lungs (Schittny, 2017; Weibel, 2017). This acts as the equivalent of a ‘pool’ exchange 
system whereby the inhaled alveolar gas equilibrates with the pulmonary circulation, 
resulting in carbon dioxide efflux and oxygen influx (Weibel, 2017). Avian lungs conversely are 
comprised of a series of relatively rigid gas exchange tubes (air capillaries) through which air 
flows unidirectionally (Harvey & Ben-Tal, 2016; Cieri & Farmer, 2016). These tubes are 
ventilated by sets of compliant ‘air sacs’; the caudal abdominal air sacs, and the cranial air 
sacs. On inspiration the air sacs expand resulting in air flowing into the lungs into the caudal 
air sacs, and air in the gas exchange region to flow into the cranial air sacs. Upon expiration 
the air sacs are compressed, causing air in the caudal sacs to enter the gas exchange region 
whilst air in the cranial sacs can exit the lungs via the bronchus (Harvey & Ben-Tal, 2016). 
Functionally this results in a higher efficiency of gas exchange owing to the counter-current 
and cross-current air and blood flows established and has led to the long-held theory of this 
type of respiration being necessary for the evolution of the metabolic demands of flight (Cieri 
& Farmer, 2016; Maina, 2015). 
 
Structurally, the gas exchange unit in the avian lung, the air capillary, arises from tubular 
parabronchi which are themselves a tertiary division of the main bronchus (Cieri & Farmer, 
2016). Several air capillaries arise from the parabronchial ‘atria’ along their length. Air 
capillaries are histologically like alveoli in that they consist of a very thin epithelium and 
basement membrane, in close proximity to the endothelium of the pulmonary circulation 
(Maina, 2015). Previous work has demonstrated that the gas exchange regions of chicken 
lungs mature in the late developmental period in a manner similar to humans (Hylka & 
Doneen, 1982; Bjørnstad et al., 2014; Sullivan & Orgeig, 2001). Specifically, there is a late-
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developmental switch towards production of type-II pneumocytes, and concomitantly 
increases in surfactant production (Bjørnstad et al., 2014). Increases in both surfactant lipids 
and proteins (such as SP-A and SP-B) have been shown during late embryonic development, 
peaking at around day 21, when chick pipping occurs (Hylka & Doneen, 1982; Bjørnstad et al., 
2014). In cell culture, it has been shown that these changes may be induced by glucocorticoid 
exposure (Sullivan and Orgeig, 2001). Structurally the air capillaries mature in late 
development, with increased parabronchial atrial diameter, increased air capillary diameter, 
and decreased distance between the lumen of air capillaries and endothelium (referred to 
here as gas exchange distance) (Bjørnstad et al., 2014; Maina, 2015).  
 
Here, we showed an increase in Dex embryos of protein levels of both caveolin-1 and SP-B 
which are known to increase towards term (Bjørnstad et al., 2014). Surfactant components 
are vital for reducing lung compliance such that the neonate can ventilate the lungs (Ballard 
et al., 1995), hence this observation is important in demonstrating the maintained beneficial 
effects of AGT on lung maturation in our chicken embryo model. We also report various 
histological indices of lung maturation following Dex exposure, including an increase in air 
capillary diameter, and in thickness of gas exchange region adjacent to the parabronchi. This 
further supports that Dex has accelerated lung maturation in these embryos.  
 
3.8.7 Conclusions 
 
The data in this chapter show that direct treatment of the chicken embryo with a human 
clinically relevant dose of dexamethasone at a developmental stage equivalent to the 27-
week-old human fetus promotes asymmetric growth restriction and adversely affects 
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cardiovascular structure and function. Specifically, hearts isolated from dexamethasone 
treated embryos were heavier with significant biventricular luminal dilatation, and evidence 
of systolic and diastolic dysfunction. Mechanisms underlying the cardiovascular dysfunction 
in dexamethasone treated embryos included blunted inotropic responses to autonomic 
receptor agonists and cardiomyocyte hypertrophy with reduced proliferation. Enhanced in 
vivo generation of mitochondria-derived ROS, protein carbonylation and activation of ROS-
induced cardiomyocyte senescence pathways provide a molecular link between 
dexamethasone treatment with adverse cardiovascular changes in the chicken embryo. 
Therefore, despite maturational beneficial effects on the lungs, the data provide evidence for 
direct adverse effects on the cardiovascular system of the developing offspring independent 
of effects on the mother and/or placenta of dexamethasone in doses relevant to those used 
in human clinical practise. It is of great importance that we further assess the mechanisms 
behind these negative effects such that clinical therapy can be adjusted to reduced negative 
effects on the cardiovascular system whilst maintaining maturational effects on the lungs. 
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CHAPTER 4: DEXAMETHASONE VS. BETAMETHASONE  
4.1 INTRODUCTION 
 
Antenatal glucocorticoid therapy (AGT) has been used extensively in the clinic for treatment 
of threatened pre-term birth since the 1990’s (NIH, 1994). It has been shown that AGT prior 
to preterm birth dramatically reduces the risk of mortality and several severe morbidities in 
the preterm infant, such as Broncho-pulmonary dysplasia (BPD) and necrotising enterocolitis 
(NEC; Roberts et al., 2017). However, AGT has also been shown to cause potential significant 
adverse side effects on other organs and systems, such as the developing brain and 
cardiovascular system (Fowden et al., 2016).  This has triggered serious questions as to how 
to optimise this therapy to maintain benefits but to minimise detrimental effects.  
 
Notably, two different synthetic steroids Dexamethasone (Dex) and Betamethasone (Beta) 
are used interchangeably for this treatment, with no clear consensus on the optimal drug of 
choice (Schmidt et al., 2019).  Beta and Dex are both fluorinated synthetic analogues of 
cortisol which is the primary endogenous fetal glucocorticoid (Fig.4.1).  Fluorination at the 9-
C position enhances the biological activity of the synthetic glucocorticoids whilst insertion of 
the 1,2 carbon-carbon double bond selectively augments glucocorticoid over 
mineralocorticoid activity (Buttgereit et al., 1999). This leads to reduced clearance from 
plasma and hence a prolonged biological half-life. Mineralocorticoid activity is further 
eliminated in synthetic glucocorticoids by methylation at the 16-C position (He et al., 2014). 
Beta and Dex are stereoisomers of each other, with the configuration of the 16-C methyl 
group varying between them (Buttgereit et al., 1999). Due to these additions Dex and Beta 
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have negligible mineralocorticoid activity, but their glucocorticoid potency is approximately 
25-fold that of natural cortisol (Parker & Schimmer, 1996; Newnham & Moss, 2001).  Further, 
the half-time for clearance from the plasma of fetal sheep of Dex and Beta is extended by 
approximately 6-8 h compared to cortisol (Jellyman et al., 2009; Gough et al., 2014). 
 
 
 
 
 
Figure 4.1 Chemical structures of the synthetic glucocorticoids. Betamethasone and Dexamethasone. A) 
Betamethasone, where * highlights the C1-C2 double bond, † highlights the fluorination of C9, and  ‡ highlights 
the stereoisomeric methyl group. B) Dexamethasone, where * highlights the C1-C2 double bond, † highlights 
the fluorination of C9, and  ‡ highlights the stereoisomeric methyl group. Taken from Garrud & Giussani (2019). 
 
The dosing protocols for the different glucocorticoids are also historically different, with Dex 
being given as 4x12mg intramuscular doses, every 6 hours over a 48-hour period, whilst Beta 
is only given as 2x24mg doses 12 hours apart (Schmidt et al., 2019). This is due to the specific 
formulations of the drugs being utilised; Dex is given as a sodium (Na+) phosphate form of the 
drug, whilst Beta is given as a 50:50 mix of Na+-phosphate and Na+-acetate form. The acetate 
form of Beta has been shown to have a substantially longer half-life than the phosphate form, 
hence it is thought it will remain active in the fetal plasma for longer and hence fewer doses 
are required (Schmidt et al., 2018). The choice between which drug will be used by an 
obstetrician depends on several factors; some countries have historically used Beta over Dex 
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such as New Zealand, however Dex is often both cheaper, and more readily available (WHO, 
2015). 
 
There are few clinical studies that have directly compared the efficacy of Dex vs. Beta when 
treating threatened preterm birth. Individual studies have demonstrated that Beta has a 
greater efficacy in preventing neonatal death and RDS, whilst others have suggested that Dex 
is superior at preventing intra-ventricular haemorrhage (IVH) while maintaining positive 
neurological outcomes (Lee et al., 2006; Elimian et al., 2007; Lee et al., 2008). Other studies 
have reported no observable differences between the two drugs (Bar-Lev et al., 2004). A 
meta-analysis by Brownfoot et al., (2014), which assessed 10 trials (1161 infants), 
demonstrated no significant difference in most primary outcomes (neonatal death, RDS, BPD, 
IVH, mean birthweight), except for a decreased incidence of IVH when Dex was used 
compared to Beta. As well as different efficacies in preventing morbidities associated with 
preterm birth, there is also evidence in animal studies for differences in adverse outcomes on 
other systems in the newborn. Beta may have a more pronounced acute effect on fetal heart 
rate and fetal body movements (Rotmensch et al., 1999).  The relatively small numbers of 
clinical or basic science studies directly comparing Beta and Dex make it difficult to assess 
what the optimum drug treatment for AGT should be. Indeed, both the UN committee on 
maternal and neonatal health, and a report by the WHO on preventing preterm birth, 
conclude that there is not adequate evidence to recommend one over the other, and that 
more research is sorely needed.  
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One of the well-known mechanisms leading to gluccocorticoid induced hypertension 
following adult or fetal Dex exposure, is generation of oxidative stress (Safaeian & Zabolian, 
2014; Tain et al., 2014). Dex is known to be a potent inducer of oxidative stress in cell culture, 
and treatment of dex-induced hypertensive animals with antioxidants can restore normal 
physiological function (Zhang et al., 2004; Tai et al., 2016; Lin et al., 2018). Beta has also been 
associated with increases in oxidative stress in fetal models (Verhaeghe et al., 2009; 
Stojanovska et al., 2018). Therefore, it is possible that molecular changes involved in AGT 
induced cardiovascular dysfunction relate to induction of oxidative stress and the associated 
cellular responses which may include activation of stress kinase pathways, cell cycle changes, 
and apoptosis (Kim et al., 2016). As the outcomes associated with Dex and Beta treatment 
have been shown to differ in some studies, it is therefore also possible that any underlying 
molecular mechanisms differ. 
 
Therefore, the main aim of this chapter was to compare the effects of the same clinically 
relevant dose of Dex and Beta on the developing cardiovascular system in the purest form 
possible, minimising any potential confounding influences of either treatment. The chicken 
embryo model is unique and appropriate for this, as the embryo develops in isolation within 
the egg.  Therefore, the model allows comparison of the direct effects on the developing 
individual of any therapy, isolated from additional effects on the mother and/or placenta. 
Studies in our laboratory have previously reported that it is possible to dose the chicken 
embryo directly via the air cell with topical application of an aqueous solution onto the chorio-
allantoic membrane (Itani et al., 2015).  In this chapter we addressed the hypothesis that Dex 
and Beta exposure in late incubation will result in cardiac and peripheral vascular dysfunction 
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in the chicken embryo and that the severity and nature of this dysfunction will differ 
depending on which steroid is administered. To test this hypothesis, there were six objectives: 
1. To develop clinically relevant models of AGT in the chicken embryo; 
2. To investigate the effects of Dex and Beta treatment on embryonic survival and 
growth of the chicken embryo; 
3. To investigate the effects of Dex and Beta treatment on the cardiac function and 
structure of the chicken embryo; 
4. To investigate the effects of Dex and Beta treatment on peripheral vascular function 
in the chicken embryo; 
5. To investigate the molecular pathways induced by Dex and Beta treatment in the 
chicken embryo; 
6. To investigate the effects of Dex and Beta on lung maturation in the chicken embryo. 
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4.2 METHODS 
4.2.1 Experimental Protocol 
 
Detailed experimental protocols are explained in Section 2.  In brief, all procedures were 
performed under the U.K. Animals (Scientific Procedures) Act 1986 and were approved by the 
Ethical Review Committee of the University of Cambridge. Fertilised Bovans Brown chicken 
eggs were weighed, irradiated with sterilising UV light, and placed into a normoxic incubator 
at 38°C and 45% humidity for 19 days (see Section 2.1.). Eggs were dosed with dexamethasone 
phosphate or betamethasone phosphate/acetate (Celestone, USA) in aqueous solution, or 
water on day 14 of development via injection through a small hole in the shell (situated above 
the air sac) onto the chorioallantoic membrane, as previously described (Itani et al., 2015).  
The Dex/Beta dose used in this study was 0.1mgkg-1. AGT was administered on day 14 of the 
21 day incubation period, at two thirds of gestation, which is equivalent to 26/27 weeks in 
human pregnancy; a relevant, early period at which glucocorticoids can realistically be 
administered in the clinical setting (Roberts & Dalziel, 2006).  
 
4.2.2 Assessment of Embryonic Growth 
 
On Day 19 of incubation embryonic growth was assessed using a high precision calliper 
(Mitutoyo 500-181-20, U.K.) to determine embryonic lengths. Embryo mass and mass of the 
eggshell, yolk, extra tissues, and any remaininf liquid was measured and recorded. The ratio 
of partitioning of resources was calculated as embryonic tissue mass/extra-embryonic tissue 
mass. Crown-rump length, head diameter, head length were recorded (Section 2.2). 
Individual organs were also dissected and weighed. 
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4.2.3 Assessment of Cardiac Structure & Function 
 
A cohort of 10 Embryos per group at day 19 of incubation were anaesthetised with sodium 
pentobarbitate (0.3mL of Pentoject; Animalcare Ltd., York, UK; intraperitoneal), then 
perfusion fixed using paraformaldehyde (Section 2.5) at 2.66kPa (embryonic day 19 blood 
pressure) infused into the left ventricle via a cannula. Fixed hearts were sectioned into 1mm 
slices and photographed. Areas of cardiac compartments in each section were counted, and 
a mid cardiac section was chosen to measure widths. Volumes were then calculated as per 
Section 2.5. The initial 5mm of the descending aorta was dissected from the level of the top 
of each fixed heart and processed in paraffin. Consecutive sections (n=10) for each aorta were 
arranged onto a microscope slide, deparaffinised, and then stained with Gill’s Haemotoxylin. 
Slides were subsequently dehydrated and imaged (Section 2.5). Thicknesses and areas were 
then counted. 
 
Cardiomyocytes were also isolated from hearts of day 19 embryos (Section 2.6)., by perfusing 
the coronary vasculature with collagenase and protease solution. After 10 minutes the hearts 
were perfused with Kreb’s buffer to remove enzymes, and then suspended in buffer for 40 
minutes. Cells were stored at 4% PFA. Cardiomyocyte suspensions were mixed with 10% 
methylene blue in a 1/1 ratio and visualised under a light microscope (Section 2.6). Cell 
nuclearity of 300 random cardiomyocytes per heart was assessed, and measurements of 
length and width were taken from 50 randomly chosen cardiomyocytes. Cell volumes were 
then calculated. 
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To assess ex vivo cardiac function, hearts were rapidly excised from another short of embryos 
and placed into icy Krebs’ Buffer solution. The aorta was cannulated onto a 19-gauge blunt 
needle and mounted onto the Langendorff apparatus. Pressure recordings were subsequently 
made (Section 2.3). Following a period of normalisation, a small non-distensible balloon made 
from saran wrap and connected to a pressure transducer was introduced through the left 
atrium into the left ventricle. The balloon was then filled with water in 5µL increments until a 
smooth baseline recording was established. Baseline recordings were made and Coronary 
Flow Rate (CFR) was assessed. In vitro responses to the sympathetic agonist Isoprenaline 
(Sigma-Aldritch, in the range 10-9 – 10-7 M) and the parasympathetic agonist Carbachol 
(Sigma-Aldrich, in the range 10-8 – 10-6 M) were then assessed by administering via the 
perfusing cannula. Analysis of the Langendorff experiments was conducted on the LabChart 
software (Version 7, ADInstruments).  
 
4.2.4 Assessment of Peripheral Vascular Function 
 
A 2nd order branch of the femoral artery was dissected into cold Krebs solutions and then 
2mm sections were mounted onto a wire myograph (Section 2.4). Vessels were maintained 
at 38°C in Krebs solution, and were aerated with 95% O2/5% CO2 gas. To assess 
vasoconstrictor responses vessels were exposed to increasing doses of NE, 5-HT, PE, and ET-
1 at 2-minute intervals. To assess vasodilator function vessels were pre-constricted with K+, 
then exposed to increasing doses of Ach, or SNP. To determine the NO dependent component 
of the Ach response, vessels were treated with 5µm L-NAME.  
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4.2.5 Assessment of Molecular Pathways in the Heart 
 
Frozen heart tissue was powdered on dry ice, and separated into 50mg aliquots, then stored 
at -80°C. Extraction of proteins was conducted in TK lysis buffer (Section 2.7.1). For Western 
blot analysis, protein extracts were separated on a 10% agarose gel, then stained with primary 
antibody and secondary antibodies (Table 2.2). Gel bands were then quantified as described 
in Secction 2.7.2. 
 
A further set of frozen tissue aliquots were used to conduct RNA extraction using a Qiagen 
RNEasy mini kit (Section 2.7.3). RNA samples were then converted into cDNA libraries using 
Qiagen Reverse Transcriptase kit. DNA primers to various mRNAs of interest were designed 
and tested – only primers that gave a single peak, with a clear dose dependent relationship 
were used further (Table 2.3). mRNA expression analysis was then conducted as per section 
2.7.4.  
 
4.2.6 Assessment of Embryonic Lung Maturation 
 
Perfusion fixed lungs were embedded in paraffin, then sectioned into 8µm sections with an 
ultramicrotome (section 2.8). Slides were stained with haemotoxylin and eosin (section 2.6) 
then imaged. Measurements (n=20) of parabronchial atrial diameter, atrial septum thickness, 
air capillary diameter, and distance between air capillary and nearest blood vessel (diffusion 
distance), and 5 measurements of thickness of gas exchange zone were taken per animal. 
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4.2.7 Statistics 
 
All data except for dose-response curves were analysed using a one-way ANOVA with Tukey 
post-hoc test, conducted on GraphPad Prism 7 (Graphpad Software, CA, USA) software. 
Statistical differences (p<0.05) are demonstrated by different letters. Dose-response curves 
were assessed using a mixed-model two-way ANOVA. All significant differences to control 
values are indicated by *, whilst significant differences between Dex and Beta values are 
indicated by †. For all comparisons, significance was taken as P<0.05. 
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4.3 EFFECTS ON EMBRYONIC GROWTH 
 
Both Dex and Beta resulted in a significant reduction in embryo mass, relative embryo mass, 
partitioning of resources, and CRL (Fig.4.2), with the effects of Beta being more pronounced. 
Beta significantly increased relative head diameter, whilst Beta and Dex increased relative 
brain and heart mass, and liquid content of the egg with Beta having a greater effect. 
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Figure 4.2 Day 19 biometry. A. Absolute embryo mass (g), B. Relative embryo mass as % of total d19 egg mass, 
C. Ratio of embryonic to extraembryonic tissues in the d19 egg, D.Liquid in the d19 egg (g), E. Crown-rump length 
(mm), F. Head diameter relative to d19 embryo mass (mmg-1), G. Brain mass as % d19 egg mass, H. Heart mass 
as % d19 egg mass, in control (n=10), dexamethasone, and betamethasone treated (n=10) embryos, at day 19 
of incubation. Ordinary one-way ANOVA with Tukey test, statistically significant differences denoted by different 
letters. 
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4.4 EFFECTS ON CARDIAC STRUCTURE & FUNCTION 
 
Both Dex and Beta induce left ventricular dilatation in terms of left lumen volume, ratio of left 
lumen to wall area and volume ratios (Fig.4.3). Beta also resulted in a significant dilatation of 
the right ventricle with a significantly increased lumen to wall area and volume ratio. This is 
also associated with a significant reduction in right ventricular wall volume. The aortic wall 
thickness was reduced following both Dex and Beta treatment, with Beta having a more 
severe effect (Fig.4.4). Dex resulted in an increase in aortic lumen diameter, whilst Beta 
resulted in a decrease. 
 
In terms of cardiomyocyte structure, Dex significantly increased cardiomyocyte volume 
(Fig.4.5) and reduced % mono-nucleation, whilst Beta resulted in a significant reduction in 
cardiomyocyte nuclear density. 
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Figure 4.3 Cardiac stereology. A. left ventricular lumen area, B. left ventricular lumen volume, C. Ratio of left 
ventricular lumen to wall area, D. ratio of left ventricular lumen to wall volume left ventricle wall volume, E. right 
ventricular volume, F. right ventricular lumen volume, G. ratio of right ventricular lumen to wall area, H. ratio of 
right ventricular lumen to wall volume, I. representaive mid-section of control heart, J. representative mid 
section of Dex treated heart, K. representative mid section of Beta treated heart, in control (n=10), 
dexamethasone (n=10), and betamethasone treated (n=10) embryos, at day 19 of incubation. Ordinary one-way 
ANOVA with Tukey test, statistically significant differences denoted by different letters. 
 
 
 
 
Figure 4.4 Aortic wall thickness and lumen diameter. A. Aortic wall thickness (µm), B. Aortic lumen diameter 
(µm) in control (n=10), dexamethasone, and betamethasone treated (n=10) embryos, at day 19 of incubation. 
Ordinary one-way ANOVA with Tukey test, statistically significant differences denoted by different letters. 
 
1 cm 
I. J. K. 
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Figure 4.5 Cardiomyocyte analysis. A. cardiomyocyte width (µm), B. calculated cardiomyocyte volume (mm3), 
C. percentage of all cardiomyocytes counted that were mononucleated, D. number of cardiomyocyte nuclei per 
mm3 of left ventricular tissue in control (n=10), dexamethasone, and betamethasone treated (n=10) embryos, 
at day 19 of incubation. Ordinary one-way ANOVA with Tukey test, statistically significant differences denoted 
by different letters. 
 
Beta significantly impaired systolic function in terms of both LVDP and contractility index 
(Fig.4.6). Both Dex and Beta significantly impaired diastolic function, with the effects of Beta 
being more pronounced. 
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Figure 4.6 Diastolic and systolic function. A. Left ventricular developed pressure, B. contractility Index, C. Left 
ventricular end diastolic pressure, D. Tau, in control (n=10), dexamethasone, and betamethasone treated (n=10) 
embryos, at day 19 of incubation. Ordinary one-way ANOVA with Tukey test, statistically significant differences 
denoted by different letters. 
 
 
 
Beta but not Dex significantly reduced CFR per unit heart mass, and cycle duration, with a 
significant reduction in systolic duration and no change in diastolic duration (Fig.4.7).  
Both Dex and Beta significantly impaired the LVDP response to carbachol at the highest dose, 
and Beta also significantly impaired the HR response at this dose (Fig.4.8). There was no 
significant effect of either drug on isoprenaline responses or overall LVDP or HR response 
ratios. 
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Figure 4.7 Coronary flow rate and heart cycle duration. A. Coronary flow rate relative to heart weight, B. Systolic 
and diastolic cycle duration in control (n=10), dexamethasone, and betamethasone treated (n=10) embryos, at 
day 19 of incubation. Ordinary one-way ANOVA with Tukey test, statistically significant differences denoted by 
different letters. 
 
Figure 4.8 Cardiac responses to autonomic agonists. A. left ventricular developed pressure response to 
isoprenaline, B. left ventricular developed pressure response to carbachol, C. ratio of the maximum developed 
pressure responses to isoprenaline and carbachol, D. heart rate response to isoprenaline, E. heart rate response 
to carbachol, F. ratio of heart rate response to isoprenaline and carbachol, in control (n=10) Dex (n=10) and Beta 
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(n=10) treated embryos at day 19 of incubation. A,B,D,E two-way ANOVA with Tukey post-hoc test, C,F ordinary 
one-way ANOVA with Tukey test statistically significant differences denoted by different letters. 
 
 
4.5 EFFECTS ON PERIPHERAL VASCULAR FUNCTION 
 
Dex significantly increased femoral vascular response to KCl, whilst Beta significantly reduced 
the area under the curve of the KCl response curve (Fig.4.9). Beta also significantly impaired 
the constriction to PE. There was no significant effect on 5-HT responses, however both Dex 
and Beta increased constriction in response to ET-1, with the effect of Dex being more 
pronounced. 
 
Beta significantly reduced the relaxation response to Ach (Fig.4.10), which was associated 
with a significant impairment of NO-independent relaxation, and an increased in NO-
dependent relaxation. Beta also significantly impaired SNP induced relaxation. 
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Figure 4.9 Vasoconstrictor responses. A. tension generated to KCl (mM), B. Area under the curve of KCL response 
(arbitrary units), C. response to PE as a % of maximal KCl response, D. pD2 of PE response, E. response to 5-HT 
as a % of maximal KCl response, F. area under the curve of 5-HT response (arbitrary units), H. response to ET-1 
as a % of maximal KCl response, H. maximal ET-1 response as a % of maximal KCl response, in control (white, 
n=10) Dex (blue, n=10) and Beta (red, n=8) treated embryos, ACEG two-way ANOVA with Tukey post-hoc test 
where * represents statistically different to control, and † represents statistically different to Dex, BDFH ordinary 
one-way ANOVA with Tukey test. Statistically significant differences denoted by different letters. 
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Figure 4.10 Vasodilator responses. A. vascular relaxation from KCl-induced pre-constriction in response to 
increasing doses of Ach, B. breakdown of the vasodilator response to Ach, by treating vessels with the eNOS 
inhibitor L-NAME, and assessing the area above the Ach dose-response curve, before and after inhibition.  The 
area above the curve is dependent on eNOS and hence NO can be determined, C. vascular relaxation from KCl-
induced pre-constriction in response to NO donor SNP, in control (white, n=10) Dex  (blue, n=10) and Beta (red, 
n=8) treated embryos. AC two-way ANOVA with Tukey post-hoc test where * represents statistically different to 
control, and † represents statistically different to Dex, B ordinary one-way ANOVA with Tukey test. statistically 
significant differences denoted by different letters. 
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4.6 EFFECTS ON MOLECULAR PATHWAYS IN THE HEART 
 
Dex significantly increased protein carbonylation in the heart whereas Beta did not (Fig.4.11). 
Whilst there is no significant effect of either drug on catalase expression. Both Dex and Beta 
increased activation of the pERK and pSAPK/JNK pathways, associated with downstream 
increased expression of hsp60 and PDI, whilst Dex also increased hsp27 and hsp70. Both drugs 
increased total caspase 3 levels but only Dex increased cleaved caspase-3 levels. Beta resulted 
in a significant upregulation of p38 and p53 mRNA. 
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Figure 4.11 Oxidative stress indices. A. Levels of protein carbonylation detected by western blot, B. mRNA 
expression of Catalase, C. mRNA expression of SOD2 (Mn dependent), in control (n=10) and dexamethasone 
(n=10) treated embryos. Ordinary one-way ANOVA with Tukey test. statistically significant differences denoted 
by different letters. 
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Figure 4.12 Cellular stress, apoptosis, and cell cycle markers. A. phosphorylated ERK protein/non-
phosphorylated levels, phosphorylated SAPK/JNk / non-phosphorylated levels, protein expression of chaperones 
HSP27, HSP70, HSP60, and PDI B.. protein levels of caspase-3 cleaved caspase-3, ratio of cleaved caspase-3 to 
total caspase 3, BCL,  C. mRNA levels relative to control of MKK3, p16, p38, p53, in control (n=6) dexamethasone 
(n=6) and betamethasone (n=6) treated embryos. Ordinary one-way ANOVA with Tukey test. statistically 
significant differences denoted by different letters. 
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When GR mRNA levels were assessed, Dex treated hearts had a significantly lower level than 
Beta hearts although neither were significantly different to controls (Fig.4.13). In the Dex 
treated embryos this resulted in a significant decrease in GR protein levels, whilst in Beta 
embryos the levels were unchanged. 
 
Figure 4.13 GR mRNA and protein levels. A. Levels of GR mRNA (fold change) B. GR protein levels (relative to 
tubulin expression), in control (n=10) dexamethasone (n=10), and betamethasone (n=8) treated embryos. 
Ordinary one-way ANOVA with Tukey test. statistically significant differences denoted by different letters. 
 
 
 
4.7 EFFECTS ON LUNG MATURATION 
 
Both Dex and Beta increased protein expression of caveolin-1 and SP-B, however only Beta 
treated hearts had levels significantly elevated relative to controls (Fig.4.14). Both drugs 
significantly increased parabronchial atrial and air capillary diameter, and decreased diffusion 
distance (Fig.4.15). However, only Dex significantly increased thickness of the gas exchange 
zone. 
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Figure 4.14 Protein markers of lung maturation. A. Expression of caveloin-1 (% control expression), B. 
expression of SP-B (% control expression), in control (n=6) dexamethasone (n=6) and betamethasone (n=6) 
treated embryos. Ordinary one-way ANOVA with Tukey test. statistically significant differences denoted by 
different letters. 
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Figure 4.15 Morphological markers of lung maturation. A. parabronchial atrial diameter (µm), B. air capillary 
diameter (µm), C. diffusion distance (µm), D. thickness of gas exchange region adjacent to parabronchi (µm), E. 
representative section of control lung showing air capillaries (A), F. representative section of Dex lung showing 
air capillaries (A), in control (n=8) dexamethasone (n=8) and betamethasone (n=6) treated embryo Ordinary one-
way ANOVA with Tukey test. statistically significant differences denoted by different letters. 
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4.8 DISCUSSION 
 
 
4.8.1 Summary 
 
The data in this chapter show that Dex and Beta have differential adverse effects on 
embryonic growth and cardiovascular development.  Both Dex and Beta resulted in a 
significant asymmetric growth restriction at day 19 of incubation, with Beta having a more 
severe effect. This is echoed in the cardiac function; Beta resulted in a significant systolic 
dysfunction, whilst both Beta and Dex induced a diastolic dysfunction, with the effects of Beta 
being more severe. Both glucocorticoids induced left ventricular dilatation, again with Beta 
being more severe, and Beta also induced a right ventricular dilatation. In terms of individual 
cardiomyocytes, Beta resulted in a significant reduction in nuclear density whilst not affecting 
cardiomyocyte volume, whereas Dex resulted in a significant increase in cardiomyocyte 
volume with only a small reduction in nuclear density. 
 
Dex and Beta also display divergent effects on peripheral vascular function. Whilst Dex 
increased the femoral constrictor response to KCl, Beta impaired this and the vasoconstrictor 
response to PE. Both drugs enhanced constriction to ET-1 with Dex having a more profound 
effect. Beta significantly impaired relaxation in response to NO donor SNP, and to vasodilator 
Ach, the latter being associated with a significant decrease in NO-independent vasodilatation. 
 
Beta did not show any significant increase in protein carbonylation (associated with oxidative 
stress) whilst Dex did, however both treatments resulted in up-regulation of cell stress kinase 
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pathways pERK and pSAPK/JNK. Both resulted in activation of downstream mitochondrial and 
ER chaperones hsp60 and PDI, and Dex also activated cytosolic chaperones hsp27 and hsp70. 
Both treatments induced an increase in total caspase-3 levels, however only Dex increased 
cleaved caspase-3 levels. Beta also resulted in significant upregulation of cell cycle mediator 
p53. Dex demonstrated negative feedback at the level of the cardiac GR, which was absent in 
Beta-treated hearts. 
 
Both glucocorticoids resulted in similar histological maturation of embryonic lungs, and both 
significantly increased expression of caveolin-1 and SPB, with Beta having a greater effect. 
 
In this chapter we addressed the hypothesis that Dex and Beta exposure in late cardiovascular 
development will result in cardiac and peripheral vascular dysfunction and that the severity 
and nature of this dysfunction will differ depending on which steroid is administered. The 
data presented here support this hypothesis. 
 
 
4.8.2    Effects on embryonic growth 
 
Both glucocorticoids resulted in a significant asymmetric growth restriction. This is a common 
side effect of glucocorticoids seen in many animal models (Newnham & Moss, 2001). It is 
likely that this is at least in part due to a switch away from tissue accretion and towards 
maturation, resulting in reduced body mass accumulation over the final period of 
development than in control embryos (Fowden & Forhead, 2015). The asymmetric nature of 
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this growth restriction is interesting as it reflects what is seen in various other antenatal 
insults such as fetal hypoxia or fetal nutrient restriction (Giussani, 2016; Elias et al., 2016). 
This is likely due to differential effects of glucocorticoids on the vascular perfusion and 
metabolism of the brain versus other organs, and is a key component of the additional role 
of glucocorticoids as a stress hormones; in times of stress when oxygen or nutrient delivery 
may be compromised it is essential to protect the developing brain even if at the expense of 
other organ systems.  
 
Plausible explanations for the more severe effect of Beta compared with Dex on late stage 
embryonic growth may relate to differences in binding affinity or clearance.  It is possible that 
the Beta stereoisomer binds to the GR with a higher affinity than Dex overall leading to 
greater levels of activation.  Alternatively, the Na+-acetate Beta formulation is known to have 
a longer plasma half-life than the Na+-phosphate formulations and hence Beta, which 
contains both formulations, may be active in the fetal circulation for longer. Most 
pharmacological studies suggest a similar glucocorticoid potency of Dex and Beta of around 
25-30x greater than hydrocortisone (Buttgereit et al., 1999; Parente, 2017). However, there 
is some evidence for subtle differences. For example, Beta has been shown to induce 
apoptosis in a lymphoblast cell line at lower concentrations than Dex (Longui et al., 2005). 
Conversely, data in the present study which show a fall in cardiac GR after Dex but not Beta 
treatment in the day 19 chicken embryo arguses against Beta having a greater affinity for GR 
compared with Dex.  There is however extensive evidence for the Beta acetate drug 
formulation remaining in the fetal circulation longer than the phosphate formulation 
(Samtani et al., 2005; Salem and Najib, 2012). Schmidt et al., (2016) demonstrated that the 
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combined Beta treatment was more effective at inducing lung maturation than either Dex or 
Beta phosphate, which had similar effects to each other. However in that study, Dex and Beta 
phosphate administered at the same dose did display subtle differences. For example, Beta 
phosphate resulted in significant upregulation of surfactant proteins -A, -B, and  -C as well as 
ATP-binding cassette family member A3 (ABCA3), suggesting that drug formulation is not the 
only difference (Schmidt et al., 2016). In order to determine whether drug formulation or 
nature of the stereoisomers is the cause of the differential effects observed in this model, a 
further study directly comparing Dex Phosphate with both Beta phosphate and Beta acetate 
would be valuable. 
 
 
4.8.3 Effects on Cardiac Structure and Function 
 
Both Dex and Beta induced cardiac diastolic dysfunction with an increased LVEDP and Tau 
(the time constant of ventricular relaxation), and further Beta significantly impaired both 
LVDP, contractility index, CFR and the systolic duration of the cardiac cycle. This was also 
associated with a significant left ventricular dilatation and divergent effects on isolated 
cardiomyocytes, with Dex inducing hypertrophy, whilst Beta significantly reducing nuclear 
density whilst not affecting mono-nucleation. 
 
 
The severe dysfunction observed in the Beta treated hearts may result from the pronounced 
decrease in cardiomyocyte number leading to markedly thinner ventricle walls and a lower 
number of total contractile units. This has ultimately resulted in a dilated cardiac phenotype, 
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worryingly resembling dilated cardiomyopathy, reminiscent of end stage cardiac failure in 
adults (Fig.4.16). The additional dilatation observed in the right ventricle in the Beta- but not 
Dex-treated embryos may also be due to the severe reduction in cardiomyocyte number, 
although this was not studied directly in the right ventricle.  Conversely, it appears that Dex 
treatment has resulted in the more traditional switch from tissue accretion to tissue 
maturation in the heart, accelerating a change from cardiomyocyte hyperplasia towards 
hypertrophy, an effect typically seen towards term (Oparil et al., 1984; Christoffels et al., 
2000; Corrigan et al., 2010).  These hypertrophic effects of Dex on the heart without 
significant reduction in cardiomyocyte number may have compensated in part for the 
ventricular dilatation, thereby better maintaining systolic and diastolic function in Dex 
compared with Beta treated hearts.  Even in the absence of dilatation, significant 
cardiomyocyte hypertrophy would still adversely affect cardiac function in Dex-treated hearts 
compared to controls, as there is evidence that premature hypertrophic maturation impairs 
electrical conductance and contractility, affecting contractility and relaxability normally 
(Fig.4.16; Severinova et al., 2019; Frey & Olson, 2003). 
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Figure 4.16 Effects of Dex and Beta on cardiac structure. 
 
 
4.8.4 Effects on peripheral vascular function 
 
Divergent effects of Dex and Beta are also reflected in the ex vivo femoral vascular function. 
Dex treatment resulted in a switch towards a vasoconstrictor phenotype with an enhanced 
KCl and ET-1 response, whilst vasodilator responses were not affected. This may be secondary 
to increased hyperplasia or hypertrophy of vascular smooth muscle cells (vSMCs; McLellan et 
al., 1992; Volk et al., 2010), and alterations to either ET-1 receptor densities (e.g. up-
regulation of ET-A) or downstream contractile pathways (Kutzler et al., 2003; Lee et al., 2014) 
resulting in an enhanced vascular response.  
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Beta treatment however results in a distinct vascular phenotype. KCl-induced constriction is 
slightly reduced compared to controls but is significantly different to the enhanced Dex 
response. This suggests that the hyperplasia/hypertrophy of the vSMCs seen following Dex 
treatment is absent when Beta is given. In addition, there is a significant impairment of the 
vascular response to PE, even when corrected for individual vessel contractility. PE is a 
selective α1-adrenergic receptor agonist that activates phospho-lipase C induced IP3 
production, downstream Ca2+ release and myosin light chain kinase (MLCK) activation, 
resulting in increased vascular constriction (Brozovich et al., 2016). This is the mechanism 
largely activated in the peripheral circulation by the sympathetic nervous system, which 
controls vascular tone via synapses with vSMCs, which mainly release noradrenaline (NA). 
However, NA is a non slective adrenergic agonist and so vascular responses will differ to those 
induced by PE if other adrenergic receptors are also present (Smith & Maani, 2019). 
Decreased PE responsiveness could be secondary to a decrease in α1-adrenergic receptor 
density in the femoral vascular bed. Whilst there is little evidence for glucocorticoids 
modulating α-adrenergic signalling in the vasculature, cross-talk between the glucocorticoid 
and α-adrenergic pathways has been demonstrated in the heart (Lister et al., 2006). It is also 
possible that there is downregulation in the downstream contractile pathway. This possibility 
is made less likely by the fact that ET-1 responses are also slightly up-regulated relative to 
control embryos following Beta treatment, and ET-1-induced vasoconstriction is also primarily 
mediated by the ET-A receptor stimulating IP3 production (Davenport et al., 2016). Vascular 
responses to ET-1 in offspring exposed to antenatal Beta have indeed been shown to be 
enhanced secondary to activation of the cyclic ADP ribose (cADPR)/ryanodine receptor 
pathway (Lee et al., 2014). cADPR is an intracellular secondary messenger which regulates 
ryanodine receptor opening allowing Ca2+ release from the sarcoplasmic reticulum. Activation 
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of the ET-B receptor can activate cADPR induced vasoconstriction in the vSMCs, whilst ET-A can 
act via cADPR or the classic IP3 pathway (Barone et al., 2002). Hence, it is possible that the 
enhanced ET-1 response is due to increased cADPR signalling, and that a downstream 
inhibition of the IP3 pathway is present. Further investigation into the effects of inhibiting 
cADPR production or blocking specific ET-1 receptors would help illuminate the specific 
altered mechanisms. 
 
Beta treatment also induces an impaired vasodilator phenotype associated with endothelial 
dysfunction. Overall relaxation to muscarinic agonist Ach was significantly impaired in Beta 
treated embryos. Ach is known to induce vasodilatation by several concurrent mechanisms, 
including the production of NO by endothelial NO synthase (eNOS), production of 
prostacyclins by cyclo-oxygenase-1 (COX-1), and production of other vascular mediators, such 
as H2S, termed endothelial derived hyperpolarising factors (EDHF; Liberman et al., 2018). To 
investigate which pathway is impaired following Beta treatment we also assessed vascular 
responses to NO donor SNP, which was also significantly impaired. NO produced in the 
endothelium in response to various receptor agonists (such as Ach and CGRP), or in response 
to shear stress, rapidly diffuses into the vSMCs whereby it activates soluble guanylate cyclase 
(sGC) leading to increased production of cyclic guanine monophosphate (cGMP) which in turn 
induces vasodilatation by enhancing Ca2+ reuptake, and opening hyperpolarising K+ channels 
(Chen et al., 2008). NO may also directly interact with sarcoplasmic reticulum Ca2+ ATPase 
(SERCA) to reduce cytosolic Ca2+ levels (Zhao et al., 2015). The impaired response to SNP 
suggests downregulation of one or more of these pathways in the vSMCs themselves. Most 
evidence from adult vascular exposure to glucocorticoids suggests that impairments in NO 
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vasodilatation are secondary to decreased production via eNOS or iNOS (induced NO 
synthase), which is at odds with the results presented here (Whitworth et al., 2002). In 
addition, when vasodilatation in response to ACh was repeated in the presence of an eNOS 
inhibitor, relaxation was more severely affected in the Beta treatment group than either 
control or Dex embryos. This suggests that femoral vessels isolated from Beta-treated 
embryos are more reliant on NO-dependent vasodilatation to maintain appropriate 
relaxation, and indeed they have a significantly enhanced NO-dependent and impaired NO-
independent vasodilator component of their relaxation capacity (see Fig.4.10B). The impaired 
response to the NO-donor SNP in the vSMCs results in an overall dilator dysfunction despite 
the upregulation of NO-dependent vasodilator mechanisms in response to ACh. It is unclear 
which NO-independent pathways are altered in these vessels; further investigation using 
specific enzyme inhibitors would help to further elucidate the dysfunctional phenotype. The 
differential vascular effects of Dex and Beta are summarised in Figure 4.17 below. 
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Figure 4.17 Vascular effects of Dex and Beta. Dashed arrows represent upregulation of a pathway, whilst dashed 
lines with flat ends represent suppression of a pathway. Interactions of vasodilators (blue) Ach which activates 
nitric-oxide synthase (eNOS), cyclo-oxygenase (COX) and endothelium derived hyperpolarising factors (EDHF). 
Production of NO and prostacyclins (PGI2) leads to production of secondary messengers cAMP and cGMP in the 
vSMCs, which activate K+ efflux channels, protein kinase A (PKA), SERCA, and inhibit myosin light-chain kinase 
(MLCK) and reduced Ca2+ sensitivity of sarcomeres. Vasoconstrictors (red) acting on 5-HT2A receptors or 
thromboxane receptors (TP Rs) on the endothelial cells stimulate production of ET-1, thromboxane (TBX2) and 
PGH2. Activation of 5-HT2A, TP, ET-A, or α1-adrenergic receptors leads to production of secondary messenger IP3 
and a subsequent increase in cytosolic Ca2+. 
 
 
 
4.8.5 Effects on molecular pathways in the heart 
 
Whilst Dex treatment results in induction of oxidative stress in the embryonic heart, 
evidenced by increased protein carbonylation, and decreased levels of antioxidants (Mn)-
SOD, and Catalase, Beta-treated hearts do not display these changes. However, it is evident 
in both cases that there is significant cellular stress as both pERK and pSAPK/JNK pathways 
are up-regulated, as are downstream chaperone proteins (mitochondrial and ER associated 
in Beta hearts, whilst also being associated with the cytosol in Dex hearts). In addition, it 
appears that apoptosis may be up-regulated in Dex-treated embryos, but not in those 
exposed to Beta, which challenges our previous observations of drastically reduced 
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cardiomyocyte numbers following Beta treatment. The lack of a fall in apoptotic markers in 
the Beta-treated embryos may reflect observations in other studies, in which Beta can 
drastically reduce cell proliferation without inducing caspase-3 mediated apoptosis 
(Scheepens et al., 2003). It is also possible that Beta exposure is reducing cardiomyocyte 
number by other pathways, such as autophagy (Wang et al., 2015). 
 
The link between Dex and cellular stress in various adult tissues has been well documented, 
and in many cases this is related to induction of oxidative stress (Mutsaers & Tofighi, 2012; Lv 
et al., 2018; Suwanjang et al., 2016; Yazıcı et al., 2018). This has also been associated with ER 
stress which matches our results of up-regulation of ER chaperone hsp60 (Liu et al., 2018). 
Oxidative stress is known to induce cardiomyocyte hypertrophy, which we see in these hearts 
(Kim et al., 2016). Whilst there is clearly cellular stress in the Beta-exposed hearts, it seems 
to be predominantly mitochondrial and there are no clear markers of oxidative stress. In other 
studies, Beta has been associated with oxidative stress in the fetal brain, umbilical vein blood, 
and the kidneys of adult offspring exposed antenatally (Bi et al., 2014; Miller et al., 2007; 
Verhaeghe et al., 2009). It is unclear in this model if a transient oxidative stress was induced 
following Beta treatment that had resolved by day 19 of incubation, and therefore it was not 
detected in this study. This however does not explain why markers of oxidative stress are still 
present in Dex-exposed embryos at day 19, if the oxidative stress is transient. It has been 
observed that Dex has a higher activation capacity for the non-canonical GR pathway, and 
hence this pathway may be responsible for some of the divergent effects between the two 
steroids (Buttgereit et al., 1999). Non-genomic effects of glucocorticoids can be categorised 
as membrane effects, effects mediated by the canonical cytosolic GR (cGR), and effects 
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mediated by the membrane bound GR (mGR) (Stahn & Buttgereit, 2008). Glucocorticoids may 
intercalate into cell membranes altering some of their biological properties, for example 
impairing ATP production by increasing proton leak which may be important in reducing 
function of immune cells (Buttgereit & Scheffold, 2002). Effects mediated by the cGR are 
secondary to release of protein mediators upon ligand binding, and include inhibition of 
arachidonic acid release (Croxtall et al., 2000). mGR is thought to be a splice isoform of the 
cGR, however its cellular role and production is unclear. Dex has however been shown to act 
via the mGR to inhibit T-cell signalling in the immune system, reducing inflammation 
(Löwenberg et al., 2006). A method to compare relative activation of the non-canonical GR 
pathway would be able to further elucidate the origin of the differences in oxidative and 
cellular stress observed here. 
 
If indeed no oxidative stress is present following Beta treatment, then other factors must be 
activating the cellular stress responses, potentially by direct activation via ligand-bound cGR. 
We observed that the negative feedback on the endogenous glucocorticoid axis, at the level 
of the cardiac GR was absent in Beta-treated embryos. Synthetic glucocorticoids are known 
to exert negative feedback via the GR, resulting in down-regulation of tissue GR levels 
(Paragliola et al., 2017). Down-regulation of GR at the level of transcription, results in lower 
protein levels and hence lower activation of GR pathways. Therefore, following Dex treatment 
there is a rapid peak of activation, followed by down-regulation of the cardiac GR. However, 
following Beta treatment this is not seen and hence GR-activated responses may be triggered 
and maintained. Additionally, the Na+-acetate prodrug formulation of Beta means Beta 
remains in the fetal circulation for longer compared to Dex, so overall activation of the GR 
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pathway may be greater and last for a longer period of development (Samtani et al., 2005). 
This may be critical in explaining the more severe effects of Beta on embryonic growth and 
cardiac function and structure.  It may also provide a further explanation for the divergent 
molecular pathways activated in the embryonic heart; essentially a dose-dependent effect 
may be seen whereby the effective dose of glucocorticoid is greater due to longer exposure 
and maintained GR-mediated responses following Beta compared with Dex administration. 
 
 
 
Figure 4.18 Molecular changes in hearts of Dex and Beta treated embryos. A. Dex treatment results in oxidative 
stress, activating cellular stress pathways and downstream chaperone proteins, caspase-3 mediated apoptosis, 
and p16 mediated decreases in cell proliferation, B. Beta treatment reaults in excessive GR activation, cell stress 
pathway activation, p53 mediated apoptosis, and p53/p16 mediated decreases in cell proliferation. 
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4.8.6 Effects on lung maturation 
 
Addtional results presented in this chapter demonstrate that both Dex and Beta accelerate 
maturation of the embryonic lungs. Histological markers of lung maturation such as increased 
parabronchial atrial diameter and air capillary diameter, are similarly enhanced by both 
glucocorticoids. However, Beta appears to have a greater effect in up-regulating lung proteins 
caveolin-1 and SP-B, both markers of late development lung maturation in the chicken 
embryo (Bjørnstad et al., 2014). This demonstrates that the beneficial pulmonary 
maturational effects associated with AGT are also seen in our avian model. There is some 
evidence in other animal models or clinical studies that Beta may be more potent in 
stimulating lung maturation and reducing risk of various pulmonary consequences of preterm 
birth, such as RDS and BPD (Jobe & Soll, 2004). It is not entirely clear if our model supports 
this difference, but what the data show is that Dex and Beta have both maturational effects 
on the lungs but they achieve this via differential mechanisms once again. 
 
4.8.7    Conclusions 
 
Adopting an integrative approach, combining functional experiments in isolated organs with 
those at the cellular and molecular levels, this chapter has isolated the direct effects of Dex 
compared with Beta on growth and the developing cardiovascular system using a chicken 
embryo model system.  We show that human clinically relevant doses of Dex or Beta result in 
significant asymmetric growth restriction, as well as cardiac and peripheral vascular 
dysfunction.  However, the mechanisms underlying these detrimental changes are highly 
divergent. Dex treatment promotes oxidative stress, cardiomyocyte hypertrophy, enhanced 
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peripheral constrictor responses to K and activation of GR-induced negative feedback 
pathways. Conversely, Beta does not promote oxidative stress but induces a marked 
reduction in cardiomyocyte number, while depressing vasoactive responses to K, PE and SNP, 
and also lacking any negative feedback at the level of the cardiac GR. Additional data show 
that both Dex and Beta accelerate lung maturation.  The more severe effects of Beta on 
embryonic growth and the developing cardiovascular system with similar maintenance of 
accelerated lung maturational responses, provide evidence that Dex compared with Beta may 
be safer for the treatment of the preterm baby.   
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CHAPTER 5: BETAMETHASONE PRODRUG FORMULATIONS  
5.1 INTRODUCTION 
 
Antenatal glucocorticoid therapy (AGT) has been used extensively in the clinic for the 
treatment of threatened pre-term birth since the 1990’s (NIH, 1994). It has been shown that 
AGT prior to preterm birth drastically reduces the risk of mortality and several severe 
morbidities such as Broncho-pulmonary dysplasia (BPD) and necrotising enterocolitis (NEC; 
Roberts et al., 2017). However, there are remaining serious questions as to how to optimise 
this therapy. Not only are two different synthetic steroids Dexamethasone (Dex) and 
Betamethasone (Beta), utilised for this therapy, but the dosing regimen and the formulations 
in which they are given (prodrugs) also differs, despite no clear evidence as to which has the 
greatest efficacy. 
 
Beta and Dex are stereoisomeric synthetic glucocorticoids with a glucocorticoid potency 
greater than cortisol, but with very little mineralocorticoid activity (He et al., 2014;  Buttgereit 
et al., 1999). Typically, both are administered via intramuscular injection to the mother 
following presentation with threatened preterm birth (Ballard, 2000). In order to solubilise 
the steroids, so they can be administered in this manner, a polar group is linked to the carbon 
backbone via an ester linkage, forming a biologically inactive pro-drug (Jornada et al., 2015). 
Dex is typically administered as a Na+-phosphate pro-drug, whilst Beta is given as a 50:50 
mixture of Na+-phosphate and acetate forms (the most common brand being Celestone 
Soluspan, produced by Merck; Fig.5.1; Schmidt et al., 2019). Dex is administered as 4x6mg 
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doses over a 48-hour period, whereas Beta is administered as 2x12mg doses, also over a 48-
hour period (Fig.5.1; Ballard, 2000). 
 
Figure 5.1 Drug regimens used for AGT. Molecular structures are shown above text, the Na+-phosphate moiety 
is shown in green, and the acetate moiety is shown in orange. 
 
For the steroids to become active in tissues they must be hydrolysed by endogenous enzymes, 
resulting in cleavage of the non-functional phosphate and acetate moieties (Miyabo et al., 
1981; Jornada et al., 2015). The rate of cleavage of the phosphate moiety is greater than that 
of the acetate moiety, leading to the acetate drug formulation having a longer half-life in 
plasma (Samtani et al., 2005). Indeed, this is the reason for only 2 doses of Beta being 
administered for AGT whereas Dex is given as 4 doses at shorter time intervals (Ballard, 2000). 
Evidence from maternal glucocorticoid administration in sheep has demonstrated that Beta 
phosphate administration results in a rapid peak of active glucocorticoid (9.3ngmL-1) in the 
fetal circulation at 2.4 hours, that is undetectable by 24 hours (Schmidt et al., 2018). 
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Conversely, maternal administration with Beta acetate doesn’t cause a rapid large peak of 
active glucocorticoid (3.13ngmL-1 is the maximal serum concentration), but a sustained 
smaller increase that is maximal at 8.5 hours and is still detectable after 24 hours (Schmidt et 
al., 2018). 
 
Despite these clear pharmacological differences, there are few clinical studies that have 
compared the efficacy of glucocorticoid prodrug formulations when treating threatened 
preterm birth. Some small clinical trials have suggested that Beta treatment has a greater 
efficacy in preventing neonatal death and BPD, whilst others have suggested that Dex 
phosphate is superior at preventing intra-ventricular haemorrhage (IVH) thus leading to 
better neurological outcomes (Lee et al., 2006; Elimian et al., 2007; Lee et al., 2008). Other 
studies have reported no observable differences between the two drugs (Bar-Lev et al., 2004). 
Schmidt et al., (2018) demonstrated in fetal sheep that a single 0.125mgkg-1 dose of Beta 
acetate was as effective at physiological lung maturation as 2 doses of 0.25mgkg-1 combined 
Beta. Further, sheep experiments have also suggested that combined Beta treatment is more 
consistently effective at increasing the expression of lung surfactant proteins than either Dex 
or Beta phosphate (Schmidt et al., 2016), suggesting that the acetate prodrug has a greater 
effect on lung maturation. As well as different efficacies in preventing morbidities associated 
with preterm birth, there is also evidence in animal studies for differences in adverse 
outcomes on other neonatal systems. For example, combined Beta may have a more 
pronounced acute effect on fetal heart rate and fetal body movements (Rotmensch et al., 
1999), and induces an increase in fetal femoral vascular resistance (Derks et al., 1997). 
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One of the well-known mechanisms leading to gluccocorticoid-induced hypertension 
following adult or fetal Dex exposure, is the generation of oxidative stress (Safaeian & 
Zabolian, 2014; Tain et al., 2014). Dex is known to be a potent inducer of oxidative stress in 
cell culture, and treatment of dex-induced hypertensive animals with antioxidants can restore 
normal physiological function (Zhang et al., 2004; Tai et al., 2016; Lin et al., 2018). Beta has 
also been associated with increases in oxidative stress in fetal animal models (Verhaeghe et 
al., 2009; Stojanovska et al., 2018). Therefore, it is possible that molecular changes involved 
in AGT-induced cardiovascular dysfunction relate to the generation of oxidative stress and 
the associated cellular responses, including activation of stress kinase pathways, cell cycle 
changes and apoptosis (Kim et al., 2016).  
 
The lack of any clear rationale for the choice of glucocorticoid, drug formulation, and dosing 
regimen used for AGT is concerning and in urgent need of further research. As preterm birth 
rates have not fallen over the past decade, a vast number of children will be exposed to these 
treatments (Harrison & Goldenberg, 2016). Both in terms of ensuring positive neonatal 
outcomes, and in reducing any potential negative side effects of this treatment, it is therefore 
necessary to have a better understanding of how all these factors influence outcomes. The 
chicken embryo model provides us with a unique opportunity to compare the direct effects 
of Dex phosphate vs combined Beta vs Beta phosphate vs Beta acetate, of clinically relevant 
doses on the developing cardiovascular system. This model has the additional benefit of 
removing any confounding influence of the mother and placenta, as the embryo develops in 
isolation within the egg. Studies in our laboratory have previously demonstrated that it is 
possible to dose the chicken embryo directly via application of aqueous solution to the 
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chorioallantoic membrane (Itani et al., 2015). Therefore this model allowed us to establish 
any differences between Dex and Beta drug formulations on embryonic growth, 
cardiovascular function and lung maturation. 
 
In this chapter we tested the hypothesis that differences in the cardiovascular dysfunction 
induced by Dex or Beta exposure in late cardiovascular development are dependent on the 
prodrug formulation administered, with combined and acetate prodrug formulations having 
a different severity and nature of dysfunction compared to the Na+-phosphate prodrug 
formulation. To address this hypothesis, there were 5 objectives:  
1. To investigate the effects of Dex phosphate, combined Beta, Beta phosphate, and Beta 
acetate treatment on embryonic survival and growth of the chicken embryo; 
2. To investigate the effects of Dex phosphate, combined Beta, Beta phosphate, and Beta 
acetate treatment on the cardiac function and structure of the chicken embryo; 
3. To investigate the effects of Dex phosphate, combined Beta, Beta phosphate, and Beta 
acetate treatment on peripheral vascular function in the chicken embryo; 
4. To investigate the molecular pathways induced by Dex phosphate, combined Beta, 
Beta phosphate, and Beta acetate treatment in the chicken embryo; 
5. To investigate the effects of dexamethasone phosphate, combined betamethasone, 
betamethasone phosphate, and betamethasone acetate on lung maturation in the 
chicken embryo. 
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5.2 METHODS 
5.2.1   Experimental Protocol 
 
Detailed experimental procedures are shown in Section 2.  In brief, all procedures were 
performed under the U.K. Animals (Scientific Procedures) Act 1986 and were approved by the 
Ethical Review Board of the University of Cambridge. Fertilised Bovans Brown chicken eggs 
were weighed, irradiated with UV light, and placed into an incubator at 38°C and 45% 
humidity for 19 days (see Section 2.1.). Eggs were dosed with Dexamethasone phosphate or 
Betamethasone phosphate/acetate/combined (Celestone, Merck, USA), or Dexamethasone 
sodium-phosphate, Betamethasone sodium-phosphate, Betamethasone acetate (Sigma, UK) 
in aqueous solution, or water on day 14 of development via injection through a small hole in 
the shell (situated above the air sac) onto the chorioallantoic membrane, as previously 
described (Itani et al., 2015).  
 
The glucocorticoid dose used in this study was 0.1mgkg-1. AGT was administered on day 14 of 
incubation, which is equivalent to 26/27 weeks in human pregnancy; a relevant, early period 
at which glucocorticoids can realistically be administered in the clinical setting (Roberts & 
Dalziel, 2006).  
 
5.2.2 Assessment of Embryonic Growth 
 
On Day 19 of incubation embryonic growth was assessed using a high precision calliper 
(Mitutoyo 500-181-20, UK) to determine embryonic lengths. Embryo mass and mass of the 
eggshell, yolk, extra tissues, and any remaining liquid was measured and recorded. The ratio 
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of partitioning of resources was calculated as embryonic tissue mass/extra-embryonic tissue 
mass. Crown-rump length, head diameter, head length were recorded (Section 2.2). 
Individual organs were also dissected and weighed. 
 
5.2.3 Assessment of Cardiac Structure & Function 
 
A cohort of 10 embryos per group at day 19 were anaesthetised with sodium pentobarbitate 
(0.3mL of Pentoject (Animalcare Ltd., York, UK), intraperitoneal) then perfusion fixed using 
paraformaldehyde (Section 2.5) at 2.66kPa (embryonic day 19 blood pressure) inserted into 
the left ventricle via a cannula. Fixed hearts were sectioned into 1mm slices and 
photographed. Areas of cardiac compartments in each section were counted, and a mid-
cardiac section was chosen for measurement. Volumes were then calculated as per Section 
2.5.  
 
Cardiomyocytes were also isolated from hearts of day 19 embryos (Section 2.6) by perfusing 
the coronary vasculature with collagenase and protease solution. After 10 minutes, the hearts 
were perfused with Krebs buffer to remove enzymes, and then suspended in buffer for 40 
minutes. Cells were stored in 4% PFA. Cardiomyocyte suspensions were mixed with 10% 
methylene blue in a 1/1 ratio and visualised under a light microscope (Section 2.6). Cell 
nuclearity of 300 random cardiomyocytes per heart was assessed, and measurements of 
length and width were taken from 50 random cardiomyocytes. Cell volumes were then 
calculated (Section 2.6). 
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To assess ex vivo cardiac function hearts were rapidly excised and placed into icy Krebs Buffer 
solution. The aorta was cannulated onto a 19-gauge blunt needle and mounted onto the 
Langendorff apparatus. Pressure recordings were subsequently made (Section 2.3). In brief; 
following a period of normalisation, a small non-distensible balloon made from saran wrap, 
and connected to a pressure transducer, was introduced through the left atrium into the left 
ventricle. The balloon was then filled with water in 5µL increments until a smooth baseline 
recording was established. Baseline recordings were made and Coronary Flow Rate (CFR) was 
assessed. In vitro responses to the sympathetic agonist Isoprenaline (Sigma-Aldritch, in the 
range 10-9 – 10-7) and the parasympathetic agonist Carbachol (Sigma-Aldrich, in the range 10-
8 – 10-6) were then determined by administering via the perfusing cannula. Analysis of the 
Langendorff experiments was conducted on the LabChart software (Version 7, 
ADInstruments).  
 
5.2.4 Assessment of Peripheral Vascular Function 
 
A second order branch of the femoral artery was dissected into cold Krebs solutions and then 
2mm sections were mounted onto a wire myograph (Section 2.4). Vessels were maintained 
at 38°C in Krebs solution, and were aerated with 95% O2/5% CO2 gas. To assess 
vasoconstrictor responses vessels were exposed to increasing doses of NE, 5-HT, PE, and ET-
1 at 2-minute intervals. To assess vasodilator function vessels were pre-constricted with K+, 
then exposed to increasing doses of Ach, or SNP. To assess the NO dependent component of 
the Ach response, vessels were treated with 5µm L-NAME (Section.2.4). 
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5.2.5 Assessment of Molecular Pathways in the Heart 
 
Frozen heart tissues were powdered on dry ice, and separated into 50mg aliquots, then stored 
at -80°C. Extraction of proteins was conducted in TK lysis buffer (Section 2.7.1). For Western 
blot analysis, protein extracts were separated on a 10% agarose gel, then stained with primary 
antibody and secondary antibodies (Table 2.2). Gel bands were then quantified as described 
in Section 2.7.2. To compare all 5 treatment groups, it was necessary to perform multiple 
blots per protein of interest. To control for intra-gel variability a set of control samples was 
run on each gel and the expression in all treatment groups was calculated relative to the mean 
of all control values. 
 
A further set of frozen tissue aliquots were used to conduct RNA extraction using a Qiagen 
RNEasy mini kit (Qiagen, NL; Section 2.7.3). RNA samples were then converted into cDNA 
libraries using Qiagen Reverse Transcriptase kit (Qiagen, NL). DNA primers to various mRNAs 
of interest were designed and tested (only primers that gave a single peak, with a clear dose 
dependent relationship were used further; Table 2.3). mRNA expression analysis was then 
conducted as per Section 2.7.4.  
 
5.2.6 Assessment of embryonic lung maturation 
 
Perfusion fixed lungs were embedded in paraffin, then sectioned into 8µm sections with an 
ultramicrotome (Section 2.8). Slides were stained with haematoxylin and eosin (Section 2.6), 
then imaged. Measurements of parabronchial atrial diameter (n=20), atrial septum thickness 
(n=20), air capillary diameter (n=20), and distance between air capillary and nearest blood 
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vessel (diffusion distance) (n=20), and thickness of gas exchange zone (n=5) were taken per 
animal. 
 
5.2.7 Statistics 
 
All data except for dose-response curves were analysed using a one-way ANOVA with Tukey 
post-hoc test, conducted on GraphPad Prism 7 (Graphpad Software, CA, USA) software. 
Statistical differences (p<0.05) are demonstrated by different letters. Dose-response curves 
were assessed using a mixed-model two-way ANOVA. In this case, significant differences to 
control values are indicated by * , whilst significant differences between Dex and Beta values 
are indicated by †. For all comparisons, significance was taken as P<0.05. 
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5.3 EFFECTS ON EMBRYONIC GROWTH 
 
All pro-drug formulations resulted in a significant embryonic growth restriction, with Beta 
prodrugs having a more severe effect than Dex (Fig.5.2 A). In terms of both absolute and 
relative embryo mass, Beta phosphate had less of an effect than either combined Beta or Beta 
acetate (Fig.5.2 A&B). Whilst the ratio of embryonic to extra-embryonic tissues was decreased 
in the Dex group relative to controls, it was decreased even more in Beta treatment groups, 
with combined Beta having the most severe effect (Fig.5.2 C). All Beta treatments increased 
liquid mass in the day 19 egg (Fig.5.2 D). Whilst CRL was unchanged, relative head diameter 
was increased in all Beta treatment groups (Fig.5.2 E&F). All treatments increased relative 
heart mass (Fig.5.2 H), however only combined Beta significantly increased relative brain 
mass (Fig.5.2 G). 
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Figure 5.2 Day 19 biometry. A. absolute embryo mass (g), B. relative embryo mass (% of d19 egg mass), C. ratio 
of embryonic to extraembryonic tissue mass, D. liquid mass in d19 egg (% d19 egg mass), E. crown-rump length 
(mm), F. relative head diameter (mm/g d19 embryo mass), G. relative brain mass (%d19 embryo mass), H. 
relative heart mass (% d19 embryo mass), in control (n=10), Dex (n=10), combined Beta (n=10), Beta phosphate 
(n=10), and Beta acetate (n=10) treated embryos. One-way ANOVA with Tukey post-hoc test, P<0.05 significant 
differences represented by different letters. 
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5.4 EFFECTS ON CARDIAC STRUCTURE & FUNCTION 
 
Combined Beta resulted in a significant decrease in left ventricle wall volume, and an 
increased in left lumen to wall area and volume ratio (Fig.5.3 A&C). Dex phosphate treatment 
resulted in a significant increase in left lumen volume (Fig.5.3 B), but no significant increase 
in lumen to wall area or volume ratio (Fig.5.3 C&D). Combined Beta treatment resulted in a 
decrease in right ventricle wall volume, an increase in right ventricle lumen volume whilst the 
other treatments did not (Fig.5.3 E&F). This resulted in an increased right ventricle wall to 
lumen area and volume ratio in the combined Beta treatment group (Fig.5.3 G&H). 
 
Only Dex phosphate significantly increased cardiomyocyte volume, and significantly reduced 
the percentage of mono-nucleated cardiomyocytes (Fig.5.4 B&C).  Both combined Beta and 
Beta phosphate treatment reduced cardiomyocyte width (Fig.5.4 A), although this had no 
significant effect on cardiomyocyte volume. All Beta treatments resulted in a significant 
reduction in the cardiomyocyte nuclear density in the left ventricle (Fig.5.4 D). 
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Figure 5.3 Cardiac stereology. A. left ventricle wall volume (mm3), B. left ventricle lumen volume (mm3), C. left 
ventricle lumen to wall area ratio, D. left ventricle lumen to wall volume ratio, E. right ventricle wall volume 
(mm3), F. right ventricle lumen volume (mm3), G. right ventricle lumen to wall area ratio, H. right ventricle lumen 
to wall volume ratio, in control (n=10), Dex (n=10), combined Beta (n=10), Beta phosphate (n=10), and Beta 
acetate (n=10) treated embryos. One-way ANOVA with Tukey post-hoc test, P<0.05 significant differences 
represented by different letters. 
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Figure 5.4 Cardiomyocyte analysis. A. cardiomyocyte width (µm), B. cardiomyocyte volume (µm3), C. % 
mononucleated cardiomyocytes, D. cardiomyocyte nuclear density (nuclei/mm3), in control (n=8), Dex (n=8), 
combined Beta (n=10), Beta phosphate (n=10), and Beta acetate (n=10) treated embryos. One-way ANOVA with 
Tukey post-hoc test, P<0.05 significant differences represented by different letters. 
 
 
 
All Beta treatments resulted in a significant impairment of LVDP. All treatment groups had a 
significantly greater LVEDP and Tau than the control treated embryos (Fig.5.5 A-D). Only 
combined Beta treatment significantly decreased CFR and total cycle duration, due to a 
significant depressive effect on the systolic component of the cardiac cycle (Fig.5.6 A&B). In 
terms of cardiac response to autonomic agonists, all Beta treatments increased the HR 
response ratio to isoprenaline relative to carbachol (Fig.5.7 B). 
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Figure 5.5 Systolic and diastolic function A. left ventricular developed pressure (mmHg), B. contractility index 
(1/s), C. left ventricular end diastolic pressure (mmHg), D. tau (s),  in control (n=10), Dex (n=10), combined Beta 
(n=10), Beta phosphate (n=10), and Beta acetate (n=10) treated embryos. One-way ANOVA with Tukey post-hoc 
test, P<0.05 significant differences represented by different letters. 
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Figure 5.6 Coronary flow rate & cycle duration. A. coronary flow rate per unit cardiac mass (mlmin-1g-1), B. cycle 
duration (s), in control (n=8), Dex (n=8), combined Beta (n=10), Beta phosphate (n=6), and Beta acetate (n=6) 
treated embryos. One-way ANOVA with Tukey post-hoc test, P<0.05 significant differences represented by 
different letters. 
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Figure 5.7 Cardiac response to autonomic agonists. A. ratio of maximal LVDP isoprenaline response to maximal 
LVDP carbachol response, B. ratio of maximal HR isoprenaline response to maximal HR carbachol response, in 
control (n=8), Dex (n=8), combined Beta (n=10), Beta phosphate (n=6), and Beta acetate (n=6) treated embryos. 
CF One-way ANOVA with Tukey post-hoc test, p<0.05 significant differences represented by different letters, 
ABDE two-way ANOVA with Tukey post-hoc test, P<0.05 *significantly different to control, † significantly 
different to Dex. 
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5.5 EFFECTS ON PERIPHERAL VASCULAR FUNCTION 
 
All Beta treatments impaired the contractile response to KCl compared to the Dex treatment 
group (Fig.5.8 A&B). However, only Beta acetate significantly reduced KCl response relative 
to control embryos (Fig.5.8 B). All Beta treatments also impaired the contractile response to 
PE compared to both control and Dex treatment groups, in terms of response to higher doses 
but not in terms of area under the curve (Fig.5.8 C&D). Beta phosphate and Beta acetate 
significantly impaired contractile response to 5-HT whilst neither Dex or combined Beta had 
any effect (Fig.5.8 E&F). Dex, combined Beta, and Beta acetate significantly increased the 
contractile response to ET-1 compared to control embryos. Beta phosphate increased the 
response to an even greater extent (Fig.5.8 G&H). 
 
All Beta treatments significantly impaired relaxation in response to SNP relative to Dex 
embryos, whilst combined Beta and Beta phosphate also significantly impaired relaxation 
relative to control embryos, however there was no significant difference in area above the 
curve (Fig.5.9 C&D). All Beta treatments also significantly impaired NO-independent 
vasodilatation compared to Dex treatment (Fig5.9 B). Beta phosphate also impaired the 
response to Ach in the centre of the dosing curve (Fig.5.9 A). 
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Figure 5.8 Vasoconstrictor responses. A. tension generated in response to KCl (mM), B. Area under the curve of 
the KCL response (arbitrary units), C. response to PE as a % of maximal KCl response, D. pD2 of PE response, E. 
response to 5-HT as a % of maximal KCl response, F. area under the curve of 5-HT response (arbitrary units), H. 
response to ET-1 as a % of maximal KCl response, H. maximal ET-1 response as a % of maximal KCl response, in 
control (white, n=10) Dex (blue, n=10) Beta (red triangles, n=10), Beta acetate (red squares, n=8) and Beta 
phosphate (red circles, n=8) treated embryos, ACEG two-way ANOVA with Tukey post-hoc test where P<0.05 * 
represents statistically different to control, and † represents statistically different to Dex, BDFH ordinary one-
way ANOVA with Tukey test. statistically significant differences denoted by different letters. 
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Figure 5.9 Vascular vasodilator responses. A. vascular relaxation from KCl-induced pre-constriction in response 
to increasing doses of Ach, B. breakdown of the vasodilator response to Ach, by treating vessels with the eNOS 
inhibitor L-NAME, and assessing the area above the Ach dose-response curve, before and after inhibition, the 
area under the curve dependent on eNOS and hence NO can be determined, C. vascular relaxation from KCl-
induced pre-constriction in response to NO donor SNP, in control (white, n=10), Dex  (blue, n=10), Beta (red 
triangles, n=10), Beta acetate (red squares, n=8) and Beta phosphate (red circles, n=8) treated embryos. AC two-
way ANOVA with Tukey post-hoc test where P<0.05 * represents statistically different to control, and † 
represents statistically different to Dex, B ordinary one-way ANOVA with Tukey test. Statistically significant 
differences denoted by different letters. 
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5.6 EFFECTS ON MOLECULAR PATHWAYS IN THE HEART 
 
Beta phosphate treatment resulted in a significant decrease in protein carbonylation levels 
(Fig.5.10 A). No treatment resulted in a significant change in expression of (Mn)-SOD or 
Catalase relative to control levels (Fig.5.10 B&C). Both Dex and combined Beta treatment 
significantly up-regulated pERK/ERK levels whilst Beta phosphate and Beta acetate 
significantly reduced them (Fig.5.11 A). Dex treatment also significantly raised the pSAPK/JNK 
/ SAPK/JNK protein expression (Fig.5.11 A). Both Dex and combined Beta treatment 
significantly raised levels of chaperones hsp60 and PDI, whilst Beta acetate increased 
expression of hsp27 (Fig.5.11 A). Whilst all glucocorticoid treatments significantly increased 
total caspase-3 levels, only Dex treatment significantly increased cleaved caspase-3 levels and 
the ratio of cleaved to total caspase-3 protein (Fig.5.11 B). Combined Beta treatment 
increased p16 mRNA expression, and Beta acetate increased p53 expression (Fig.5.11 C). 
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Figure 5.10 Oxidative stress indices. A. Levels of protein carbonylation detected by western blot, B. mRNA 
expression of Catalase, C. mRNA expression of SOD2 (Mn dependent), in control (n=6), Dex  (n=6), Beta (n=5), 
Beta acetate (n=5) and Beta phosphate (n=5) treated embryos. Ordinary one-way ANOVA with Tukey test. 
P<0.05, statistically significant differences denoted by different letters. 
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Figure 5.11 Cellular stress, apoptosis, and cell cycle markers. A. phosphorylated ERK protein/non-
phosphorylated levels, phosphorylated SAPK/JNK / non-phosphorylated levels, protein expression of 
chaperones HSP27, HSP70, HSP60, and PDI B. mRNA levels relative to control of MKK3, p16, p38, p53 C. protein 
levels of caspase-3 cleaved caspase-3, ratio of cleaved caspase-3 to total caspase 3, BCL,  in control (n=6), Dex  
(n=6)(only in B.), Beta (n=5), Beta acetate (n=5) and Beta phosphate (n=5) treated embryos. Ordinary one-way 
ANOVA with Tukey test. P<0.05, statistically significant differences denoted by different letters. 
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Both Dex and Beta phosphate treatment groups resulted in a significant reduction in GR 
protein levels relative to control levels, however Combined Beta and beta acetate had no 
effect (Fig.5.12). 
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Figure 5.12 GR protein levels. GR protein levels (relative to tubulin expression), in control (n=16), Dex (n=6), 
Beta (n=5), Beta acetate (n=5) and Beta phosphate (n=5) treated embryos. Ordinary one-way ANOVA with Tukey 
test. P<0.05, statistically significant differences denoted by different letters. 
 
 
5.7 EFFECTS ON LUNG MATURATION 
 
Only combined Beta treatment resulted in a significant increase in protein expression of 
caveolin-1 and SP-B (Fig.5.13 A&B). All treatments resulted in significantly increased 
parabronchial atrial diameter, air capillary diameter, and reduced diffusion distance (Fig.5.14 
A-C). Dex treatment also significantly increased the thickness of gas exchange zone in the 
embryonic lungs, relative to control embryos (Fig.5.14 D). 
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Figure 5.13 Protein markers of lung maturation. A. Expression of caveloin-1 (% control expression), B. 
expression of SP-B (% control expression), in control (n=6), Beta (n=6), Beta acetate (n=5), and Beta phosphate 
(n=5) treated embryos. Ordinary one-way ANOVA with Tukey test. P<0.05, statistically significant differences 
denoted by different letters. 
 
Figure 5.14 Morphological markers of lung maturation. A. parabronchial atrial diameter (µm), B. air capillary 
diameter (µm), C. diffusion distance (µm), D. thickness of gas exchange region adjacent to parabronchi (µm), in 
control (n=8) Dex (n=8) Beta (n=6) Beta acetate (n=6) and Beta phosphate (n=6) treated embryo Ordinary one-
way ANOVA with Tukey test. P<0.05 statistically significant differences denoted by different letters. 
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5.8   DISCUSSION 
 
5.8.1 Summary 
 
The data in this chapter show that prodrug formulations resulted in a significant asymmetric 
embryonic growth restriction at day 19 of incubation. Combined Beta and Beta acetate 
resulted in a more severe asymmetric growth restriction (in terms of relative embryo mass, 
and relative head diameter), compared with either Dex or Beta Phosphate. However, 
combined Beta had a more severe effect promoting asymmetric growth restriction than the 
other treatments as relative brain mass was also increased. Relative heart mass was 
significantly increased by all drug treatments, with a more severe effect when combined Beta 
was given. In terms of cardiac structure, only combined Beta had a significant left ventricular 
dilatation compared to control embryos. Dex treatment resulted in a significant hypertrophy 
of individual cardiomyocytes and a decrease in the percentage of mononucleation. All Beta 
treatments did not affect cardiomyocyte volume but did significantly reduce nuclear density. 
All drug treatments impaired cardiac diastolic function, whilst all Beta treatments also 
impaired systolic function. Only combined Beta treatment resulted in a decrease in CFR and 
cardiac cycle duration, whist all Beta treatments resulted in a significant increase in the heart 
rate response ratio of the maximal heart rate change to isoprenaline relative to carbachol, 
indicating sympathetic dominance. 
 
In the peripheral vasculature, Beta treatment impaired responses to vasoconstrictors KCl, PE 
and 5-HT, with Beta acetate being the most severely affected. All drug treatments increased 
vascular responses to ET-1, with Beta phosphate having the largest effect. All Beta treatment 
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groups had an impaired vasodilator response to NO donor SNP and had a reduced NO-
independent vasodilator response to Ach. 
 
There was no evidence for oxidative stress in any Beta treatment group as protein 
carbonylation levels were unchanged relative to controls and decreased by Beta phosphate. 
Beta acetate and Beta phosphate treatment appeared to reduce cellular stress by reducing 
the pERK/ERK whilst not affecting pSAPK/JNK / SAPK/JNK protein ratios. Beta phosphate also 
resulted in a decrease of downstream chaperone PDI, whilst not affecting cellular chaperones 
hsp27, hsp70, or hsp60. Beta acetate and Beta phosphate also reduced the ratio of cleaved 
caspase-3 to total caspase-3 protein. GR protein was down-regulated in hearts from Dex and 
Beta phosphate treated embryos, suggesting active negative feedback. 
 
In the embryonic lungs combined Beta treatment alone significantly increased levels of 
surfactant proteins caveolin-1 and SP-B. All Beta treatment groups significantly increased 
histological measures of pulmonary maturation to the same extent as Dex treatment. Dex 
treatment alone increased the thickness of the pulmonary gas exchange zone. 
 
In this chapter we addressed the hypothesis that differences in the cardiovascular dysfunction 
induced by Dex or Beta exposure in late cardiovascular development is dependent on the 
prodrug formulation administered, with combined and acetate prodrug formulations having 
a different severity and nature of dysfunction compared to Na+-phosphate prodrug 
formulations. The evidence here partially support the hypothesis that the prodrug 
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formulation administered affects the severity and nature of growth restriction and the 
induced cardiovascular dysfunction.   
 
5.8.2 Effects on Embryonic Growth 
 
As with the Dex and combined Beta treatments, treatment of the developing chicken embryo 
with either Beta acetate or Beta phosphate prodrug formulation resulted in a significant 
asymmetric growth restriction. The severity of the growth restriction is greater following 
combined Beta treatment than Dex treatment. Beta acetate resulted in a similar severity of 
growth restriction as the combined Beta treatment, whereas Beta phosphate acted more like 
Dex treatment. The observation that Beta acetate seems to be responsible for the worst 
growth restriction is likely related to the different pharmacokinetics of the prodrugs. There is 
extensive evidence for the Beta acetate drug formulation remaining in the fetal circulation 
for longer than the phosphate formulation, following maternal administration (Samtani et al., 
2005; Salem & Najib, 2012). Therefore, it is likely that embryos exposed to the acetate 
prodrug have an overall greater activation of the GR pathways over time, which are known to 
stimulate the switch from tissue accretion to maturation (Fowden & Forhead, 2015; Fowden 
et al., 2016). However, we also observed subtle differences between Dex phosphate and Beta 
phosphate prodrug formulations (for example in liquid mass in the day 19 egg), suggesting 
that the nature of the stereoisomer itself is also partly responsible for nutrient resource 
distribution and conversion into fetal mass. Most pharmacological studies suggest a similar 
glucocorticoid potency of Dex and Beta of around 25-30x greater than hydrocortisone 
(Buttgereit et al., 1999; Parente, 2017). However, there is some evidence for subtle 
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differences, for example Dex and Beta phosphate administered at the same dose display 
differences in molecular markers of lung maturation (Schmidt et al., 2016).  
 
 
5.8.3 Effects on the Embryonic Heart 
 
Effects of the various glucocorticoid treatments on the embryonic heart were more divergent 
than those on growth. All treatments resulted in a significant increase in relative heart mass, 
however combined Beta had a more severe effect than Dex. Similarly, only combined Beta 
treatment resulted in a significant left and right ventricle dilatation in the heart, associated 
with decreases in left and right ventricle wall volumes. At the level of individual 
cardiomyocytes, Dex treatment induced a significant increase in cell volume, and a decrease 
in the % mononucleation. All Beta treatments induced a significant decrease in nuclear 
density in the left ventricle, without affecting cardiomyocyte volume or nuclearity. Whilst all 
drug treatments resulted in a significant increase in LVEDP and Tau, indicative of diastolic 
dysfunction, only Beta treatment groups impaired LVDP, indicative of systolic dysfunction. 
 
 It appears that Dex treatment has resulted in a premature switch away from cardiomyocyte 
hyperplasia towards hypertrophy (Oparil et al., 1984; Christoffels et al., 2000; Corrigan et al., 
2010). Significant cardiomyocyte hypertrophy, and a decrease in % mono-nucleation in the 
Dex treated hearts may explain the diastolic dysfunction as premature maturation may impair 
electrical conductance and contractility, leading to an inability of the left ventricle to relax 
normally (Fig.5.15; Severinova et al., 2019). It may be that the Dex hearts have undergone 
hypertrophy as an adaptive response to prevent further ventricle dilatation, and this is why 
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hearts in this group are less severely affected. The severe dysfunction observed in the Beta 
treated hearts appears to be a result of the significant decrease in cardiomyocyte number 
leading to thinner ventricle walls and lower myofibril density. This has ultimately resulted in 
a dilated cardiac phenotype (see Fig.5.15; Bollen et al., 2017). The additional dilatation 
observed in the right ventricle in the Beta treated embryos may also be due to the severe 
reduction in cardiomyocyte number, or the increased dilatation in the left ventricle leading 
to a greater resistance in the pulmonary circulation and via the foramen ovale (Kurmani and 
Squire, 2017). The observation that combined Beta treatment is substantially more severe in 
terms of cardiac dilatation than either acetate or phosphate prodrugs alone, suggests that 
exposure to both prodrug forms has additional negative effects. Whilst the phosphate 
prodrug results in a rapid peak of free glucocorticoid in the circulation, the acetate form 
results in a lower sustained release (Samtani et al., 2005). The combination of the two may 
lead to a greater overall exposure; essentially the embryo is receiving a ‘double hit’ of 
activated glucocorticoid (Samtani et al., 2005). However, other studies have suggested that 
fetal exposure to active Beta is actually greater when the phosphate form is given compared 
to the combined form (Schwab et al., 2006). Clearly there are difficulties associated with 
measuring active glucocorticoid in the circulation, and our lack of knowledge of movement 
between the prodrug and active drug pools makes interpretation difficult.  
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Figure 5.15 Summary of effects of glucocorticoids administered as different prodrug formulations on left 
ventricle structure. Dexamethasone results in a significant hypertrophy of individual cardiomyocytes, whilst 
Beta treatment drastically reduces cardiomyocyte number without altering cardiomyocyte volume. This is most 
severe in the combined Beta treatment group where a significant left ventricle dilatation is present. 
 
 
5.8.4 Effects on the Peripheral Vasculature 
 
Dex treatment results in a switch towards a vasoconstrictor phenotype with an enhanced KCl 
and ET-1 response, whilst vasodilator responses are not affected. This may be secondary to 
increased hyperplasia or hypertrophy of vascular smooth muscle cells (vSMCs; McLellan et 
al., 1992; Volk et al., 2010), and alterations to either ET-1 receptor densities (e.g. upregulation 
of ET-A) and/or downstream contractile pathways (Kutzler et al., 2003; Lee et al., 2014).  
 
Beta treatments however resulted in distinct vascular phenotypes. KCl induced constriction is 
slightly reduced compared to controls thereby significantly impaired when compared to the 
enhanced Dex response in all Beta treatment groups, with Beta acetate being most severely 
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affected. All Beta treatments also resulted in a significant impairment of the vasoconstrictor 
response to higher doses of α1-adrenergic receptor agonist PE, and this effect is similar 
between the different prodrug formulations. This decreased PE responsiveness is likely 
secondary to a decrease in α1-adrenergic receptor density, or decreased receptor binding 
affinity in the femoral vascular bed (Brozovich et al., 2016; Ullian, 1999). ET-1 induced 
vasoconstriction, like PE induced vasoconstriction, is also primarily mediated by stimulating 
IP3 production, downstream Ca2+ release and myosin light chain kinase (MLCK) activation, 
resulting in increased vascular constriction (Brozovich et al., 2016; Davenport et al., 2016). 
There is also evidence that enhanced ET-1 responses may be secondary to activation of the 
cyclic ADP ribose (cADPR)/ryanodine receptor pathway (Lee et al., 2014). cADPR is an 
intracellular secondary messenger which regulates ryanodine receptor opening allowing Ca2+ 
release from the sarcoplasmic reticulum. Activation of the ET-B receptor can activate cADPR 
induced vasoconstriction in the vSMCs, whilst ET-A can act via cADPR or the classic IP3 pathway 
(Barone et al., 2002). Hence, it is possible that the enhanced ET-1 response is due to increased 
cADPR signalling, and that a downstream inhibition of the IP3 pathway is present in the Beta 
treatment groups. Clearly, further investigation into the effects of inhibiting cADPR 
production or blocking specific ET-1 receptors would help illuminate the specific altered 
mechanisms.  
 
 
An additional vasoconstrictor dysregulation is seen in the Beta phosphate and acetate 
treatment groups, as both have a severely attenuated response to 5-HT. Serotonin (5-HT) is 
known to act via a multitude of receptors and to have divergent effects in different vascular 
system (Watts, 2016). The dose-dependent vasoconstriction is thought to mainly be due to 
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action of the 5-HT-2A receptor (Watts, 2005), and excess 5-HT has long been associated with 
hypertension in the adult (Huzoor-Akbar et al., 1989; Watts & Thompson, 2004; Nichols, 
2009). The reduced response in Beta phosphate and acetate exposed embryos could be 
secondary to a variety of factors including distribution and identity of 5-HT receptors in the 
femoral artery. Other studies have demonstrated that glucocorticoids can attenuate 5-HT 
mediated vasoconstriction (Angeles et al., 2006; Selli & Tosun, 2016). A further study of 5-HT 
receptors sub-types would help elucidate the mechanism behind the altered 5-HT vascular 
constriction reported here, and why this dysfunction is not seen in the combined Beta 
treatment group. 
 
A similar effect on vasodilator function was seen in all Beta treatment groups. Overall 
relaxation to muscarinic agonist Ach was not significantly altered, however the NO-
independent component of the response was down-regulated. Ach is known to induce 
vasodilatation by several concurrent mechanisms, including production of NO by endothelial 
NO synthase (eNOS), production of prostacyclins by cyclo-oxygenase-1 (COX-1), and 
production of other vascular mediators, such as H2S, termed endothelial derived 
hyperpolarising factor (EDHF; Liberman et al., 2018). This suggests that Beta femoral vessels 
are more reliant on NO-dependent vasodilatation to relax. We also observed a significant 
impairment in the response to NO delivered by NO donor SNP. NO produced in the 
endothelium in response to various receptor agonists (such as Ach), or in response to shear 
stress, rapidly diffuses into the vSMCs whereby it activates soluble guanylate cyclase (sGC) 
leading to increased production of cyclic guanine monophosphate (cGMP). This in turn 
induces vasodilatation by enhancing Ca2+ reuptake, and opening hyperpolarising K+ channels 
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(Chen et al., 2008). NO may also directly interact with sarcoplasmic reticulum Ca2+ ATPase 
(SERCA) to reduce cytosolic Ca2+ levels (Zhao et al., 2015). The impaired response to SNP in 
femoral vessels from all Beta groups suggests down-regulation of one or more of these 
pathways in the vSMCs themselves. Hence the down-regulation of NO-independent 
vasodilatation, and the impaired response to SNP in the Beta treated embryos is evidence of 
an impaired vasodilator function at the level of the vascular smooth muscle and the 
endothelium. It is unclear which NO-independent pathways are altered in these Beta-exposed 
vessels; further investigation using selective enzyme inhibitors would help to further 
elucidate the dysfunctional phenotype. Nevertheless, it appears broadly that the vascular 
dysfunction mirrors the cardiac dysfunction in glucocorticoid treated embryos. Whilst Beta 
treatment in these embryos seems to impair cardiac and vascular function, Dex treatment 
does not. 
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Figure 5.16 Vascular interactions following glucocorticoid exposure. Arrows represent upregulation of a 
pathway, whilst dashed lines represent suppression of a pathway. Interactions of vasodilators (blue) Ach which 
activates nitric-oxide synthase (eNOS), cyclo-oxygenase (COX) and endothelium derived hyperpolarising factors 
(EDHF). Production of NO and prostacyclins (PGI2) leads to production of secondary messengers cAMP and cGMP 
in the vSMCs, which activate K+ efflux channels, protein kinase A (PKA), SERCA, and inhibit myosin light-chain 
kinase (MLCK) and reduced Ca2+ sensitivity of sarcomeres. Vasoconstrictors (red) acting on 5-HT2A receptors or 
thromboxane receptors (TP Rs) on the endothelial cells stimulate production of ET-1, thromboxane (TBX2) and 
PGH2. Activation of 5-HT2A, TP, ET-A, or α1-adrenergic receptors leads to production of secondary messenger IP3 
and a subsequent increase in cytosolic Ca2+. 
 
 
5.8.5  Activation of molecular pathways in the heart 
 
Unlike Dex-treated hearts, none of the Beta treatment groups demonstrated any evidence of 
oxidative stress, and Beta phosphate has a significantly decreased level of protein 
carbonylation. Interestingly, whilst our previous results in Chapter 4 suggested an up-
regulation of cellular stress in both Dex and Beta treated embryos, there was no up-regulation 
in stress kinase pathways or downstream chaperones seen in the Beta acetate or Beta 
phosphate groups. In fact, we measured a significant decrease in the pERK/ERK ratio and in 
chaperone protein PDI in the Beta phosphate group, which suggests that cell stress pathways 
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are less likely to be active in these cells. Whilst Dex treated hearts had an increased ratio of 
cleaved caspase-3 to total caspase-3 protein, this was not present in any of the Beta 
treatment groups, suggesting that caspase-3 mediated apoptosis is not active in these 
embryos. p53 was significantly up-regulated in the Beta acetate group which is known to be 
a vital mediator of cellular senescence and known to be involved in architectural changes in 
the heart (p53 cardiac-specific knock-out in mice results in significant hypertrophy; Mak et 
al., 2017).  
 
It is well known in the adult that glucocorticoids have an immunosuppressive effect, reducing 
cellular stress signalling (Sapolsky et al., 2000). The pERK and pSAPK/JNK pathways are both 
highly associated with immune signalling, as both up-regulate production of NFκB and 
cytokine production (Meyerovich et al., 2016). There is also evidence in specific cell lines of 
Beta down-regulating pERK/ERK protein ratio, whilst initiating cellular differentiation (Jin et 
al., 2015). The difference in cell stress markers seen between the combined and individual 
Beta treatments may be linked to a dose-dependent effect of GR activation, with the 
combined treatment having a greater overall dose of GR activation leading to cellular stress, 
whereas lower levels of GR activation may reduce cellular stress pathway activation. There is 
indeed evidence in many different cell types of biphasic or more complex dose-dependent 
glucocorticoid responses (Richardson & Dodge, 2003; Yokoyama et al., 2008; Scheschowitsch 
et al., 2017). 
 
We also assessed negative feedback at the level of the GR protein in the embryonic heart. 
Synthetic glucocorticoids are known to exert negative feedback via the GR, resulting in down-
 211 
 
211 Chapter 5: Betamethasone Prodrug Formulations 
regulation of tissue GR levels (Paragliola et al., 2017). Down-regulation of GR at the level of 
transcription, results in lower protein levels and hence lower activation of GR pathways. 
Therefore, following Dex treatment there is a rapid peak of activation, followed by down-
regulation of the cardiac GR. However, following combined Beta, and Beta acetate treatment 
this is not seen. Interestingly, the negative feedback response is still present in the Beta 
phosphate treatment group, suggesting that the prolonged exposure of the Beta acetate 
prodrug is responsible for the lack of GR downregulation. Whilst a loss of GR negative 
feedback may explain the more serve effects of combined Beta and Beta acetate treatment 
through greater overall GR activation, it doesn’t explain why Beta phosphate has divergent 
effects on the embryonic heart when compared to Dex phosphate. Combined, the molecular 
data presented in this chapter suggest that following Dex exposure, oxidative stress activates 
cell stress pathways, the caspase-3 mediated apoptotic pathway, and altered cell cycle 
dynamics, whilst combined Beta treatment also induced cellular stress, decreased cell 
proliferation and non-caspase-3 mediated apoptosis secondary to greater activation of the 
GR pathways. Beta acetate also stimulates the excessive GR activation and increased p53 
expression, although without the associated cell stress.  Conversely, Beta phosphate restores 
GR negative feedback and reduces cellular stress, but still leads to a significant decrease in 
cardiomyocyte number via pathways that remain to be identified. 
 212 
 
212 Chapter 5: Betamethasone Prodrug Formulations 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17 Molecular changes in hearts of Dex and Beta treated embryos. A., Dex treament results in oxidative 
stress which activates cell stress pathways, caspase-3 mediated apoptosis and decreased cellular proliferation, 
B. combined Beta treatment results in excessive GR activation, cellular stress, apoptosis and decreased cellular 
proliferation, C. Beta phosphate treatment reduces GR activation, and activation of cell stress pathways (blue 
arrows), whilst resulting in apoptosis and decreased proliferation via as of yet uninvestigated pathways (dashed 
red arrow), D. Beta acetate also results in excessive GR activation and p53 mediated apoptosis and decreased 
cell proliferation.  
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5.8.6 Effects on Lung Maturation 
 
In our study both Dex and Beta induced maturation of the embryonic lungs. Histological 
markers of lung maturation such as increased parabronchial atrial diameter and air capillary 
diameter, are similarly enhanced by all glucocorticoid prodrugs. However, Beta acetate and 
phosphate appear to have little effect in up-regulating lung proteins caveolin-1 and SP-B (both 
markers of late development lung maturation in the chicken embryo; Bjørnstad et al., 2014), 
whereas combined Beta significantly up-regulated these proteins. There is some evidence in 
other animal models or clinical studies that Beta may be more potent in promoting lung 
maturation and reducing risk of adverse pulmonary consequences of preterm birth than Dex, 
such as RDS and BPD (Jobe and Soll, 2004).  
 
5.8.7 Conclusions 
 
The data in this chapter show that the severe growth restriction resulting from combined Beta 
treatment is likely secondary to the use of the slow-release acetate prodrug formulation. 
However, the severe effects of combined Beta on the embryonic heart and circulation appear 
to be caused by exposure to the combined acetate and phosphate drug forms, with the 
combined treatment having worse effects than either individual prodrug form alone. It is 
unclear how the pharmacokinetics of the two prodrug formulations interact to induce the 
cellular stress seen in the combined treatment group, but it appears unlikely that oxidative 
stress is responsible. We also observed sufficient components of embryonic lung maturation 
in all glucocorticoid treatment groups. Therefore, based on this evidence, to avoid the more 
severe effects of any Beta drug formulation on the developing cardiovascular system, it may 
be safer to use Dex for AGT clinically.  
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CHAPTER 6: GENERAL DISCUSSION 
6.1 HISTORICAL PERSPECTIVE 
 
Antenatal glucocorticoid therapy (AGT) for treatment of preterm birth is widely regarded as 
one of the most successful translations of basic science to clinical practise in recent history. 
The series of events leading up to the eventual adoption of AGT by the wider obstetric 
community is an example of both serendipitous scientific discovery and also of the relative 
inertia of obstetric medicine. Graham Liggins, an obstetrician in New Zealand, was funded by 
the Wellcome Trust in 1969 to conduct experiments in sheep to elucidate the mechanisms 
that trigger parturition. The ultimate goal of this research was to create a clinical therapy that 
could halt the normal mechanisms inducing labour in humans to try and prevent preterm 
birth. Liggins would go on to administer pregnant sheep with cortisol, and other synthetic 
glucocorticoids in attempts to initiate the parturition cascade. In the seminal 1969 paper, he 
reported not only that he had successfully induced preterm labour in his sheep model, but 
that the preterm born lambs had partial aeration of the lungs despite their prematurity 
(Liggins, 1969): 
‘Gross examination of the lungs of ten lambs delivered spontaneously at 117-123 days 
after dexamethasone infusions showed that in six, none of which had been artificially 
ventilated, there was partial aeration. In most instances the aeration consisted of 
patchy expansion in the upper lobes, but in one lamb delivered at 123 days the lower 
lobes were also partly expanded. This lamb was found alive at least an hour after being 
born and survived for a further hour until killed.’ 
 
Liggins correctly saw these observations as evidence that the pre-natal cortisol surge in sheep 
was not only responsible for initiating parturition, but also for maturing fetal organs ready for 
the neonatal transition. Indeed, it is now understood in sheep that the cortisol surge itself 
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directly stimulates labour by inducing high expression of the placental enzyme 17α-
hydroxylase which promotes placental oestrogen biosynthesis (Mason et al., 1989). 
Additionally, cortisol acts as a maturational signal for all physiological systems in the fetus, 
switching tissues from a state of accretion to that of differentiation and maturation (Fowden 
et al., 2016). Some of the most well-known effects of the prepartum cortisol surge are on the 
fetal lungs whereby cortisol, both directly and indirectly, promotes surfactant production, 
lung liquid removal, and increased lung compliance; all helping to ensure the neonate can 
ventilate when born (Ballard, 2000). 
 
The human situation however is dissimilar from that of the sheep in that the cortisol surge 
itself does not directly stimulate parturition; rather androgen of adrenal origin serves as the 
precursor for placental oestrogen synthesis (as the primate placenta does not express 17α-
hydroxylase; Mecenas et al., 1996; Nathanielsz et al., 1998). This difference means that the 
maturational potential of antenatal glucocorticoid treatment can be harnessed clinically 
without also directly inducing preterm labour. Liggins’ observations rapidly led to the 
initiation of a clinical trial in 1972, in which women presenting at hospital with threatened 
preterm labour were administered with the synthetic glucocorticoid betamethasone (Beta). 
Beta treatment significantly reduced instances of respiratory distress syndrome (RDS) in the 
neonates, and neonatal death (Liggins & Howie, 1972). Initially Beta was chosen because 
synthetic glucocorticoids Beta and dexamethasone (Dex) can readily cross the placenta as 
they are not inactivated by endogenous enzyme 11β-HSD2, and they have a longer plasma 
half-life than cortisol, therefore maximising the likelihood that maturational changes in the 
fetus will be initiated. A number of other clinical trials followed, all reporting the same 
 217 
 
217 Chapter 6: General Discussion 
beneficial effects of AGT. Despite the wealth of evidence demonstrating the life-saving 
potential of this treatment, it was not until the 1990’s that AGT was adopted as standard by 
the wider obstetric community. In 1994 the National Institutes of Health (NIH, 1994) released 
a consensus statement, purporting that: 
‘Antenatal corticosteroid therapy is indicated for women at risk of premature delivery 
with few exceptions and will result in a substantial decrease in neonatal morbidity and 
mortality, as well as substantial savings in health care costs.’ 
 
 
In the decades since this statement, AGT has become standard obstetric practise and most 
developed countries have high coverage rates with over 80% of women threatened with 
preterm labour receiving treatment. However, there is increasing evidence that whilst AGT is 
clearly lifesaving, it may have undesired detrimental effects on other organ systems. Indeed, 
the glucocorticoid receptor (GR) is ubiquitously expressed in the developing fetus, and its 
activation has a myriad of diverse tissue specific effects. Hence, while accelerated maturation 
of the lungs may be beneficial, the same may not be true for other organ systems. The work 
in this thesis has isolated direct adverse effects of Dex and Beta and their formulation of 
administration on the developing cardiovascular system. 
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6.2  SUMMARY OF RESULTS 
 
 
 
Table 6.1 Summary of results. Blue arrows represent an increase, red arrows a decrease, and dashes no change.  
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The data in this thesis show that direct treatment of the chicken embryo with a human 
clinically relevant dose of dexamethasone (Dex) or betamethasone (Beta) at a developmental 
stage equivalent to the 26-week-old human fetus promotes asymmetric growth restriction 
and adversely affects cardiovascular structure and function (key results shown in Table 6.1). 
Specifically, hearts isolated from Dex-treated embryos had biventricular lumenal dilatation, 
and evidence of systolic and diastolic dysfunction. Hearts from Beta-treated embryos had a 
more severe dilated phenotype, impaired systolic and diastolic function, as well as 
impairments to coronary flow and heart rate. Mechanisms underlying the cardiovascular 
dysfunction in Dex-treated embryos included blunted inotropic responses to autonomic 
receptor agonists and cardiomyocyte hypertrophy with reduced proliferation. Enhanced in 
vivo generation of mitochondria-derived ROS, protein carbonylation and activation of ROS-
induced cardiomyocyte senescence pathways provide a molecular link between 
dexamethasone treatment with adverse cardiovascular changes in the chicken embryo. In 
Beta treated embryos, a severe reduction in cardiomyocyte proliferation and increased 
cellular stress without evidence for oxidative stress was determined, suggesting a key 
divergence in mechanisms of cardiac dysfunction between the two synthetic glucocorticoids. 
 
Further, we aimed to understand the role of different Beta prodrugs in inducing the severe 
cardiovascular dysfunction witnessed in these embryos. We have demonstrated that the 
acetate prodrug is primarily responsible for the more severe effects of Beta on embryonic 
growth, likely secondary to loss of GR negative feedback. However, we have also 
demonstrated that a combined prodrug treatment is significantly worse for the developing 
cardiovascular system than either phosphate or acetate prodrug alone; potentially delivering 
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a ‘double-hit’ of both short-term and prolonged active glucocorticoid exposure. The 
molecular pathways activated by Beta acetate seem to largely result in up-regulation of p53, 
and severe impairment of cell proliferation without activation of cell stress pathways. It is 
unclear how Beta phosphate also results in the significant reduction in cardiomyocyte number 
observed, as none of the pathways we assessed appeared to be activated, and indeed it 
appears as though Beta phosphate acts to reduce cellular stress. 
 
Finally, we demonstrated that combined Beta had the most beneficial effects on the 
embryonic lungs, leading to significant up-regulation of surfactant proteins caveolin-1 and SP-
B. Dex also increased protein expression of these maturational markers although to a lesser 
extent. Neither Beta acetate or phosphate significantly altered expression of either protein 
relative to controls. Histological indices of lung maturation were similarly altered in all 
glucocorticoid treatment groups except for thickness of gas exchange region which was only 
increased following Dex treatment. 
 
Therefore, despite maturational beneficial effects on the lungs, the data provide robust 
evidence for direct adverse effects on the cardiovascular system of the developing offspring 
independent of effects on the mother and/or placenta of synthetic glucocorticoids in doses 
relevant to those used in human clinical practise. Further, these effects are dependent on 
which drug and formulation is used, with Dex possibly being the safer choice. It is of great 
importance that we further assess the mechanisms behind these negative effects such that 
clinical therapy can be adjusted to reduced negative effects on the cardiovascular system 
whilst maintaining maturational effects on the lungs. 
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6.3 MODEL OF AGT 
 
As with any study on the effects of AGT, interpretation of results depends on the dose and 
timing of glucocorticoid administration, as well as the specific drug utilised. Here, we used a 
dose of 0.1mg.kgEmb-1. This is lower than the maternal clinical dose of 24mg, which, accounting 
for placental expulsion of glucocorticoid, equates to a fetal dose of glucocorticoid in the order 
of 8mg (Ballard, 2000). The average fetus at 27 weeks is 0.875kg which would give a fetal dose 
of 9.1mg.kgFet-1 which is 91 times higher than the dose used in these experiments. Therefore, 
we might expect that if we were to use a higher dose, of closer resemblance to the human 
clinical dose, the effects describe in this study may be significantly more severe. Additionally, 
it is now commonplace for fetuses to experience multiple courses of AGT, if after 48 hours of 
the initial treatment delivery has not occurred (Bonanno et al., 2007) and/or due to steroid 
exposure in the neonatal period. Therefore, the cumulative exposure in the clinic may be even 
greater, and thereby, of greater concern. The chicken embryo model allows for the 
opportunity to conduct a dose-response trial to determine the effective fetal dose at which 
beneficial lung maturation occurs, and the dose at which detrimental cardiovascular and 
growth effects occur. Repeating measurements of fetal biometry, cardiac outcomes (e.g. 
stereology and isolated organ function), and lung maturation at initial doses of 0.01mgkg-1, 
1mgkg-1, and 10mgkg-1 would allow us to establish the order of magnitude over which these 
effects occur. 
 
We chose day 14 of chicken embryo development to give our glucocorticoid treatment as this 
is the equivalent to roughly 26/27 weeks of human pregnancy, which is an early preterm time-
point at which majority large proportion of threatened preterm fetuses would receive AGT 
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(Roberts & Dalziel, 2006). However, the administration of AGT clinically runs through a large 
spectrum of gestational ages including late preterm or even term babies (Romejko-
Wolniewic, et al., 2014). There is evidence that AGT differs in efficacy depending on 
gestational age of the fetus at exposure (Porto et al., 2011; Gyamfi-Bannerman et al., 2016). 
Similarly, in animal models it is likely that the reported effects of AGT will be dependent on 
the timing of administration. Therefore, we cannot directly extrapolate results from this study 
to AGT administration at other developmental time-points. 
 
Another limitation to our model of AGT administration is the associated pharmacokinetics in 
the fetal plasma. In the clinic AGT is administered over 48 hours, as combined Beta treatment 
has an estimated half-life of 12.5 hours, this may result in up to 60.5 hours of glucocorticoid 
exposure, or 0.9% of gestation (Salem & Najib, 2012). Assuming a similar half-life in our model, 
the chicken embryo following a single dose may have up to 12.5 hours of exposure, which is 
2.5% of incubation, thereby equivalent to 1 week exposure to synthetic glucocorticoid for the 
human fetus. Therefore, it is possible that in our chicken embryo model the developing 
cardiovascular and other physiological systems are exposed for a comparatively greater 
percentage of development. This may be offset by the exposure of a comparatively much 
lower dose of glucocorticoid in the chicken embryo than in the human situation.  
Nevertheless, these differences need to be taken into account. Additionally, the profile of 
exposure of the specific synthetic glucocorticoid used needs to be taken into consideration. 
Differences in pharmacokinetics between the different drug formulations in the chicken 
embryo compared with the human fetus may also result in differential effects. 
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Clearly, it is essential in further studies to assess the pharmacokinetic profile of both Dex and 
Beta in this model. It is possible to measure synthetic glucocorticoid concentrations in plasma 
with a variety of methods including mass spectrometry, and radioactivity assays (Fletcher et 
al., 2000; Samtani et al., 2005). However due to the small volume of plasma in the embryonic 
chicken (Barnes & Jensen, 1959) it is not possible to take serial measurements from the same 
animal over a time course. As such it will be necessary to conduct a cross-sectional study 
whereby embryos are sacrificed at a series of time points post glucocorticoid administration 
(e.g. 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, as plasma half-life has been measured to 
be within this time frame; Schmidt et al., 2018), such that plasma concentrations can be 
measured. In this study it would also be possible to assess GR pathway activation in specific 
tissues (e.g. the embryonic heart) by assessing the ratio of nuclear to cytoplasmic GR via 
western blot (Barrientos et al., 2015), phosphorylated GR levels (relative to total GR) also via 
western blot, or assessing early transcripts known to be up-regulated following GR canonical 
pathway activation by RT-QPCR (Gupta et al., 2007). 
 
6.4 SEX DIFFERENCES 
 
There is evidence in both human clinical data and animal studies that the effects of AGT may 
differ depending on fetal gender (Stevenson et al., 2000). For example, following AGT in the 
sheep, females are protected from renal oxidative stress whilst males are not (Bi et al., 2014), 
however females also display impaired glucose tolerance whilst males do not (Massmann et 
al., 2017). In both guinea pigs and mice, significant differences in brain development based 
on fetal sex have been reported (McArthur et al., 2016; Constantinof et al., 2019). In general 
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it is well established that fetal sex may have a significant effect on programming effects of 
various developmental insults, for example males may be more susceptible to hypertension 
(Aiken & Ozanne, 2013). 
 
In this study we have not provided any sex-specific data. This is due to the difficulty in sexing 
chicken embryos at day 19 of incubation. Whilst morphological sexing by eye based on intra-
abdominal gonad structure is possible, it is practically difficult and not reliable (González-
Morán, 2011). Therefore, during this project we have additionally aimed to develop a method 
for genetically sexing frozen embryonic chicken tissues. Female chickens possess the ZW sex 
chromosome configuration, whilst the males have the homogeneous ZZ configuration (Hirst 
et al., 2018). Basing our protocol on previous work by other groups (Wan et al., 2016), we 
generated oligo primers (custom, Sigma, UK) for a genetic sequence on the W chromosome, 
and a control ribosomal sequence present in both genders (Fig.6.2). DNA was extracted from 
frozen liver samples using a DNeasy blood & tissue kit (Qiagen, NL). A PCR reaction was then 
set up using ReadyStart PCR Master Mix (Sigma, U.K.), 10ng DNA extract, 0.5µM of W and R 
primers, and distilled H2O. The following reaction cycle was then used: 
• 94°C 1 minute 
• 72°C 2 minutes 
• 54°C 3 minutes 
• 30 cycles 
 
Once PCR was completed, the products were separated on a 1% agarose gel (Agarose, Sigma, 
UK, Varigel electrophoresis chamber, Scie-plas, UK). DNA bands were then visualised using 
ethidium bromide (EtBr) (Sigma, UK, GelDoc-It, UVP, USA). Females possess both a W and an 
R band, whilst males only have an R band.  
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Figure 6.1 PCR-based sexing of chicken embryos. A. Primer sequences, B. Gel visualised under fluorescence light 
after exposure to EtBr, with PCR product bands labelled. 
 
 
It is not possible to retrospectively separate all results in this study by gender due to tissues 
not being frozen for embryos from which functional cardiovascular data were generated. 
However, it has been possible to retrospectively analyse embryonic growth data by fetal sex 
(Fig.6.3). Whilst embryo mass, relative head diameter, and relative heart mass are only 
significantly affected by Dex treatment, relative brain mass has a secondary main effect of 
gender with females having a greater relative brain mass than males. For future studies sex 
specific analysis will be conducted on all outcome variables. 
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Figure 6.2 Sex-specific embryonic biometry following Dex treatment. A. absolute embryo mass (g), B. relative 
head diameter (mm/g embryo mass), C. relative brain mass (% embryo mass), D. relative heart mass (% embryo 
mass), in male and female control (white) (n=13) and Dex (blue) (n=10) treated embryos. 2-way ANOVA with 
Tukey post-hoc test. * main effect of Dex treatment, p<0.05, † main effect of sex, p<0.05. 
 
 
6.5 TRANSLATION OF FINDINGS TO THE CLINICAL SITUATION 
 
6.5.1 Mammalian Models 
 
Whilst the cardiovascular changes we have documented in this study are linked to negative 
effects on the developing embryo prior to hatching, we have not demonstrated whether the 
cardiovascular dysfunction extends into adult life, and if it results in overt disease. It is 
becoming increasingly apparent that insults experienced during development may result in 
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physiological changes that confer increased disease risk in adulthood (Fowden et al., 2016). 
In terms of the clinical situation, as well as immediate neonatal outcomes, it is also important 
that we investigate any lifelong dysfunction induced by AGT exposure. The chicken model has 
been used to assess the long-term programming effects of e.g. incubation in hypoxia, 
demonstrating altered cardiovascular function at adulthood (Itani et al., 2018). Therefore, it 
would be valuable to allow glucocorticoid-treated embryos to hatch, and to follow up their 
growth, and cardiovascular functioning at various adult ages (such as young adults at 6 
months, and an aged adult at 3 years). Our laboratory has also previously demonstrated that 
it is possible to assess in vivo cardiovascular function in the chicken via insertion of arterial 
and venous catheters, and arterial flow probes (Skeffington et al., 2018).  
 
In order to establish long-term effects of AGT that are of greater translational importance, it 
will also be necessary to repeat these experiments in a mammalian model. Whilst the chicken 
embryo provides a good model for isolating direct adverse effects on cardiovascular 
development, the lack of placental and maternal physiological changes means it is not 
possible to extrapolate these results directly to human clinical practise. However, there is 
already a wealth of evidence demonstrating long-term dysregulation of cardiovascular 
physiology following glucocorticoid exposure in various mammalian models, predominantly 
in rodents, sheep and primates. In rats exposed postnatally to human clinically-relevant dose 
of Dex, there is significant cardiac and peripheral vascular dysfunction at adulthood, with 
systolic function decreasing more severely with increasing age (Herrera et al., 2010; Bal et al., 
2008). In the sheep model there is also evidence for altered vascular function, hypertension, 
altered cardiac function (including impaired cardiac reserve), and changes in the renin-
 228 
 
228 Chapter 6: General Discussion 
angiotensin system (RAS) at adulthood following prenatal glucocorticoid exposure (Dodic et 
al., 1998, 2001; Pulgar & Figueroa, 2006; Moritz et al., 2011). Nevertheless, much of the 
literature in mammalian animal models is complicated by use of varying doses and timing of 
administration of AGT, again making it difficult to relate this work to human clinical practise. 
There is some human clinical data also available demonstrating altered long term 
cardiovascular outcomes following AGT. For instance, adult men and women born to mothers 
who were given AGT have been shown to have increased aortic arch stiffness, elevated blood 
pressure, altered cardiac structure, right ventricle dysfunction and stress-induced left 
ventricle dysfunction (Kelly et al., 2012; Lewandowski et al., 2013b, 2015; Huckstep et al., 
2018). However, there is a lack of consensus on the long-term cardiovascular implications of 
AGT as there is also clinical data that suggests no alterations to blood pressure at age 30 
following fetal exposure to AGT (Dalziel et al., 2005). The difficulty in interpreting much of the 
human clinical work is that it is not possible to disentangle the effects on long-term outcomes 
in the offspring of being born preterm vs being exposed to AGT, as one rarely occurs without 
the other, and preterm birth itself is known to increase risk of cardiovascular disease in late 
life (Luu et al., 2017). 
 
In order to better assess the impact of glucocorticoid exposure alone on long-term 
cardiovascular outcomes, our laboratory has developed an ongoing programme of work in  a 
sheep model in which we can isolate these effects, independent from preterm birth. In this 
model, pregnant sheep are treated with 2x12mg doses of intramuscular Dex (total 24mg) on 
days 115 and 116 of gestation, which is the equivalent of 30 weeks of human pregnancy. In 
order to prevent the initiation of premature labour following the Dex administration, the 
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ewes are also treated with progesterone at 80 days of gestation, with an additional 
progesterone only group to control for possible effects of progesterone alone. Using this 
model, data thus far show that, aat term, in dexamethsone-treated pregnancies, the fetal 
heart demonstrated impaired systolic and diastolic function independent of effects of 
progesterone treatment; similar to our results in the chicken embryo (Botting et al., 2017; 
Fig.6.1 A). Another cohort of lambs were born at term and then raised until 9 months of age. 
Crucially, birth mass, blood pressure, and heart rate were not different between Dex-exposed 
and control lambs (Fig.6.1 B). However, ex vivo cardiac function was still impaired, and the 
left ventricle and aorta showed significantly increased fibrosis (Fig.6.1 A&C). In vivo functional 
echocardiography in live animals demonstrated an impaired ejection fraction and left atrial 
dilatation, associated with impaired compliance of the left ventricle wall (Fig.6.2 D). These 
results demonstrate that in the absence of preterm birth, exposure to a clinically-relevant 
model of AGT still results in significant cardiac dysfunction in a mammal in which temporal 
cardiovascular development also matches the human situation. Many of the outcomes we 
measured are themselves associated with increased risk of negative cardiovascular outcomes 
(Bouzas-Mosquera et al., 2011; Gulati et al., 2013; Cikes & Solomon, 2016). It also 
demonstrates an in vivo method with greater clinical translatability to detect these cardiac 
changes. These data show that using functional echocardiography, it is possible to assess 
cardiac dysfunction in adults exposed to AGT in utero, even in the absence of hypertension or 
preterm birth.  
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Figure 6.3 Cardiovascular outcomes in fetal and adult sheep exposed to antenatal Dex. A. Left ventricular 
developed pressure in foetuses and 9 month old lambs, B. Left ventricular end diastolic pressure in foetuses and 
9-month-old lambs, C. Blood pressure in 9-month-old lambs, D. Left ventricle ejection fraction in 9-month-old 
lambs, from control (n=7) or Dex treated (n=6) pregnancy, all born at term. All stats are parametric t-test, P<0.05 
*, P<0.01 **< P<0.001 ***. Data from (Botting et al., 2017). 
 
 
6.5.2 Measurable Outcomes in Clinical Practice 
 
The observations in our sheep model of AGT that adult cardiac dysfunction can be detected 
by use of in vivo functional echocardiography demonstrates it is possible to measure 
predictive cardiac outcomes in humans, even without the presence of hypertension. In order 
to translate our findings to human clinical practise it would first be necessary to confirm the 
observations of impaired cardiac function seen in the fetal sheep in babies and children 
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exposed to AGT, by use of the echocardiography technique. Whilst blood pressure has been 
assessed in neonates and children exposed to AGT, surprisingly there are no clinical data 
assessing cardiac function in these individuals (McKinlay et al., 2015; Cartwright et al., 2018). 
 
In order to be able to dissect the effects of AGT vs prematurity it would be necessary to recruit 
a large enough human cohort such that a suitable number of pregnancies are covered that 
are born preterm following AGT, born at term following AGT, or born at term with no AGT. 
Increasing numbers of children are being born at term or late preterm who have been 
exposed to AGT, making it possible to compare this group to those born preterm following 
AGT (Saccone & Berghella, 2016). The ASTECs trial reported outcomes of neonates exposed 
to Betamethasone who were delivered at term suggesting no negative outcomes in an initial 
cohort of 937 children (Stutchfield et al., 2005). As AGT is routine treatment, it does not pose 
great ethical problems, and recruiting a large enough population will not be difficult. To 
establish whether the fetal cardiac dysfunction seen in the sheep is present in humans, it 
would be necessary to conduct functional echocardiography on the neonate to record 
primary outcomes of ejection fraction, atrial diameter, and the ventricular E to A wave ratio. 
Echocardiography is a readily available technique in most maternity units, as it is already 
employed for assessments of various fetal and neonatal morbidities, such as detection of fetal 
heart defects (Liu et al., 2016). Further, it has been demonstrated that this technique has an 
excellent level of reproducibility, which would limit any differences in results collected from 
different collaborating institutions (Kou et al., 2014). 
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6.5.3 Refining Current Clinical Therapy 
 
If it can be demonstrated that a functional cardiac impairment is present in children exposed 
to AGT, then this opens the door for further clinical trials aimed at fine-tuning current clinical 
practise to maintain the benefits of AGT but to diminish the negative cardiac effects. The 
results in this thesis demonstrate that in our chicken embryo model of AGT, Beta 
administration has more severe negative effects on growth, cardiac, and vascular function 
than Dex administration. These results therefore suggest that it may be safer to use Dex 
rather than Beta for AGT in clinical practise. However, there is no current consensus on which 
steroid should be utilised, largely owing to lack of clear experimental data, and the relatively 
few clinical studies that directly compare the two drugs (WHO, 2015; Schmidt et al., 2019). 
The choice of which steroid to use is largely based on availability, price, and in some countries 
historical usage of one over the other. Dex is currently the primary steroid used for AGT in 
most countries, likely due to the fact that it is both cheaper (price per unit estimated at $0.22-
1.56 for injectible Dex phosphate, $9.51 for Celestone Soluspan (Celestone Soluspan Prices, 
2019; Dexamethasone Prices, 2019) and more widely available than Beta (Lawn et al., 2012). 
The countries that continue to rely on Beta for AGT, such as New Zealand, tend to have done 
so historically. Due to these factors and that intramuscular Dex is used for many other clinical 
treatments, thishas led to it being named an essential medicine by the WHO (Lawn & Althabe, 
2013). Using the echocardiography techniques and outcomes from an initial clinical study to 
assess cardiac dysfunction in children following AGT, it would then be possible to conduct a 
follow-up study to directly compare the cardiac implications of antenatal exposure to either 
Dex or Beta on cardiac function in babies and children. It would also be vital to measure 
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otheroutcomes, such as pulmonary or neurological complications, to test whether the 
beneficial outcomes of AGT are also promoted to the same extent by both steroids. 
 
A further way in which clinical therapy can be fine-tuned to reduce negative cardiac effects is 
to give a co-treatment at the time of AGT administration that can help negate the damaging 
changes to the cardiovascular system, whilst allowing the beneficial effects of AGT to remain. 
Accumulating evidence suggests that in mammals one pathway by which glucocorticoids may 
promote their deleterious effects is through the inappropriate generation of reactive oxygen 
species (ROS). Once generated, ROS may subsequently damage cellular components, affect 
signalling pathways, and alter the oxidant tone of the vasculature by decreasing nitric oxide 
(NO) bio-availability (Chen & Keaney, 2004; Chen et al., 2008). Indeed, there is evidence of 
oxidative stress in the heart and brain in mammalian models of antenatal glucocorticoid 
exposure (Antonow-Schlorke et al., 2009; Camm et al., 2011; Niu et al., 2013; Tijsseling et al., 
2013). In a series of studies using neonatal rat pups treated with a tapering course of Dex, it 
has been demonstrated that co-treatment with the antioxidants vitamins C and E (ingested 
via drinking water) reduced oxidative stress and helped prevent the detrimental effects of 
Dex treatment on the brain, heart and peripheral vasculature (Herrera et al., 2010; Camm et 
al., 2011; Niu et al., 2013). A second series of studies tested whether agents that are not 
antioxidants per se but are known to increase NO bioavailability could also be used to diminish 
the adverse side-effects of postnatal glucocorticoid therapy. Statins are known to have 
pleiotropic effects on the vasculature that include increased NO bioavailability. Dex combined 
with pravastatin treatment restored circulating NOx and prevented the adverse effects of 
dexamethasone on the developing brain at weaning (Camm EJ, et al. 2018; Tijsseling et al., 
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2013).  In a separate study it was also demonstrated that pravastatin normalized placental 
vascular defects, fetal growth and cardiac function in a murine model of glucocorticoid excess 
(Wyrwoll et al., 2016).  
 
These experiments demonstrate that it is possible to ameliorate the negative cardiac side 
effects of AGT whilst maintaining the clinical benefits. It therefore is of interest to pursue a 
further clinical study in which a co-treatment (either an antioxidant, or a statin) is 
administered concurrently with AGT and cardiac outcomes in children are assessed. Various 
antioxidants have been used in clinical trials for several complications of pregnancy with 
varied success (Polyzos et al., 2007; Ardalić et al., 2014). Generic Antioxidants, such as vitamin 
C, have been used in human pregnancy complicated with poor fetal growth, pre-eclampsia, 
or preterm birth, without any beneficial effects being observed (Rumbold et al., 2015). 
However, it is difficult to establish high plasma levels of vitamin C without increasing risk of 
other complications such as kidney stones in the expectant mother (Ferraro et al., 2016). A 
statin may be a better choice for clinical use as fewer contra-indications and side effects have 
been observed and various clinical trials administering statins in pregnancy are ongoing 
(Karalis et al., 2016). In order to maximise the potential of the statin treatment to successfully 
reduce oxidative stress following Dex administration, it is necessary to chose a drug with a 
relatively long half-life in plasma (which can vary significantly from 1-9 hours, depending on 
the specific compound), which is also highly lipophilic and may cross the placenta readily 
(Schachter, 2005; Costantine & Cleary, 2013). Pravastatin can readily cross the placenta, and 
so may be a good choice for future clinical studies (Nanovskaya et al., 2013). 
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6.6   CLOSING REMARKS 
 
Whilst the initial clinical trial of Liggins and Howie would kick start a change in obstetric 
medicine that has likely saved the lives of thousands of premature children, the resistance of 
the wider community meant that it was not until 22 years and 12 trials (involving an additional 
2138 infants) later that the NIH consensus statement recommending AGT for threatened 
preterm labour was released (Ballard & Ballard, 1995; Roberts & Dalziel, 2006). Clearly if the 
available evidence had been adopted into clinical practise sooner, then thousands of preterm 
infants would not have suffered unnecessarily. Similarly, we have had accumulating evidence 
for many years of the potential unwanted side effects of AGT on other developing 
physiological systems, yet many aspects of this therapy still have not been optimised. Clearly, 
this is an ethically sensitive topic, as AGT has been demonstrated over and over again to be 
life-saving for premature infants (Roberts et al., 2017). However, as our knowledge of how 
factors in early life can alter future risk of disease increases, it is necessary to reflect on and 
review current clinical practise such that we can fine tune AGT to maintain its benefits whilst 
eliminating the adverse side effects on other organ systems. The plastic physiology of the 
fetus makes it susceptible to adaptive changes that can turn detrimental and last into adult 
life, however it widens the window of opportunity for preventative treatment and correct 
these changes. Increasingly, we are aware that the earlier a healthcare intervention is made, 
the greater the return in terms of economic production at a societal level, and health and 
wellbeing at an individual level (Heckman, 2012). It seems that in the case of prematurely 
born individuals, we can be doing better than simply ensuring survival. 
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APPENDIX 
 
Publications arisen from this thesis thus far 
Topical review: 
 
• Garrud, TA & Giussani, DA, ‘Combined Antioxidant and Glucocorticoid Therapy for 
Safer Treatment of Preterm Birth’, Trends Endocrinol Metab, 30(4):258-269, 2019. 
 
Conference abstracts accepted for oral presentation: 
 
• Garrud TA, Teulings NE, Conlon FG, Ford SG, Niu Y, Nicholas LM, Derks JB, Ozanne 
SE, and Giussani DA. ‘Adverse Effects of Antenatal Glucocorticoids on the Fetal 
Heart: A Study in the Chick Embryo.’ 44th Annual Meeting of the Fetal & Neonatal 
Physiology Society, Osaka, Japan, Sep 6-10, 2017. 
 
• Garrud TA, Teulings NE, Conlon FG, Ford SG, Niu Y, Nicholas LM, Derks JB, Ozanne 
SE, and Giussani DA. ‘Adverse Effects of Antenatal Glucocorticoids on the Fetal 
Heart: A Study in the Chick Embryo.’ 65th Annual Meeting of the Society of 
Reproductive Investigation, San Diego, California, USA, March 6-10, 2018. Young 
investigator travel award. 
 
Conference abstracts accepted for poster presentation: 
• Garrud TA, Tuelings NE, Conlon FG, Ford SG, Niu Y, Nicholas LM, Derks JB, Ozanne 
SE, and Giussani DA. ‘Adverse Effects of Antenatal Glucocorticoids on Fetal Heart 
Structure & Function.’ 66th Annual Meeting of the Society of Reproductive 
Investigation, Paris, France, March 12-16, 2019. Young investigator travel award. 
 
 
 
 
 
 
 
 
 
 
 237 
 
237 References 
REFERENCES 
 
Aagaard-Tillery, K. M. et al. (2008) ‘Developmental origins of disease and determinants of chromatin 
structure: maternal diet modifies the primate fetal epigenome.’, Journal of molecular endocrinology, 
41(2), pp. 91–102. doi: 10.1677/JME-08-0025. 
Aboelwafa, H. R. and Yousef, H. N. (2015) ‘The ameliorative effect of thymol against hydrocortisone-
induced hepatic oxidative stress injury in adult male rats.’, Biochemistry and cell biology = Biochimie 
et biologie cellulaire, 93(4), pp. 282–9. doi: 10.1139/bcb-2014-0154. 
Aden, P. et al. (2011) ‘Glucocorticoids dexamethasone and hydrocortisone inhibit proliferation and 
accelerate maturation of chicken cerebellar granule neurons’, Brain Research, 1418, pp. 32–41. doi: 
10.1016/j.brainres.2011.08.053. 
Adler, A. et al. (2010) ‘Investigation of the use of antioxidants to diminish the adverse effects of 
postnatal glucocorticoid treatment on mortality and cardiac development.’, Neonatology, 98(1), pp. 
73–83. doi: 10.1159/000275561. 
Aiken, C. E. and Ozanne, S. E. (2013) ‘Sex differences in developmental programming models’, 
REPRODUCTION, 145(1), pp. R1–R13. doi: 10.1530/REP-11-0489. 
Alexander, N. et al. (2012) ‘Impact of antenatal synthetic glucocorticoid exposure on endocrine 
stress reactivity in term-born children.’, The Journal of clinical endocrinology and metabolism, 
97(10), pp. 3538–44. doi: 10.1210/jc.2012-1970. 
Almeida, O. F. et al. (2000) ‘Subtle shifts in the ratio between pro- and antiapoptotic molecules after 
activation of corticosteroid receptors decide neuronal fate.’, FASEB journal : official publication of 
the Federation of American Societies for Experimental Biology, 14(5), pp. 779–90. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10744634. 
Altimiras, J. and Crossley, D. A. (2000) ‘Control of blood pressure mediated by baroreflex changes of 
heart rate in the chicken embryo (Gallus gallus).’, American journal of physiology. Regulatory, 
integrative and comparative physiology, 278(4), pp. R980-6. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10749787 (Accessed: 12 July 2017). 
Andrews, K. W., Savitz, D. A. and Hertz-Picciotto, I. (1994) ‘Prenatal lead exposure in relation to 
gestational age and birth weight: a review of epidemiologic studies.’, American journal of industrial 
medicine, 26(1), pp. 13–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8074121 (Accessed: 
7 July 2019). 
Angeles, D. M. et al. (2006) ‘Dexamethasone Alters Vascular Reactivity by Enhancing COX-Related 
Vasodilatation in Fetal Ovine Carotids’, Neonatology, 90(1), pp. 1–8. doi: 10.1159/000090340. 
Antonow-Schlorke, I. et al. (2009) ‘Adverse effects of antenatal glucocorticoids on cerebral 
myelination in sheep.’, Obstetrics and gynecology, 113(1), pp. 142–51. doi: 
10.1097/AOG.0b013e3181924d3b. 
Anwar, M. A. et al. (2016) ‘Glucocorticoid-induced fetal origins of adult hypertension: Association 
with epigenetic events’, Vascular Pharmacology, 82, pp. 41–50. doi: 10.1016/j.vph.2016.02.002. 
Aperia, A., Larsson, L. and Zetterström, R. (1981) ‘Hormonal induction of Na-K-ATPase in developing 
proximal tubular cells.’, The American journal of physiology, 241(4), pp. F356-60. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/6274204. 
Ardalić, D. et al. (no date) ‘The influence of maternal smoking habits before pregnancy and 
 238 
 
238 References 
antioxidative supplementation during pregnancy on oxidative stress status in a non-complicated 
pregnancy.’, Advances in clinical and experimental medicine : official organ Wroclaw Medical 
University, 23(4), pp. 575–83. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25166442 
(Accessed: 11 September 2019). 
Audette, M. C. et al. (2014) ‘Synthetic glucocorticoid reduces human placental system a transport in 
women treated with antenatal therapy.’, The Journal of clinical endocrinology and metabolism, 
99(11), pp. E2226-33. doi: 10.1210/jc.2014-2157. 
Austdal, L. P. E. et al. (2016) ‘Glucocorticoid Effects on Cerebellar Development in a Chicken Embryo 
Model: Exploring Changes in PAX6 and Metalloproteinase-9 After Exposure to Dexamethasone’, 
Journal of Neuroendocrinology, 28(12). doi: 10.1111/jne.12438. 
Bal MP, de Vries WB, van Oosterhout MF, Baan J, van der Wall EE, van Bel F, S. P. (2008) ‘Long-term 
cardiovsacular effects of neonatal dexamethasone treatment: haemodynamic follow-up by left 
ventricular pressure-volume loops in rats’, J Appl Physiol, 104(2), pp. 446–50. 
Ballabh, P. (2010) ‘Intraventricular hemorrhage in premature infants: mechanism of disease.’, 
Pediatric research. NIH Public Access, 67(1), pp. 1–8. doi: 10.1203/PDR.0b013e3181c1b176. 
Ballard, P. L. (2000) ‘Scientific Rationale for the Use of Antenatal Glucocorticoids to Promote Fetal 
Development’, NeoReviews. American Academy of Pediatrics, 1(5), pp. 83e – 90. doi: 10.1542/neo.1-
5-e83. 
Banks, B. A. et al. (1999) ‘Multiple courses of antenatal corticosteroids and outcome of premature 
neonates. North American Thyrotropin-Releasing Hormone Study Group.’, American journal of 
obstetrics and gynecology, 181(3), pp. 709–17. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10486488. 
Bar-Lev, M. R. R. et al. (2004) ‘Short-Term Outcomes in Low Birth Weight Infants Following Antenatal 
Exposure to Betamethasone Versus Dexamethasone’, Obstetrics & Gynecology, 104(3), pp. 484–488. 
doi: 10.1097/01.AOG.0000137351.71015.ac. 
Barker, D. J. P. (2007) ‘The origins of the developmental origins theory’, Journal of Internal Medicine, 
261(5), pp. 412–417. doi: 10.1111/j.1365-2796.2007.01809.x. 
Barnes, A. E. and Jensen, W. N. (1959) ‘Blood volume and red cell concentration in the normal chick 
embryo’, American Journal of Physiology-Legacy Content. American Physiological Society, 197(2), pp. 
403–405. doi: 10.1152/ajplegacy.1959.197.2.403. 
BARONE, F. et al. (2002) ‘A pivotal role for cADPR-mediated Ca 2+ signaling: regulation of endothelin-
induced contraction in peritubular smooth muscle cells’, The FASEB Journal, 16(7), pp. 697–705. doi: 
10.1096/fj.01-0749com. 
Barrientos, R. M. et al. (2015) ‘Greater glucocorticoid receptor activation in hippocampus of aged 
rats sensitizes microglia.’, Neurobiology of aging. NIH Public Access, 36(3), pp. 1483–95. doi: 
10.1016/j.neurobiolaging.2014.12.003. 
Bartelds, B. et al. (2000) ‘Perinatal Changes in Myocardial Metabolism in Lambs’, Circulation. 
Lippincott Williams & Wilkins, 102(8), pp. 926–931. doi: 10.1161/01.CIR.102.8.926. 
Behrman, R. E., Butler, A. S. and Institute of Medicine (U.S.). Committee on Understanding 
Premature Birth and Assuring Healthy Outcomes. (2007) Preterm birth : causes, consequences, and 
prevention. National Academies Press. Available at: 
https://books.google.co.uk/books?hl=en&lr=&id=Wh5KAt_X3RkC&oi=fnd&pg=PR1&ots=z412bRNG
mq&sig=rmAKGacZJmThNTvzHwYxl0_VuVU&redir_esc=y#v=onepage&q&f=false (Accessed: 5 July 
2019). 
 239 
 
239 References 
Belteki, G. et al. (2010) ‘Paraoxonase-3, a Putative Circulating Antioxidant, Is Systemically Up-
Regulated in Late Gestation in the Fetal Rat, Sheep, and Human’, The Journal of Clinical 
Endocrinology & Metabolism, 95(8), pp. 3798–3805. doi: 10.1210/jc.2010-0037. 
Benson, P. F. (2008) ‘METABOLIC CHANGES IN THE NEWBORN’, Developmental Medicine & Child 
Neurology, 4(6), pp. 651–652. doi: 10.1111/j.1469-8749.1962.tb04163.x. 
Berghella, V. et al. (2010) ‘Effectiveness of cerclage according to severity of cervical length 
shortening: a meta-analysis’, Ultrasound in Obstetrics and Gynecology. John Wiley & Sons, Ltd, 35(4), 
pp. 468–473. doi: 10.1002/uog.7547. 
Berrington, J. E. et al. (2012) ‘Deaths in Preterm Infants: Changing Pathology Over 2 Decades’, The 
Journal of Pediatrics. Mosby, 160(1), pp. 49-53.e1. doi: 10.1016/J.JPEDS.2011.06.046. 
Bhutta, A. T. et al. (2002) ‘Cognitive and Behavioral Outcomes of School-Aged Children Who Were 
Born Preterm’, JAMA. American Medical Association, 288(6), p. 728. doi: 10.1001/jama.288.6.728. 
Bi, J. et al. (2014) ‘Sex-specific effect of antenatal betamethasone exposure on renal oxidative stress 
induced by angiotensins in adult sheep.’, American journal of physiology. Renal physiology, 307(9), 
pp. F1013-22. doi: 10.1152/ajprenal.00354.2014. 
Bird, A. D. et al. (2015) ‘Glucocorticoid regulation of lung development: lessons learned from 
conditional GR knockout mice.’, Molecular endocrinology (Baltimore, Md.), 29(2), pp. 158–71. doi: 
10.1210/me.2014-1362. 
Bjørnstad, S. et al. (2014a) ‘Type I and II Pneumocyte Differentiation in the Developing Fetal Chicken 
Lung: Conservation of Pivotal Proteins from Birds to Human in the Struggle for Life at Birth’, 
Neonatology, 105(2), pp. 112–120. doi: 10.1159/000355346. 
Bjørnstad, S. et al. (2014b) ‘Type I and II Pneumocyte Differentiation in the Developing Fetal Chicken 
Lung: Conservation of Pivotal Proteins from Birds to Human in the Struggle for Life at Birth’, 
Neonatology, 105(2), pp. 112–120. doi: 10.1159/000355346. 
Blanco, C. E. et al. (1988) ‘Carotid baroreceptors in fetal and newborn sheep.’, Pediatric research, 
24(3), pp. 342–6. doi: 10.1203/00006450-198809000-00014. 
Blanco, C. L. et al. (2014) ‘Antenatal corticosteroids alter insulin signaling pathways in fetal baboon 
skeletal muscle.’, The Journal of endocrinology, 221(2), pp. 253–60. doi: 10.1530/JOE-13-0504. 
De Blasio, M. J. et al. (2015) ‘Developmental Expression and Glucocorticoid Control of the Leptin 
Receptor in Fetal Ovine Lung.’, PloS one, 10(8), p. e0136115. doi: 10.1371/journal.pone.0136115. 
Bogdarina, I. et al. (2007) ‘Epigenetic modification of the renin-angiotensin system in the fetal 
programming of hypertension.’, Circulation research, 100(4), pp. 520–6. doi: 
10.1161/01.RES.0000258855.60637.58. 
Bollen, I. A. E. et al. (2017) ‘Cardiomyocyte Hypocontractility and Reduced Myofibril Density in End-
Stage Pediatric Cardiomyopathy’, Frontiers in Physiology. Frontiers, 8, p. 1103. doi: 
10.3389/fphys.2017.01103. 
Bonanno, C., Fuchs, K. and Wapner, R. J. (2007) ‘Single Versus Repeat Courses of Antenatal Steroids 
to Improve Neonatal Outcomes: Risks and Benefits’, Obstetrical & Gynecological Survey, 62(4), pp. 
261–271. doi: 10.1097/01.ogx.0000259226.62431.78. 
Botting, K. et al. (2017) ‘Human clinically relevant antenatal glucocorticoid therapy programmes 
cardiac dysfunction and fibrosis in adult offspring’, in International Society for Developmental Origins 
of Health and Disease. 
 240 
 
240 References 
Bouzas-Mosquera, A. et al. (2011) ‘Left atrial size and risk for all-cause mortality and ischemic 
stroke’, Canadian Medical Association Journal, 183(10), pp. E657–E664. doi: 10.1503/cmaj.091688. 
Brenner, B. M., Garcia, D. L. and Anderson, S. (1988) ‘Glomeruli and Blood Pressure: Less of One, 
More the Other?’, American Journal of Hypertension, 1(4 Pt 1), pp. 335–347. doi: 
10.1093/ajh/1.4.335. 
Brownfoot, F. C. et al. (2013) ‘Different corticosteroids and regimens for accelerating fetal lung 
maturation for women at risk of preterm birth.’, The Cochrane database of systematic reviews, (8), 
p. CD006764. doi: 10.1002/14651858.CD006764.pub3. 
Brozovich, F. V et al. (2016) ‘Mechanisms of Vascular Smooth Muscle Contraction and the Basis for 
Pharmacologic Treatment of Smooth Muscle Disorders.’, Pharmacological reviews. American Society 
for Pharmacology and Experimental Therapeutics, 68(2), pp. 476–532. doi: 10.1124/pr.115.010652. 
Buttgereit, F., Brand, M. D. and Burmester, G. R. (1999) ‘Equivalent doses and relative drug 
potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy.’, Biochemical 
pharmacology, 58(2), pp. 363–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10423179. 
Camm, E. J. et al. (2011) ‘Oxidative stress in the developing brain: effects of postnatal glucocorticoid 
therapy and antioxidants in the rat.’, PloS one, 6(6), p. e21142. doi: 10.1371/journal.pone.0021142. 
Camm EJ, Itani N, Kane AD, Cross CM, Tijsseling D, Derks JB, Herrera EA, Niu Y, Ashmore TJ, G. DA (no 
date) ‘Statins prevent elevated arterial pressure and nephron deficit in rat offspring following 
postnatal glucocorticoid therapy’, Ped Res. 
Carr, H. et al. (2017) ‘Preterm Birth and Risk of Heart Failure Up to Early Adulthood’, Journal of the 
American College of Cardiology, 69(21), pp. 2634–2642. doi: 10.1016/j.jacc.2017.03.572. 
Carsia, R. V. et al. (1987) ‘Ontogenic Corticosteroidogenesis of the Domestic Fowl: Response of 
Isolated Adrenocortical Cells’, Experimental Biology and Medicine. SAGE PublicationsSage UK: 
London, England, 184(4), pp. 436–445. doi: 10.3181/00379727-184-42498. 
Cartwright, R. D. et al. (2018) ‘Repeat Antenatal Betamethasone and Cardiometabolic Outcomes’, 
Pediatrics, 142(1), p. e20180522. doi: 10.1542/peds.2018-0522. 
Celsi, G. et al. (1998) ‘Prenatal dexamethasone causes oligonephronia, sodium retention, and higher 
blood pressure in the offspring.’, Pediatric research, 44(3), pp. 317–22. doi: 10.1203/00006450-
199809000-00009. 
Chang, C.-H. et al. (2003) ‘Quantitative three-dimensional power Doppler sonography for 
assessment of the fetal renal blood flow in normal gestation.’, Ultrasound in medicine & biology, 
29(7), pp. 929–33. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12878237. 
Chen, J. and Smith, L. E. H. (2007) ‘Retinopathy of prematurity’, Angiogenesis, 10(2), pp. 133–140. 
doi: 10.1007/s10456-007-9066-0. 
Chen, K., Pittman, R. N. and Popel, A. S. (2008) ‘Nitric oxide in the vasculature: where does it come 
from and where does it go? A quantitative perspective.’, Antioxidants & redox signaling. Mary Ann 
Liebert, Inc., 10(7), pp. 1185–98. doi: 10.1089/ars.2007.1959. 
Chen, X. and Wang, Y. (2008) ‘Tracking of Blood Pressure From Childhood to Adulthood’, Circulation, 
117(25), pp. 3171–3180. doi: 10.1161/CIRCULATIONAHA.107.730366. 
Cheong, J. L. Y. et al. (2014) ‘Association between postnatal dexamethasone for treatment of 
bronchopulmonary dysplasia and brain volumes at adolescence in infants born very preterm.’, The 
Journal of pediatrics, 164(4), pp. 737-743.e1. doi: 10.1016/j.jpeds.2013.10.083. 
 241 
 
241 References 
Chien, L.-Y. et al. (2002) ‘Variations in antenatal corticosteroid therapy: a persistent problem despite 
30 years of evidence.’, Obstetrics and gynecology, 99(3), pp. 401–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11864666 (Accessed: 9 July 2019). 
Christoffels, V. M. et al. (2000) ‘Chamber Formation and Morphogenesis in the Developing 
Mammalian Heart’, Developmental Biology. Academic Press, 223(2), pp. 266–278. doi: 
10.1006/DBIO.2000.9753. 
Cieri, R. L. and Farmer, C. G. (2016) ‘Unidirectional pulmonary airflow in vertebrates: a review of 
structure, function, and evolution’, Journal of Comparative Physiology B. Springer Berlin Heidelberg, 
186(5), pp. 541–552. doi: 10.1007/s00360-016-0983-3. 
Cikes, M. and Solomon, S. D. (2016) ‘Beyond ejection fraction: an integrative approach for 
assessment of cardiac structure and function in heart failure’, European Heart Journal. Narnia, 
37(21), pp. 1642–1650. doi: 10.1093/eurheartj/ehv510. 
Cochemé, H. M. et al. (2012) ‘Using the mitochondria-targeted ratiometric mass spectrometry probe 
MitoB to measure H2O2 in living Drosophila’, Nature Protocols, 7(5), pp. 946–958. doi: 
10.1038/nprot.2012.035. 
Connors, N. et al. (2010) ‘Fetal and postnatal renin secretion in female sheep exposed to prenatal 
betamethasone.’, Reproductive sciences (Thousand Oaks, Calif.), 17(3), pp. 239–46. doi: 
10.1177/1933719109351752. 
Constantinof, A. et al. (2019) ‘Antenatal Glucocorticoid Exposure Results in Sex-Specific and 
Transgenerational Changes in Prefrontal Cortex Gene Transcription that Relate to Behavioural 
Outcomes’, Scientific Reports, 9(1), p. 764. doi: 10.1038/s41598-018-37088-3. 
Contag, S. A. et al. (2010) ‘Developmental effect of antenatal exposure to betamethasone on renal 
angiotensin II activity in the young adult sheep.’, American journal of physiology. Renal physiology, 
298(4), pp. F847-56. doi: 10.1152/ajprenal.00497.2009. 
‘Context | Preterm labour and birth | Guidance | NICE’ (no date). NICE. Available at: 
https://www.nice.org.uk/guidance/ng25/chapter/context (Accessed: 5 July 2019). 
Corrigan, N., Brazil, D. P. and McAuliffe, F. M. (2010) ‘High-Frequency Ultrasound Assessment of the 
Murine Heart From Embryo Through to Juvenile’, Reproductive Sciences. SAGE PublicationsSage CA: 
Los Angeles, CA, 17(2), pp. 147–157. doi: 10.1177/1933719109348923. 
Costantine, M. M. and Cleary, K. (2013) ‘Pravastatin for the Prevention of Preeclampsia in High-Risk 
Pregnant Women’, Obstetrics & Gynecology, 121(2, PART 1), pp. 349–353. doi: 
10.1097/AOG.0b013e31827d8ad5. 
Costantini, D., Marasco, V. and Møller, A. P. (2011) ‘A meta-analysis of glucocorticoids as modulators 
of oxidative stress in vertebrates.’, Journal of comparative physiology. B, Biochemical, systemic, and 
environmental physiology, 181(4), pp. 447–56. doi: 10.1007/s00360-011-0566-2. 
Crowther, C. A. et al. (2015) ‘Repeat doses of prenatal corticosteroids for women at risk of preterm 
birth for improving neonatal health outcomes.’, The Cochrane database of systematic reviews, (7), p. 
CD003935. doi: 10.1002/14651858.CD003935.pub4. 
Crudo, A. et al. (2012) ‘Prenatal synthetic glucocorticoid treatment changes DNA methylation states 
in male organ systems: multigenerational effects.’, Endocrinology, 153(7), pp. 3269–83. doi: 
10.1210/en.2011-2160. 
Dalziel, S. R. et al. (2007) ‘Cardiovascular risk factors at age 30 following pre-term birth’, 
International Journal of Epidemiology, 36(4), pp. 907–915. doi: 10.1093/ije/dym067. 
 242 
 
242 References 
Dalziel, S. R. et al. (no date) ‘Cardiovascular risk factors after antenatal exposure to betamethasone: 
30-year follow-up of a randomised controlled trial.’, Lancet (London, England), 365(9474), pp. 1856–
62. doi: 10.1016/S0140-6736(05)66617-2. 
Davenport, A. P. et al. (2016) ‘Endothelin.’, Pharmacological reviews. American Society for 
Pharmacology and Experimental Therapeutics, 68(2), pp. 357–418. doi: 10.1124/pr.115.011833. 
Davies, M P et al. (1996) ‘Developmental changes in ionic channel activity in the embryonic murine 
heart.’, Circulation research, 78(1), pp. 15–25. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8603498. 
Davies, M.P. et al. (1996) ‘Developmental Changes in Ionic Channel Activity in the Embryonic Murine 
Heart’, Circulation Research. Lippincott Williams & Wilkins, 78(1), pp. 15–25. doi: 
10.1161/01.RES.78.1.15. 
Davis, E. P. et al. (2006) ‘Antenatal betamethasone treatment has a persisting influence on infant 
HPA axis regulation.’, Journal of perinatology : official journal of the California Perinatal Association, 
26(3), pp. 147–53. doi: 10.1038/sj.jp.7211447. 
DeMauro, S. B., Dysart, K. and Kirpalani, H. (2014) ‘Stopping the Swinging Pendulum of Postnatal 
Corticosteroid Use’, The Journal of Pediatrics, 164(1), pp. 9–11. doi: 10.1016/j.jpeds.2013.10.020. 
Dempsey, E. M. (2017) ‘What Should We Do about Low Blood Pressure in Preterm Infants’, 
Neonatology, 111(4), pp. 402–407. doi: 10.1159/000460603. 
Derks, J. B. et al. (1997) ‘A comparative study of cardiovascular, endocrine and behavioural effects of 
betamethasone and dexamethasone administration to fetal sheep.’, The Journal of physiology, 499 ( 
Pt 1, pp. 217–26. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9061651. 
Dieber-Rotheneder, M. et al. (2006) ‘Up-regulation of the Endothelin Receptor A in Placental Tissue 
From First Trimester Delayed Miscarriages’, Journal of the Society for Gynecologic Investigation, 
13(6), pp. 435–441. doi: 10.1016/j.jsgi.2006.05.006. 
Dieber-Rotheneder, M. et al. (2012) ‘Complex expression changes of the placental endothelin system 
in early and late onset preeclampsia, fetal growth restriction and gestational diabetes’, Life Sciences, 
91(13–14), pp. 710–715. doi: 10.1016/j.lfs.2012.04.040. 
DiFiore, J. W. and Wilson, J. M. (1994) ‘Lung development.’, Seminars in pediatric surgery, 3(4), pp. 
221–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7850362. 
Docherty, C. C. et al. (2001) ‘Effect of in vivo fetal infusion of dexamethasone at 0.75 GA on fetal 
ovine resistance artery responses to ET-1.’, American journal of physiology. Regulatory, integrative 
and comparative physiology, 281(1), pp. R261-8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11404302. 
Dodic, M. et al. (1998) ‘An early prenatal exposure to excess glucocorticoid leads to hypertensive 
offspring in sheep.’, Clinical science (London, England : 1979), 94(2), pp. 149–55. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9536923 (Accessed: 9 August 2018). 
Dodic, M. et al. (2001) ‘Impaired cardiac functional reserve and left ventricular hypertrophy in adult 
sheep after prenatal dexamethasone exposure.’, Circulation research, 89(7), pp. 623–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11577028. 
Dodic, M. et al. (2002) ‘Programming effects of short prenatal exposure to dexamethasone in 
sheep.’, Hypertension (Dallas, Tex. : 1979), 40(5), pp. 729–34. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12411469. 
Doyle, L. W. et al. (2007) ‘Outcome at 2 years of age of infants from the DART study: a multicenter, 
 243 
 
243 References 
international, randomized, controlled trial of low-dose dexamethasone.’, Pediatrics, 119(4), pp. 716–
721. doi: 10.1542/peds.2006-2806. 
Doyle, L. W. and Anderson, P. J. (2010) ‘Pulmonary and Neurological Follow-Up of Extremely Preterm 
Infants’, Neonatology. Karger Publishers, 97(4), pp. 388–394. doi: 10.1159/000297771. 
Doyle, L. W., Ehrenkranz, R. A. and Halliday, H. L. (2014a) ‘Early (< 8 days) postnatal corticosteroids 
for preventing chronic lung disease in preterm infants.’, The Cochrane database of systematic 
reviews, (5), p. CD001146. doi: 10.1002/14651858.CD001146.pub4. 
Doyle, L. W., Ehrenkranz, R. A. and Halliday, H. L. (2014b) ‘Late (&gt; 7 days) postnatal 
corticosteroids for chronic lung disease in preterm infants’, in Doyle, L. W. (ed.) Cochrane Database 
of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. doi: 
10.1002/14651858.CD001145.pub3. 
Drake, A. J. et al. (2010) ‘Prenatal dexamethasone programs expression of genes in liver and adipose 
tissue and increased hepatic lipid accumulation but not obesity on a high-fat diet.’, Endocrinology, 
151(4), pp. 1581–7. doi: 10.1210/en.2009-1088. 
Drake, A. J. et al. (2011) ‘Multigenerational programming in the glucocorticoid programmed rat is 
associated with generation-specific and parent of origin effects.’, Epigenetics, 6(11), pp. 1334–43. 
doi: 10.4161/epi.6.11.17942. 
Du, J. et al. (2009) ‘Dynamic regulation of mitochondrial function by glucocorticoids’, Proceedings of 
the National Academy of Sciences, 106(9), pp. 3543–3548. doi: 10.1073/pnas.0812671106. 
Dudley, K. J. et al. (2011) ‘Offspring of mothers fed a high fat diet display hepatic cell cycle inhibition 
and associated changes in gene expression and DNA methylation.’, PloS one, 6(7), p. e21662. doi: 
10.1371/journal.pone.0021662. 
Dumortier, O. et al. (2011) ‘Impairment of rat fetal beta-cell development by maternal exposure to 
dexamethasone during different time-windows.’, PloS one, 6(10), p. e25576. doi: 
10.1371/journal.pone.0025576. 
Egerman, R. S. et al. (1998) ‘A randomized, controlled trial of oral and intramuscular dexamethasone 
in the prevention of neonatal respiratory distress syndrome.’, American journal of obstetrics and 
gynecology, 179(5), pp. 1120–3. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9822485. 
Elimian, A. et al. (2007) ‘Antenatal Betamethasone Compared With Dexamethasone (Betacode 
Trial)’, Obstetrics & Gynecology, 110(1), pp. 26–30. doi: 10.1097/01.AOG.0000268281.36788.81. 
Elwany, E. et al. (2018) ‘Antenatal dexamethasone effect on Doppler blood flow velocity in women 
at risk for preterm birth: prospective case series’, African Health Sciences, 18(3), p. 596. doi: 
10.4314/ahs.v18i3.17. 
Erenberg, A. et al. (1982) ‘Pulmonary Superoxide Dismutase Activity in the Euthyroid and 
Hypothyroid Ovine Fetus’, Pediatric Research, 16(7), pp. 570–572. doi: 10.1203/00006450-
198207000-00017. 
Fahmi, A. et al. (2004) Cortisol influences the ontogeny of both alpha-and beta-subunits of the 
cardiac sodium channel in fetal sheep Regulation of CFTR View project Experimental design for 
improved characterisation of ion currents in patch clamp electrophysiology View project Cortisol 
influences the ontogeny of both-and-subunits of the cardiac sodium channel in fetal sheep, Article in 
Journal of Endocrinology. Available at: http://www.endocrinology.org (Accessed: 12 June 2019). 
Fanaroff, J. M. and Fanaroff, A. A. (2006) ‘Blood pressure disorders in the neonate: Hypotension and 
hypertension’, Seminars in Fetal and Neonatal Medicine, 11(3), pp. 174–181. doi: 
 244 
 
244 References 
10.1016/j.siny.2006.01.002. 
Farstad, T. et al. (2011) ‘Bronchopulmonary dysplasia - prevalence, severity and predictive factors in 
a national cohort of extremely premature infants.’, Acta paediatrica (Oslo, Norway : 1992), 100(1), 
pp. 53–8. doi: 10.1111/j.1651-2227.2010.01959.x. 
Fasenko, G. M. (2007) ‘Egg Storage and the Embryo’, Poultry Science, 86(5), pp. 1020–1024. doi: 
10.1093/ps/86.5.1020. 
Faul, F. et al. (2007) ‘G*Power 3: A flexible statistical power analysis program for the social, 
behavioral, and biomedical sciences’, Behavior Research Methods. Springer-Verlag, 39(2), pp. 175–
191. doi: 10.3758/BF03193146. 
Fernandez-Twinn, D. S. and Ozanne, S. E. (2006) ‘Mechanisms by which poor early growth programs 
type-2 diabetes, obesity and the metabolic syndrome’, Physiology and Behavior, 88(3), pp. 234–243. 
doi: 10.1016/j.physbeh.2006.05.039. 
Ferraro, P. M. et al. (2016) ‘Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident 
Kidney Stones’, American Journal of Kidney Diseases, 67(3), pp. 400–407. doi: 
10.1053/j.ajkd.2015.09.005. 
Figueroa, J. P. et al. (2005) ‘Alterations in fetal kidney development and elevations in arterial blood 
pressure in young adult sheep after clinical doses of antenatal glucocorticoids.’, Pediatric research, 
58(3), pp. 510–5. doi: 10.1203/01.PDR.0000179410.57947.88. 
Finken, M. J. J. et al. (2008) ‘Antenatal glucocorticoid treatment is not associated with long-term 
metabolic risks in individuals born before 32 weeks of gestation.’, Archives of disease in childhood. 
Fetal and neonatal edition, 93(6), pp. F442-7. doi: 10.1136/adc.2007.128470. 
Finken, M. J. J. et al. (2011) ‘Abdominal fat accumulation in adults born preterm exposed antenatally 
to maternal glucocorticoid treatment is dependent on glucocorticoid receptor gene variation.’, The 
Journal of clinical endocrinology and metabolism, 96(10), pp. E1650-5. doi: 10.1210/jc.2011-0288. 
Fletcher, A. J. W. et al. (2000) ‘Low Doses of Dexamethasone Suppress Pituitary-Adrenal Function 
but Augment the Glycemic Response to Acute Hypoxemia in Fetal Sheep during Late Gestation’, 
Pediatric Research. Nature Publishing Group, 47(5), pp. 684–691. doi: 10.1203/00006450-
200005000-00021. 
Fletcher, A. J. W. et al. (2002) ‘Effects of low dose dexamethasone treatment on basal cardiovascular 
and endocrine function in fetal sheep during late gestation’, The Journal of Physiology, 545(2), pp. 
649–660. doi: 10.1113/jphysiol.2001.015693. 
Fletcher, A. J. W. et al. (2005) ‘Effects of gestational age and cortisol treatment on ovine fetal heart 
function in a novel biventricular Langendorff preparation.’, The Journal of physiology, 562(Pt 2), pp. 
493–505. doi: 10.1113/jphysiol.2004.074161. 
Fletcher, A. J. W. et al. (2006) ‘Development of the ovine fetal cardiovascular defense to hypoxemia 
towards full term’, American Journal of Physiology-Heart and Circulatory Physiology, 291(6), pp. 
H3023–H3034. doi: 10.1152/ajpheart.00504.2006. 
Forhead, A. J. et al. (2006) ‘Developmental control of iodothyronine deiodinases by cortisol in the 
ovine fetus and placenta near term.’, Endocrinology, 147(12), pp. 5988–94. doi: 10.1210/en.2006-
0712. 
Forhead, A. J. et al. (2015) ‘Maternal Dexamethasone Treatment Alters Tissue and Circulating 
Components of the Renin-Angiotensin System in the Pregnant Ewe and Fetus’, Endocrinology, 
156(8), pp. 3038–3046. doi: 10.1210/en.2015-1197. 
 245 
 
245 References 
Forhead, A. J., Broughton Pipkin, F. and Fowden, A. L. (2000) ‘Effect of cortisol on blood pressure and 
the renin-angiotensin system in fetal sheep during late gestation.’, The Journal of physiology, 526 Pt 
1, pp. 167–76. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10878109. 
Fowden, A. L. et al. (2005) ‘Maturation of pancreatic beta-cell function in the fetal horse during late 
gestation.’, The Journal of endocrinology, 186(3), pp. 467–73. doi: 10.1677/joe.1.06176. 
Fowden, A. L. et al. (2016) ‘Glucocorticoid programming of intrauterine development.’, Domestic 
animal endocrinology, 56 Suppl, pp. S121-32. doi: 10.1016/j.domaniend.2016.02.014. 
Fowden, A. L. (no date) ‘The insulin-like growth factors and feto-placental growth.’, Placenta, 24(8–
9), pp. 803–12. Available at: http://www.ncbi.nlm.nih.gov/pubmed/13129676. 
Fowden, A. L. and Forhead, A. J. (2009a) ‘Endocrine Regulation of Feto-Placental Growth’, Hormone 
Research. Karger Publishers, 72(5), pp. 257–265. doi: 10.1159/000245927. 
Fowden, A. L. and Forhead, A. J. (2009b) ‘Hormones as epigenetic signals in developmental 
programming’, Experimental Physiology. John Wiley & Sons, Ltd (10.1111), 94(6), pp. 607–625. doi: 
10.1113/expphysiol.2008.046359. 
Fowden, A. L. and Forhead, A. J. (2015) ‘Glucocorticoids as regulatory signals during intrauterine 
development.’, Experimental physiology, 100(12), pp. 1477–87. doi: 10.1113/EP085212. 
Fowden, A. L., Giussani, D. A. and Forhead, A. J. (2006) ‘Intrauterine programming of physiological 
systems: causes and consequences.’, Physiology (Bethesda, Md.), 21, pp. 29–37. doi: 
10.1152/physiol.00050.2005. 
Fowden, A. L., Li, J. and Forhead, A. J. (1998) ‘Glucocorticoids and the preparation for life after birth: 
are there long-term consequences of the life insurance?’, The Proceedings of the Nutrition Society, 
57(1), pp. 113–22. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9571716. 
Fraser, M. et al. (2001) ‘Developmental regulation of corticotrophin receptor gene expression in the 
adrenal gland of the ovine fetus and newborn lamb: effects of hypoxia during late pregnancy.’, The 
Journal of endocrinology, 169(1), pp. 1–10. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11250641. 
Frey, N. and Olson, E. N. (2003) ‘Cardiac Hypertrophy: The Good, the Bad, and the Ugly’, Annual 
Review of Physiology, 65(1), pp. 45–79. doi: 10.1146/annurev.physiol.65.092101.142243. 
G, L. (1969) ‘Premature delivery of foetal lambs infused with glucocorticoids’, J Endocrinol, 45, pp. 
515–523. 
Garite, T. J. et al. (2009) ‘Impact of a “rescue course” of antenatal corticosteroids: a multicenter 
randomized placebo-controlled trial’, American Journal of Obstetrics and Gynecology, 200(3), pp. 
248.e1-248.e9. doi: 10.1016/j.ajog.2009.01.021. 
Garton, T. et al. (2017) ‘Challenges for intraventricular hemorrhage research and emerging 
therapeutic targets.’, Expert opinion on therapeutic targets. NIH Public Access, 21(12), pp. 1111–
1122. doi: 10.1080/14728222.2017.1397628. 
Gay, M. S. et al. (2015) ‘Dexamethasone Treatment of Newborn Rats Decreases Cardiomyocyte 
Endowment in the Developing Heart through Epigenetic Modifications.’, PloS one, 10(4), p. 
e0125033. doi: 10.1371/journal.pone.0125033. 
Ghafoor, T. et al. (2003) ‘Incidence of respiratory distress syndrome.’, Journal of the College of 
Physicians and Surgeons--Pakistan : JCPSP, 13(5), pp. 271–3. doi: 05.2003/JCPSP.271273. 
Gilbert, W. M. et al. (2001) ‘Fetal monkey surfactants after intra-amniotic or maternal administration 
 246 
 
246 References 
of betamethasone and thyroid hormone’, Obstetrics & Gynecology. No longer published by Elsevier, 
98(3), pp. 466–470. doi: 10.1016/S0029-7844(01)01417-X. 
Giussani, D. A. et al. (2012) ‘Developmental Programming of Cardiovascular Dysfunction by Prenatal 
Hypoxia and Oxidative Stress’, PLoS ONE. Edited by J. A. L. Calbet, 7(2), p. e31017. doi: 
10.1371/journal.pone.0031017. 
Giussani, D. A. (2016) ‘The fetal brain sparing response to hypoxia: physiological mechanisms.’, The 
Journal of physiology. Wiley-Blackwell, 594(5), pp. 1215–30. doi: 10.1113/JP271099. 
Giussani, D. A., Forhead, A. J. and Fowden, A. L. (2005) ‘Development of cardiovascular function in 
the horse fetus.’, The Journal of physiology, 565(Pt 3), pp. 1019–30. doi: 
10.1113/jphysiol.2004.078469. 
Goldenberg, R. L. et al. (2008) ‘Epidemiology and causes of preterm birth’, The Lancet. Elsevier, 
371(9606), pp. 75–84. doi: 10.1016/S0140-6736(08)60074-4. 
Goldenthal, M. J. (2016) ‘Mitochondrial involvement in myocyte death and heart failure.’, Heart 
failure reviews, 21(2), pp. 137–55. doi: 10.1007/s10741-016-9531-1. 
Gonçalves, L. F., Chaiworapongsa, T. and Romero, R. (2002) ‘Intrauterine infection and prematurity’, 
Mental Retardation and Developmental Disabilities Research Reviews. John Wiley & Sons, Ltd, 8(1), 
pp. 3–13. doi: 10.1002/mrdd.10008. 
Gonzales, L. W. et al. (1986) ‘Glucocorticoids and thyroid hormones stimulate biochemical and 
morphological differentiation of human fetal lung in organ culture.’, The Journal of clinical 
endocrinology and metabolism, 62(4), pp. 678–91. doi: 10.1210/jcem-62-4-678. 
González-Morán, M. G. (2011) ‘Histological and Stereological Changes in Growing and Regressing 
Chicken Ovaries During Development’, The Anatomical Record: Advances in Integrative Anatomy and 
Evolutionary Biology, 294(5), pp. 893–904. doi: 10.1002/ar.21364. 
‘Good clinical practice advice: Antenatal corticosteroids for fetal lung maturation’ (2019) 
International Journal of Gynecology & Obstetrics. John Wiley & Sons, Ltd, 144(3), pp. 352–355. doi: 
10.1002/ijgo.12746. 
Goodman, Y. et al. (1996) ‘Estrogens attenuate and corticosterone exacerbates excitotoxicity, 
oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons.’, Journal of 
neurochemistry, 66(5), pp. 1836–44. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8780008 
(Accessed: 13 June 2019). 
Gough, A. et al. (2014) ‘Impaired lung function and health status in adult survivors of 
bronchopulmonary dysplasia’, European Respiratory Journal, 43(3), pp. 808–816. doi: 
10.1183/09031936.00039513. 
Graham, H. K. et al. (2016) ‘Cerebral palsy’, Nature Reviews Disease Primers. Nature Publishing 
Group, 2(1), p. 15082. doi: 10.1038/nrdp.2015.82. 
Gulati, A. et al. (2013) ‘Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients 
With Nonischemic Dilated Cardiomyopathy’, JAMA, 309(9), p. 896. doi: 10.1001/jama.2013.1363. 
Gundersen, H. J. et al. (1988) ‘Some new, simple and efficient stereological methods and their use in 
pathological research and diagnosis.’, APMIS : acta pathologica, microbiologica, et immunologica 
Scandinavica, 96(5), pp. 379–94. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3288247 
(Accessed: 31 July 2017). 
Gupta, V., Awasthi, N. and Wagner, B. J. (2007) ‘Specific activation of the glucocorticoid receptor and 
modulation of signal transduction pathways in human lens epithelial cells.’, Investigative 
 247 
 
247 References 
ophthalmology & visual science. NIH Public Access, 48(4), pp. 1724–34. doi: 10.1167/iovs.06-0889. 
Gyamfi-Bannerman, C. et al. (2016) ‘Antenatal Betamethasone for Women at Risk for Late Preterm 
Delivery’, New England Journal of Medicine, 374(14), pp. 1311–1320. doi: 10.1056/NEJMoa1516783. 
Gynaecologists, R. C. of O. & (no date) ‘Antenatal Corticosteroids to Reduce Neonatal Morbidity and 
Mortality - Green-top Guidline No.7’. 
Hack, M. et al. (2000) ‘Neurodevelopment and Predictors of Outcomes of Children With Birth 
Weights of Less Than 1000 g’, Archives of Pediatrics & Adolescent Medicine. American Medical 
Association, 154(7), p. 725. doi: 10.1001/archpedi.154.7.725. 
Hafizi Abu Bakar, M. et al. (2015) ‘Mitochondrial dysfunction as a central event for mechanisms 
underlying insulin resistance: the roles of long chain fatty acids.’, Diabetes/metabolism research and 
reviews, 31(5), pp. 453–75. doi: 10.1002/dmrr.2601. 
Halvorsen, T et al. (no date) ‘Pulmonary outcome in adolescents of extreme preterm birth: a regional 
cohort study’, Acta Pñdiatr, 93. doi: 10.1080/08035250410028101. 
Harada, K. et al. (1999) ‘Serial echocardiographic and Doppler evaluation of left ventricular systolic 
performance and diastolic filling in premature infants’, Early Human Development. Elsevier, 54(2), 
pp. 169–180. doi: 10.1016/S0378-3782(98)00093-0. 
Harding, R. and Hooper, S. B. (1996) ‘Regulation of lung expansion and lung growth before birth.’, 
Journal of applied physiology (Bethesda, Md. : 1985), 81(1), pp. 209–24. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8828667. 
Harrison, M. S. and Goldenberg, R. L. (2016) ‘Global burden of prematurity’, Seminars in Fetal and 
Neonatal Medicine. W.B. Saunders, 21(2), pp. 74–79. doi: 10.1016/J.SINY.2015.12.007. 
Harvey, E. P. and Ben-Tal, A. (2016) ‘Robust Unidirectional Airflow through Avian Lungs: New Insights 
from a Piecewise Linear Mathematical Model.’, PLoS computational biology. Public Library of 
Science, 12(2), p. e1004637. doi: 10.1371/journal.pcbi.1004637. 
He, Y. et al. (2014) ‘Structures and mechanism for the design of highly potent glucocorticoids’, Cell 
Research, 24(6), pp. 713–726. doi: 10.1038/cr.2014.52. 
Heckman, J. J. (2012) Invest in early childhood development: Reduce deficits, strengthen the 
economy. Available at: www.heckmanequation.org (Accessed: 12 September 2019). 
Herrera, E. A. et al. (2010) ‘Antioxidant treatment alters peripheral vascular dysfunction induced by 
postnatal glucocorticoid therapy in rats.’, PloS one, 5(2), p. e9250. doi: 
10.1371/journal.pone.0009250. 
Hill, A. et al. (2016) ‘A systematic review and meta-analysis of intimate partner violence during 
pregnancy and selected birth outcomes’, International Journal of Gynecology & Obstetrics, 133(3), 
pp. 269–276. doi: 10.1016/j.ijgo.2015.10.023. 
Hinchliffe, S. A. et al. (1992) ‘The effect of intrauterine growth retardation on the development of 
renal nephrons.’, British journal of obstetrics and gynaecology, 99(4), pp. 296–301. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1581274. 
Hirst, C. E., Major, A. T. and Smith, C. A. (2018) ‘Sex determination and gonadal sex differentiation in 
the chicken model’, The International Journal of Developmental Biology, 62(1-2–3), pp. 153–166. doi: 
10.1387/ijdb.170319cs. 
Hitzert, M. M. et al. (2014) ‘Functional outcome at school age of preterm-born children treated with 
high-dose dexamethasone.’, Early human development, 90(5), pp. 253–8. doi: 
 248 
 
248 References 
10.1016/j.earlhumdev.2014.01.013. 
Holtbäck, U. and Aperia, A. C. (2003) ‘Molecular determinants of sodium and water balance during 
early human development.’, Seminars in neonatology : SN, 8(4), pp. 291–9. doi: 10.1016/S1084-
2756(03)00042-3. 
Horbar, J. D. et al. (2012) ‘Mortality and neonatal morbidity among infants 501 to 1500 grams from 
2000 to 2009.’, Pediatrics. American Academy of Pediatrics, 129(6), pp. 1019–26. doi: 
10.1542/peds.2011-3028. 
Hotamisligil, G. S. and Davis, R. J. (2016) ‘Cell Signaling and Stress Responses.’, Cold Spring Harbor 
perspectives in biology. Cold Spring Harbor Laboratory Press, 8(10). doi: 
10.1101/cshperspect.a006072. 
Hovi, P. et al. (2016) ‘Blood Pressure in Young Adults Born at Very Low Birth Weight’, Hypertension, 
68(4), pp. 880–887. doi: 10.1161/HYPERTENSIONAHA.116.08167. 
Huckstep, O. J. et al. (2018) ‘Physiological Stress Elicits Impaired Left Ventricular Function in Preterm-
Born Adults’, Journal of the American College of Cardiology, 71(12), pp. 1347–1356. doi: 
10.1016/j.jacc.2018.01.046. 
Huzoor-Akbar et al. (1989) ‘Increased vascular contractile sensitivity to serotonin in spontaneously 
hypertensive rats is linked with increased turnover of phosphoinositide.’, Life sciences, 45(7), pp. 
577–83. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2549317 (Accessed: 12 June 2019). 
Hylka, V. W. and Doneen, B. A. (1982) ‘Lung phospholipids in the embryonic and immature chicken: 
Changes in lipid composition and biosynthesis during maturation of the surfactant system’, Journal 
of Experimental Zoology, 220(1), pp. 71–80. doi: 10.1002/jez.1402200110. 
IKEGAMI, M. et al. (1997) ‘Repetitive Prenatal Glucocorticoids Improve Lung Function and Decrease 
Growth in Preterm Lambs’, American Journal of Respiratory and Critical Care Medicine, 156(1), pp. 
178–184. doi: 10.1164/ajrccm.156.1.9612036. 
Itani, N. et al. (2015) ‘Melatonin rescues cardiovascular dysfunction during hypoxic development in 
the chick embryo.’, Journal of pineal research. doi: 10.1111/jpi.12283. 
Itani, N. et al. (2018) ‘The highs and lows of programmed cardiovascular disease by developmental 
hypoxia: studies in the chicken embryo’, The Journal of Physiology. John Wiley & Sons, Ltd (10.1111), 
596(15), pp. 2991–3006. doi: 10.1113/JP274111. 
Iuchi, T. et al. (2003) ‘Glucocorticoid excess induces superoxide production in vascular endothelial 
cells and elicits vascular endothelial dysfunction.’, Circulation research, 92(1), pp. 81–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12522124. 
Jain, L. and Eaton, D. C. (2006) ‘Physiology of fetal lung fluid clearance and the effect of labor.’, 
Seminars in perinatology, 30(1), pp. 34–43. doi: 10.1053/j.semperi.2006.01.006. 
Jain, N. J. et al. (2009) ‘Impact of mode of delivery on neonatal complications: Trends between 1997 
and 2005’, The Journal of Maternal-Fetal & Neonatal Medicine, 22(6), pp. 491–500. doi: 
10.1080/14767050902769982. 
Jang, H. and Serra, C. (2014) ‘Nutrition, epigenetics, and diseases.’, Clinical nutrition research, 3(1), 
pp. 1–8. doi: 10.7762/cnr.2014.3.1.1. 
Japp, A. G. et al. (2016) ‘The Diagnosis and Evaluation of Dilated Cardiomyopathy’, Journal of the 
American College of Cardiology. Elsevier, 67(25), pp. 2996–3010. doi: 10.1016/J.JACC.2016.03.590. 
Jellyman, J. K. et al. (2004) ‘Effects of dexamethasone on the uterine and umbilical vascular beds 
 249 
 
249 References 
during basal and hypoxemic conditions in sheep.’, American journal of obstetrics and gynecology, 
190(3), pp. 825–35. doi: 10.1016/j.ajog.2003.09.046. 
Jellyman, J. K. et al. (2005) ‘Fetal cardiovascular, metabolic and endocrine responses to acute 
hypoxaemia during and following maternal treatment with dexamethasone in sheep.’, The Journal of 
physiology, 567(Pt 2), pp. 673–88. doi: 10.1113/jphysiol.2005.089805. 
Jellyman, J. K. et al. (2009a) ‘Antenatal glucocorticoid therapy increases glucose delivery to cerebral 
circulations during acute hypoxemia in fetal sheep during late gestation’, American Journal of 
Obstetrics and Gynecology, 201(1), pp. 82.e1-82.e8. doi: 10.1016/j.ajog.2009.01.012. 
Jellyman, J. K. et al. (2009b) ‘Antenatal glucocorticoid therapy increases glucose delivery to cerebral 
circulations during acute hypoxemia in fetal sheep during late gestation’, American Journal of 
Obstetrics and Gynecology, 201(1), pp. 82.e1-82.e8. doi: 10.1016/j.ajog.2009.01.012. 
Jellyman, J. K. et al. (2012) ‘Effects of cortisol and dexamethasone on insulin signalling pathways in 
skeletal muscle of the ovine fetus during late gestation.’, PloS one, 7(12), p. e52363. doi: 
10.1371/journal.pone.0052363. 
Jenkins, S. A. and Porter, T. E. (2004) ‘Ontogeny of the hypothalamo–pituitary–adrenocortical axis in 
the chicken embryo: a review’, Domestic Animal Endocrinology. Elsevier, 26(4), pp. 267–275. doi: 
10.1016/J.DOMANIEND.2004.01.001. 
JF, C. K. & K. (2004) ‘Reactive Oxygen Species-Mediated Signal Transduction in the Endothelium.’, 
Endothelium, 11, pp. 109–121. 
Jin, T. et al. (2015) ‘Differentiation-inducing effects of betamethasone on human glioma cell line 
U251’, Genetics and Molecular Research, 14(3), pp. 7841–7849. doi: 10.4238/2015.July.14.10. 
Jobe, A. H. et al. (1993) ‘Lung responses to ultrasound-guided fetal treatments with corticosteroids 
in preterm lambs’, Journal of Applied Physiology, 75(5), pp. 2099–2105. doi: 
10.1152/jappl.1993.75.5.2099. 
Jobe, A. H. et al. (1998) ‘Fetal versus maternal and gestational age effects of repetitive antenatal 
glucocorticoids.’, Pediatrics, 102(5), pp. 1116–25. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9794943. 
Jobe, A. H. et al. (2009) ‘Betamethasone dose and formulation for induced lung maturation in fetal 
sheep.’, American journal of obstetrics and gynecology, 201(6), pp. 611.e1–7. doi: 
10.1016/j.ajog.2009.07.014. 
Jobe, A. H. and Soll, R. F. (2004) ‘Choice and dose of corticosteroid for antenatal treatments’, 
American Journal of Obstetrics and Gynecology. Mosby, 190(4), pp. 878–881. doi: 
10.1016/J.AJOG.2004.01.044. 
Jornada, D. et al. (2015) ‘The Prodrug Approach: A Successful Tool for Improving Drug Solubility’, 
Molecules, 21(1), p. 42. doi: 10.3390/molecules21010042. 
Joy Lawn, A. et al. (2012) Antenatal Corticosteroids for the reduction of deaths in preterm babies 
Prepared for the United Nations Commission on Live--Saving Commodities for Women and Children 
Children’s Health. Available at: 
http://www.everywomaneverychild.org/images/Final_AN_Steroids_report_for_UN-COMPLETE.pdf 
(Accessed: 11 June 2019). 
Kalliecharan, R. and Hall, B. K. (1974) ‘A developmental study of the levels of progesterone, 
corticosterone, cortisol, and cortisone circulating in plasma of chick embryos’, General and 
Comparative Endocrinology. Academic Press, 24(4), pp. 364–372. doi: 10.1016/0016-6480(74)90149-
 250 
 
250 References 
X. 
Kanse, S. M. et al. (1991) ‘Glucocorticoids induce endothelin release from vascular smooth muscle 
cells but not endothelial cells.’, European journal of pharmacology, 199(1), pp. 99–101. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1893930 (Accessed: 12 June 2019). 
Karalis, D. G. et al. (2016) ‘The risks of statin use in pregnancy: A systematic review’, Journal of 
Clinical Lipidology, 10(5), pp. 1081–1090. doi: 10.1016/j.jacl.2016.07.002. 
Karssen, A. et al. (2002) ‘The role of the efflux transporter P-glycoprotein in brain penetration of 
prednisolone’, Journal of Endocrinology, 175(1), pp. 251–260. doi: 10.1677/joe.0.1750251. 
Kelly, B. A. et al. (2012) ‘Antenatal glucocorticoid exposure and long-term alterations in aortic 
function and glucose metabolism.’, Pediatrics, 129(5), pp. e1282-90. doi: 10.1542/peds.2011-3175. 
Khan, K. et al. (2015) ‘Economic costs associated with moderate and late preterm birth: a 
prospective population-based study’, BJOG: An International Journal of Obstetrics & Gynaecology. 
John Wiley & Sons, Ltd (10.1111), 122(11), pp. 1495–1505. doi: 10.1111/1471-0528.13515. 
Kim, H. K. et al. (2016) ‘Cardiac Response to Oxidative Stress Induced by Mitochondrial Dysfunction’, 
in. Springer, Cham, pp. 101–127. doi: 10.1007/112_2015_5004. 
Knuesel, I. et al. (2014) ‘Maternal immune activation and abnormal brain development across CNS 
disorders’, Nature Reviews Neurology, 10(11), pp. 643–660. doi: 10.1038/nrneurol.2014.187. 
Kobaly, K. et al. (2008) ‘Outcomes of extremely low birth weight (<1 kg) and extremely low 
gestational age (<28 weeks) infants with bronchopulmonary dysplasia: effects of practice changes in 
2000 to 2003.’, Pediatrics, 121(1), pp. 73–81. doi: 10.1542/peds.2007-1444. 
Koenen, S. V et al. (2002) ‘Effects of maternal betamethasone administration on fetal and maternal 
blood pressure and heart rate in the baboon at 0.7 of gestation.’, American journal of obstetrics and 
gynecology, 186(4), pp. 812–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11967513. 
Kou, S. et al. (2014) ‘Echocardiographic reference ranges for normal cardiac chamber size: results 
from the NORRE study’, European Heart Journal - Cardiovascular Imaging. Narnia, 15(6), pp. 680–
690. doi: 10.1093/ehjci/jet284. 
Koullali, B. et al. (2016) ‘Risk assessment and management to prevent preterm birth’, Seminars in 
Fetal and Neonatal Medicine. W.B. Saunders, 21(2), pp. 80–88. doi: 10.1016/J.SINY.2016.01.005. 
Kreider, M. L. et al. (2006) ‘Lasting effects of developmental dexamethasone treatment on neural 
cell number and size, synaptic activity, and cell signaling: critical periods of vulnerability, dose-effect 
relationships, regional targets, and sex selectivity.’, Neuropsychopharmacology : official publication 
of the American College of Neuropsychopharmacology, 31(1), pp. 12–35. doi: 
10.1038/sj.npp.1300783. 
Kurmani, S. and Squire, I. (2017) ‘Acute Heart Failure: Definition, Classification and Epidemiology.’, 
Current heart failure reports. Springer, 14(5), pp. 385–392. doi: 10.1007/s11897-017-0351-y. 
Kutzler, M. A. et al. (2003) ‘Maternal dexamethasone increases endothelin-1 sensitivity and 
endothelin a receptor expression in ovine foetal placental arteries.’, Placenta, 24(4), pp. 392–402. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/12657514 (Accessed: 12 July 2017). 
Labaune, J., Boutroy, M.-J. and Bairam, A. (2002) ‘Antenatal treatment with corticosteroids affects 
mRNA expression of dopamine D1 and D2 receptors in the striatum of developing rabbit.’, Biology of 
the neonate, 82(2), pp. 142–4. doi: 63093. 
Latour, M. A. et al. (no date) EDUCATION AND PRODUCTION Effects of Breeder Hen Age and Dietary 
 251 
 
251 References 
Fat on Embryonic and Neonatal Broiler Serum Lipids and Glucose 1 ’ 2. Available at: 
https://academic.oup.com/ps/article-abstract/75/6/695/1588683 (Accessed: 7 September 2019). 
Lawn, J. and Althabe, F. (2013) ‘Proposal for the inclusion (as an additional purpose) on the WHO 
Model List of Essential Medicines of DEXAMETHASONE FOR ACCELERATING LUNG MATURATION IN 
PRETERM BABIES’, 19th Expert Committee on the Selection and Use of Essential Medicines. 
Lee, B. H. et al. (2006) ‘Adverse Neonatal Outcomes Associated With Antenatal Dexamethasone 
Versus Antenatal Betamethasone’, PEDIATRICS, 117(5), pp. 1503–1510. doi: 10.1542/peds.2005-
1749. 
Lee, B. H. et al. (2008) ‘Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants 
Exposed Prenatally to Dexamethasone Versus Betamethasone’, PEDIATRICS, 121(2), pp. 289–296. 
doi: 10.1542/peds.2007-1103. 
Lee, J.-H. et al. (2014) ‘Antenatal betamethasone increases vascular reactivity to endothelin-1 by 
upregulation of CD38/cADPR signaling.’, Journal of developmental origins of health and disease. NIH 
Public Access, 5(1), pp. 56–62. doi: 10.1017/S2040174413000512. 
Lee, S.-R. et al. (2013) ‘Glucocorticoids and their receptors: insights into specific roles in 
mitochondria.’, Progress in biophysics and molecular biology, 112(1–2), pp. 44–54. doi: 
10.1016/j.pbiomolbio.2013.04.001. 
Lewandowski, A. J. et al. (2013a) ‘Preterm Heart in Adult Life’, Circulation, 127(2), pp. 197–206. doi: 
10.1161/CIRCULATIONAHA.112.126920. 
Lewandowski, A. J. et al. (2013b) ‘Preterm Heart in Adult LifeClinical Perspective’, Circulation, 127(2), 
pp. 197–206. doi: 10.1161/CIRCULATIONAHA.112.126920. 
Lewandowski, A. J. et al. (2015) ‘Elevated Blood Pressure in Preterm-Born Offspring Associates With 
a Distinct Antiangiogenic State and Microvascular Abnormalities in Adult LifeNovelty and 
Significance’, Hypertension, 65(3), pp. 607–614. doi: 10.1161/HYPERTENSIONAHA.114.04662. 
Li, S. et al. (2013) ‘The impact of maternal synthetic glucocorticoid administration in late pregnancy 
on fetal and early neonatal hypothalamic-pituitary-adrenal axes regulatory genes is dependent upon 
dose and gestational age at exposure.’, Journal of developmental origins of health and disease, 4(1), 
pp. 77–89. doi: 10.1017/S2040174412000591. 
Liberman, M., Fernandes, D. C. and Leite, P. F. (2018) ‘Endothelium-Dependent Vasodilation: Nitric 
Oxide and Other Mediators’, Endothelium and Cardiovascular Diseases. Academic Press, pp. 97–113. 
doi: 10.1016/B978-0-12-812348-5.00008-8. 
Lie, S. et al. (2014) ‘Periconceptional undernutrition programs changes in insulin-signaling molecules 
and microRNAs in skeletal muscle in singleton and twin fetal sheep.’, Biology of reproduction, 90(1), 
p. 5. doi: 10.1095/biolreprod.113.109751. 
Liggins, G. C. (1994) ‘Fetal Lung Maturation’, The Australian and New Zealand Journal of Obstetrics 
and Gynaecology, 34(3), pp. 247–250. doi: 10.1111/j.1479-828X.1994.tb01066.x. 
Liggins, G C (1994) ‘The role of cortisol in preparing the fetus for birth.’, Reproduction, fertility, and 
development, 6(2), pp. 141–50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7991781. 
LIGGINS, G. C. (1969) ‘PREMATURE DELIVERY OF FOETAL LAMBS INFUSED WITH GLUCOCORTICOIDS’, 
Journal of Endocrinology, 45(4), pp. 515–523. doi: 10.1677/joe.0.0450515. 
Liggins, G. C. and Howie, R. N. (1972) ‘A controlled trial of antepartum glucocorticoid treatment for 
prevention of the respiratory distress syndrome in premature infants.’, Pediatrics, 50(4), pp. 515–25. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/4561295. 
 252 
 
252 References 
Liley, H. G. et al. (1987) ‘Surfactant protein of molecular weight 28,000-36,000 in cultured human 
fetal lung: cellular localization and effect of dexamethasone.’, Molecular endocrinology (Baltimore, 
Md.), 1(3), pp. 205–15. doi: 10.1210/mend-1-3-205. 
Lin, H.-Y. et al. (2014) ‘Prevention of necrotizing enterocolitis in preterm very low birth weight 
infants: Is it feasible?’, Journal of the Formosan Medical Association. Elsevier, 113(8), pp. 490–497. 
doi: 10.1016/J.JFMA.2013.03.010. 
Lin, Y.-J. et al. (2018) ‘Early Postweaning Treatment with Dimethyl Fumarate Prevents Prenatal 
Dexamethasone- and Postnatal High-Fat Diet-Induced Programmed Hypertension in Male Rat 
Offspring’, Oxidative Medicine and Cellular Longevity, 2018, pp. 1–8. doi: 10.1155/2018/5343462. 
Lindsay, R. S. et al. (1996) ‘Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the 
rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone.’, Diabetologia, 
39(11), pp. 1299–305. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8932995. 
Liu, L. et al. (2016) ‘Global, regional, and national causes of under-5 mortality in 2000-15: an updated 
systematic analysis with implications for the Sustainable Development Goals.’, Lancet (London, 
England). Elsevier, 388(10063), pp. 3027–3035. doi: 10.1016/S0140-6736(16)31593-8. 
Liu, S., Elkayam, U. and Naqvi, T. Z. (2016) ‘Echocardiography in Pregnancy: Part 1’, Current 
Cardiology Reports, 18(9), p. 92. doi: 10.1007/s11886-016-0760-7. 
Livak, K. J. and Schmittgen, T. D. (2001) ‘Analysis of Relative Gene Expression Data Using Real-Time 
Quantitative PCR and the 2−ΔΔCT Method’, Methods, 25(4), pp. 402–408. doi: 
10.1006/meth.2001.1262. 
Luu, T. M., Rehman Mian, M. O. and Nuyt, A. M. (2017) ‘Long-Term Impact of Preterm Birth’, Clinics 
in Perinatology, 44(2), pp. 305–314. doi: 10.1016/j.clp.2017.01.003. 
Lv, Z.-P. et al. (2018) ‘Glucose and lipid metabolism disorders in the chickens with dexamethasone-
induced oxidative stress’, Journal of Animal Physiology and Animal Nutrition, 102(2), pp. e706–e717. 
doi: 10.1111/jpn.12823. 
Ma, Z. A., Zhao, Z. and Turk, J. (2012) ‘Mitochondrial dysfunction and β-cell failure in type 2 diabetes 
mellitus.’, Experimental diabetes research, 2012, p. 703538. doi: 10.1155/2012/703538. 
Maina, J. N. (2015) ‘The design of the avian respiratory system: development, morphology and 
function’, Journal of Ornithology. Springer Berlin Heidelberg, 156(S1), pp. 41–63. doi: 
10.1007/s10336-015-1263-9. 
Mak, T. W. et al. (2017) ‘p53 regulates the cardiac transcriptome.’, Proceedings of the National 
Academy of Sciences of the United States of America. National Academy of Sciences, 114(9), pp. 
2331–2336. doi: 10.1073/pnas.1621436114. 
Makhija NK., Tronnes AA., Dunlap BS., Schulkin J., L. S. (2016) ‘Antenatal corticosteroid timing: 
accuracy after the introduction of a rescue course protocol’, American journal of obstetrics and 
gynecology, 214(1), pp. e1-6. doi: 10.1016/j.ajog.2015.08.018. 
Mammel, M. C. et al. (1983) ‘Controlled trial of dexamethasone therapy in infants with 
bronchopulmonary dysplasia.’, Lancet (London, England), 1(8338), pp. 1356–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/6134136. 
Mangham, L. J. et al. (2009) ‘The cost of preterm birth throughout childhood in England and Wales.’, 
Pediatrics. American Academy of Pediatrics, 123(2), pp. e312-27. doi: 10.1542/peds.2008-1827. 
Marcela, S. G. et al. (2012) ‘Chronological and Morphological Study of Heart Development in the 
Rat’, The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, 295(8), pp. 
 253 
 
253 References 
1267–1290. doi: 10.1002/ar.22508. 
Marlow, N. et al. (2005) ‘Neurologic and Developmental Disability at Six Years of Age after Extremely 
Preterm Birth’, New England Journal of Medicine, 352(1), pp. 9–19. doi: 10.1056/NEJMoa041367. 
Martin, R. J. and Fanaroff, A. A. (2013) ‘The Preterm Lung and Airway: Past, Present, and Future’, 
Pediatrics & Neonatology. Elsevier, 54(4), pp. 228–234. doi: 10.1016/J.PEDNEO.2013.03.001. 
Martinerie, L. et al. (2009) ‘Low renal mineralocorticoid receptor expression at birth contributes to 
partial aldosterone resistance in neonates.’, Endocrinology, 150(9), pp. 4414–24. doi: 
10.1210/en.2008-1498. 
Mason, J. I. et al. (1989) ‘Ovine placental steroid 17α-hydroxylase/C-17,20-lyase, aromatase and 
sulphatase in dexamethasone-induced and natural parturition’, Journal of Endocrinology, 122(1), pp. 
351–359. doi: 10.1677/joe.0.1220351. 
Massmann, G. A. et al. (2017) ‘Sex-dependent effects of antenatal glucocorticoids on insulin 
sensitivity in adult sheep: role of the adipose tissue renin angiotensin system’, American Journal of 
Physiology-Regulatory, Integrative and Comparative Physiology, 312(6), pp. R1029–R1038. doi: 
10.1152/ajpregu.00181.2016. 
MASTORAKOS, G. and ILIAS, I. (2003) ‘Maternal and Fetal Hypothalamic-Pituitary-Adrenal Axes 
During Pregnancy and Postpartum’, Annals of the New York Academy of Sciences. John Wiley & Sons, 
Ltd (10.1111), 997(1), pp. 136–149. doi: 10.1196/annals.1290.016. 
MASTORAKOS, G. and ILIAS, I. (2006) ‘Maternal Hypothalamic-Pituitary-Adrenal Axis in Pregnancy 
and the Postpartum Period: Postpartum-Related Disorders’, Annals of the New York Academy of 
Sciences, 900(1), pp. 95–106. doi: 10.1111/j.1749-6632.2000.tb06220.x. 
McArthur, S. et al. (2016) ‘Sex-specific disruption of murine midbrain astrocytic and dopaminergic 
developmental trajectories following antenatal GC treatment’, Brain Structure and Function, 221(5), 
pp. 2459–2475. doi: 10.1007/s00429-015-1049-0. 
McCowan, L. M. E. et al. (2009) ‘Spontaneous preterm birth and small for gestational age infants in 
women who stop smoking early in pregnancy: prospective cohort study.’, BMJ (Clinical research ed.). 
British Medical Journal Publishing Group, 338, p. b1081. doi: 10.1136/bmj.b1081. 
McKinlay, C. J. D. et al. (2015) ‘Cardiovascular risk factors in children after repeat doses of antenatal 
glucocorticoids: an RCT.’, Pediatrics. American Academy of Pediatrics, 135(2), pp. e405-15. doi: 
10.1542/peds.2014-2408. 
McKinlay, C. J. D., Dalziel, S. R. and Harding, J. E. (2015) ‘Antenatal glucocorticoids: where are we 
after forty years?’, Journal of developmental origins of health and disease, 6(2), pp. 127–42. doi: 
10.1017/S2040174414000579. 
McLellan, A. R. et al. (1992) ‘Effects of dexamethasone on G protein levels and adenylyl cyclase 
activity in rat vascular smooth muscle cells.’, Journal of molecular endocrinology, 9(3), pp. 237–44. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/1335725 (Accessed: 12 June 2019). 
Mecenas, C. A. et al. (1996) ‘Production of premature delivery in pregnant rhesus monkeys by 
androstenedione infusion.’, Nature medicine, 2(4), pp. 443–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8597955 (Accessed: 12 September 2019). 
Mendez, D. D., Hogan, V. K. and Culhane, J. F. (2014) ‘Institutional racism, neighborhood factors, 
stress, and preterm birth’, Ethnicity & Health, 19(5), pp. 479–499. doi: 
10.1080/13557858.2013.846300. 
Meyerovich, K. et al. (2016) ‘Endoplasmic reticulum stress and the unfolded protein response in 
 254 
 
254 References 
pancreatic islet inflammation’, Journal of Molecular Endocrinology, 57(1), pp. R1–R17. doi: 
10.1530/JME-15-0306. 
Miyabo, S. et al. (1981) A Comparison of the Bioavailability and Potency of Dexamethasone 
Phosphate and Sulphate in Man, European Journal of Clinical Pharmacology. Available at: 
https://link.springer.com/content/pdf/10.1007%2FBF00618778.pdf (Accessed: 7 August 2019). 
Mizuno, M. et al. (2010) ‘Antenatal glucocorticoid therapy accelerates ATP production with creatine 
kinase increase in the growth-enhanced fetal rat heart.’, Circulation journal : official journal of the 
Japanese Circulation Society, 74(1), pp. 171–80. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19952437. 
Moisiadis, V. G. and Matthews, S. G. (2014a) ‘Glucocorticoids and fetal programming part 1: 
outcomes’, Nature Reviews Endocrinology, 10(7), pp. 391–402. doi: 10.1038/nrendo.2014.73. 
Moisiadis, V. G. and Matthews, S. G. (2014b) ‘Glucocorticoids and fetal programming part 2: 
mechanisms’, Nature Reviews Endocrinology, 10(7), pp. 403–411. doi: 10.1038/nrendo.2014.74. 
Moritz, K. M. et al. (2011) ‘Prenatal glucocorticoid exposure in the sheep alters renal development in 
utero: implications for adult renal function and blood pressure control.’, American journal of 
physiology. Regulatory, integrative and comparative physiology, 301(2), pp. R500-9. doi: 
10.1152/ajpregu.00818.2010. 
Moritz, K. M., Dodic, M. and Wintour, E. M. (2003) ‘Kidney development and the fetal programming 
of adult disease’, BioEssays, 25(3), pp. 212–220. doi: 10.1002/bies.10240. 
Moss, T. J. . et al. (2003) ‘Intra-amniotic corticosteroids for preterm lung maturation in sheep’, 
American Journal of Obstetrics and Gynecology. Mosby, 189(5), pp. 1389–1395. doi: 10.1067/S0002-
9378(03)00622-7. 
Msall, M. E. and Tremont, M. R. (2002) ‘MEASURING FUNCTIONAL OUTCOMES AFTER PREMATURITY: 
DEVELOPMENTAL IMPACT OF VERY LOW BIRTH WEIGHT AND EXTREMELY LOW BIRTH WEIGHT 
STATUS ON CHILDHOOD DISABILITY’. doi: 10.1002/mrdd.10046. 
Mulder, E. J. H., de Heus, R. and Visser, G. H. A. (2009) ‘Antenatal corticosteroid therapy: short-term 
effects on fetal behaviour and haemodynamics.’, Seminars in fetal & neonatal medicine, 14(3), pp. 
151–6. doi: 10.1016/j.siny.2008.10.003. 
Murray, C. J. L. et al. (2012) ‘Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 
regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010’, The Lancet, 
380(9859), pp. 2197–2223. doi: 10.1016/S0140-6736(12)61689-4. 
Mutsaers, H. A. M. and Tofighi, R. (2012) ‘Dexamethasone enhances oxidative stress-induced cell 
death in murine neural stem cells.’, Neurotoxicity research, 22(2), pp. 127–37. doi: 10.1007/s12640-
012-9308-9. 
Nanovskaya, T. N. et al. (2013) ‘Transplacental transfer and distribution of pravastatin.’, American 
journal of obstetrics and gynecology, 209(4), pp. 373.e1–5. doi: 10.1016/j.ajog.2013.05.038. 
Nanthakumar, N. N. et al. (2000) ‘Inflammation in the developing human intestine: A possible 
pathophysiologic contribution to necrotizing enterocolitis’, Proceedings of the National Academy of 
Sciences, 97(11), pp. 6043–6048. doi: 10.1073/pnas.97.11.6043. 
Narang, I. et al. (2008) ‘Longitudinal Evaluation of Airway Function 21 Years after Preterm Birth’, 
American Journal of Respiratory and Critical Care Medicine, 178(1), pp. 74–80. doi: 
10.1164/rccm.200705-701OC. 
Nathanielsz, P. W. et al. (1998) ‘Local paracrine effects of estradiol are central to parturition in the 
 255 
 
255 References 
rhesus monkey.’, Nature medicine, 4(4), pp. 456–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9546793 (Accessed: 12 September 2019). 
Newby, E. A., Myers, D. A. and Ducsay, C. A. (2015) ‘Fetal endocrine and metabolic adaptations to 
hypoxia: the role of the hypothalamic-pituitary-adrenal axis.’, American journal of physiology. 
Endocrinology and metabolism, 309(5), pp. E429-39. doi: 10.1152/ajpendo.00126.2015. 
Newnham, J. P. et al. (no date) ‘Maternal, but not fetal, administration of corticosteroids restricts 
fetal growth.’, The Journal of maternal-fetal medicine, 8(3), pp. 81–7. doi: 10.1002/(SICI)1520-
6661(199905/06)8:3<81::AID-MFM3>3.0.CO;2-N. 
Newnham, J. P. and Moss, T. J. (2001) ‘Antenatal glucocorticoids and growth: single versus multiple 
doses in animal and human studies.’, Seminars in neonatology : SN, 6(4), pp. 285–92. doi: 
10.1053/siny.2001.0064. 
Nichols, C. D. (2009) ‘Serotonin 5- Receptor Function as a Contributing Factor to Both 
Neuropsychiatric and Cardiovascular Diseases’, Cardiovascular Psychiatry and Neurology, 2009, pp. 
1–8. doi: 10.1155/2009/475108. 
NIH (1994) ‘The effect of antenatal steroids for fetal maturation on perinatal outcomes-interim draft 
statement’, NIH Consens Statement Online, 12(2), pp. 1–24. 
Niu, Y. et al. (2013) ‘Antioxidant treatment improves neonatal survival and prevents impaired cardiac 
function at adulthood following neonatal glucocorticoid therapy.’, The Journal of physiology, 
591(20), pp. 5083–93. doi: 10.1113/jphysiol.2013.258210. 
NJ, S. (1970) ‘Developmental landmarks in cardiac morphogenesis: Comparative chronology.’, The 
American Journal of Cardiology, 25, pp. 141–148. 
Noorlander, C. W. et al. (2014) ‘Antenatal glucocorticoid treatment affects hippocampal 
development in mice.’, PloS one, 9(1), p. e85671. doi: 10.1371/journal.pone.0085671. 
Northway, W. H., Rosan, R. C. and Porter, D. Y. (1967) ‘Pulmonary disease following respirator 
therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.’, The New England journal of 
medicine, 276(7), pp. 357–68. doi: 10.1056/NEJM196702162760701. 
Norwitz, E. R. et al. (2015) ‘Molecular Regulation of Parturition: The Role of the Decidual Clock.’, Cold 
Spring Harbor perspectives in medicine. Cold Spring Harbor Laboratory Press, 5(11), p. a023143. doi: 
10.1101/cshperspect.a023143. 
Nyirenda, M. J. et al. (1998) ‘Glucocorticoid exposure in late gestation permanently programs rat 
hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes 
glucose intolerance in adult offspring.’, The Journal of clinical investigation, 101(10), pp. 2174–81. 
doi: 10.1172/JCI1567. 
O’Connor, S. J. et al. (2006) ‘Development of baroreflex function and hind limb vascular reactivity in 
the horse fetus.’, The Journal of physiology, 572(Pt 1), pp. 155–64. doi: 
10.1113/jphysiol.2006.105635. 
O’Reilly, M., Sozo, F. and Harding, R. (2013) ‘Impact of preterm birth and bronchopulmonary 
dysplasia on the developing lung: Long-term consequences for respiratory health’, Clinical and 
Experimental Pharmacology and Physiology, 40(11), pp. 765–773. doi: 10.1111/1440-1681.12068. 
Oakley, R. H. and Cidlowski, J. A. (2013) ‘The biology of the glucocorticoid receptor: New signaling 
mechanisms in health and disease’, Journal of Allergy and Clinical Immunology, 132(5), pp. 1033–
1044. doi: 10.1016/j.jaci.2013.09.007. 
Oakley, R. H. and Cidlowski, J. A. (2015) ‘Glucocorticoid signaling in the heart: A cardiomyocyte 
 256 
 
256 References 
perspective’, The Journal of Steroid Biochemistry and Molecular Biology. Pergamon, 153, pp. 27–34. 
doi: 10.1016/J.JSBMB.2015.03.009. 
Oliveira, M. et al. (2006) ‘Induction of a hyperanxious state by antenatal dexamethasone: a case for 
less detrimental natural corticosteroids.’, Biological psychiatry, 59(9), pp. 844–52. doi: 
10.1016/j.biopsych.2005.08.020. 
Oliveira, M. et al. (2012) ‘The bed nucleus of stria terminalis and the amygdala as targets of 
antenatal glucocorticoids: implications for fear and anxiety responses.’, Psychopharmacology, 
220(3), pp. 443–53. doi: 10.1007/s00213-011-2494-y. 
Oparil, S., Bishop, S. P. and Clubb, F. J. (1984) ‘Myocardial cell hypertrophy or hyperplasia.’, 
Hypertension (Dallas, Tex. : 1979), 6(6 Pt 2), pp. III38-43. doi: 10.1161/01.HYP.6.6_PT_2.III38. 
Orr, S. T., James, S. A. and Blackmore Prince, C. (2002) ‘Maternal Prenatal Depressive Symptoms and 
Spontaneous Preterm Births among African-American Women in Baltimore, Maryland’, American 
Journal of Epidemiology, 156(9), pp. 797–802. doi: 10.1093/aje/kwf131. 
Ortiz, L. A. et al. (2001) ‘Effect of prenatal dexamethasone on rat renal development.’, Kidney 
international, 59(5), pp. 1663–9. doi: 10.1046/j.1523-1755.2001.0590051663.x. 
Österman, H. et al. (2015) ‘Chronic hypoxia during development does not trigger pathologic 
remodeling of the chicken embryonic heart but reduces cardiomyocyte number’, American Journal 
of Physiology-Regulatory, Integrative and Comparative Physiology, 309(10), pp. R1204–R1214. doi: 
10.1152/ajpregu.00499.2014. 
Paragliola, R. M. et al. (2017) ‘Treatment with Synthetic Glucocorticoids and the Hypothalamus-
Pituitary-Adrenal Axis.’, International journal of molecular sciences. Multidisciplinary Digital 
Publishing Institute  (MDPI), 18(10). doi: 10.3390/ijms18102201. 
Parente, L. (2017) ‘Deflazacort: therapeutic index, relative potency and equivalent doses versus 
other corticosteroids’, BMC Pharmacology and Toxicology. BioMed Central, 18(1), p. 1. doi: 
10.1186/s40360-016-0111-8. 
Parker, K. L. and Schimmer, B. P. (1996) ‘The roles of the nuclear receptor steroidogenic factor 1 in 
endocrine differentiation and development.’, Trends in endocrinology and metabolism: TEM, 7(6), 
pp. 203–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18406748 (Accessed: 25 June 2018). 
Parkinson, J. R. C. et al. (2013) ‘Preterm Birth and the Metabolic Syndrome in Adult Life: A 
Systematic Review and Meta-analysis’, PEDIATRICS, 131(4), pp. e1240–e1263. doi: 
10.1542/peds.2012-2177. 
Pascual, R. et al. (2014) ‘Single course of antenatal betamethasone produces delayed changes in 
morphology and calbindin-D28k expression in a rat’s cerebellar Purkinje cells.’, Acta neurobiologiae 
experimentalis, 74(4), pp. 415–23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25576972. 
Patel, R. M. (2016) ‘Short- and Long-Term Outcomes for Extremely Preterm Infants.’, American 
journal of perinatology. NIH Public Access, 33(3), pp. 318–28. doi: 10.1055/s-0035-1571202. 
Patel, R. M. and Denning, P. W. (2015) ‘Intestinal microbiota and its relationship with necrotizing 
enterocolitis.’, Pediatric research. NIH Public Access, 78(3), pp. 232–8. doi: 10.1038/pr.2015.97. 
Payne, A. H. et al. (2013) ‘Neurodevelopmental Outcomes of Extremely Low-Gestational-Age 
Neonates With Low-Grade Periventricular-Intraventricular Hemorrhage’, JAMA Pediatrics, 167(5), p. 
451. doi: 10.1001/jamapediatrics.2013.866. 
Peffer, M. E. et al. (2014) ‘Caveolin-1 Regulates Genomic Action of the Glucocorticoid Receptor in 
Neural Stem Cells’, Molecular and Cellular Biology, 34(14), pp. 2611–2623. doi: 10.1128/MCB.01121-
 257 
 
257 References 
13. 
Pham, T. D. et al. (2003) ‘Uteroplacental insufficiency increases apoptosis and alters p53 gene 
methylation in the full-term IUGR rat kidney.’, American journal of physiology. Regulatory, 
integrative and comparative physiology, 285(5), pp. R962-70. doi: 10.1152/ajpregu.00201.2003. 
Pignatelli, D. et al. (2006) ‘Adrenarche in the rat’, Journal of Endocrinology, 191(1), pp. 301–308. doi: 
10.1677/joe.1.06972. 
Ping, N.-N. et al. (2014) ‘The Determination of Optimal Initial Tension in Rat Coronary Artery Using 
Wire Myography’, Physiol. Res, 63, pp. 143–146. Available at: www.biomed.cas.cz/physiolres 
(Accessed: 31 May 2019). 
Planer, B. C. et al. (1996) ‘ANTENATAL CORTICOSTEROID (ANCS) USE IN PRETERM LABOR IN THE USA. 
647’, Pediatric Research. Nature Publishing Group, 39(4), pp. 110–110. doi: 10.1203/00006450-
199604001-00669. 
Pohjoismäki, J. L. O. et al. (2013) ‘Postnatal cardiomyocyte growth and mitochondrial reorganization 
cause multiple changes in the proteome of human cardiomyocytes’, Molecular BioSystems, 9(6), p. 
1210. doi: 10.1039/c3mb25556e. 
Polyzos, N. P. et al. (2007) ‘Combined Vitamin C and E Supplementation During Pregnancy For 
Preeclampsia Prevention: A Systematic Review’, Obstetrical & Gynecological Survey, 62(3), pp. 202–
206. doi: 10.1097/01.ogx.0000256787.04807.da. 
Porrello, E. R., Widdop, R. E. and Delbridge, L. M. (2008) ‘EARLY ORIGINS OF CARDIAC HYPERTROPHY: 
DOES CARDIOMYOCYTE ATTRITION PROGRAMME FOR PATHOLOGICAL “CATCH-UP” GROWTH OF 
THE HEART?’, Clinical and Experimental Pharmacology and Physiology, 35(11), pp. 1358–1364. doi: 
10.1111/j.1440-1681.2008.05036.x. 
Porto, A. M. F. et al. (2011) ‘Effectiveness of antenatal corticosteroids in reducing respiratory 
disorders in late preterm infants: randomised clinical trial’, BMJ, 342(apr12 1), pp. d1696–d1696. 
doi: 10.1136/bmj.d1696. 
‘Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia’ (2010) Pediatrics, 
126(4), pp. 800 LP – 808. Available at: 
http://pediatrics.aappublications.org/content/126/4/800.abstract. 
Pulgar, V. M. and Figueroa, J. P. (2006) ‘Antenatal betamethasone administration has a dual effect 
on adult sheep vascular reactivity.’, Pediatric research, 60(6), pp. 705–10. doi: 
10.1203/01.pdr.0000246481.05231.17. 
Purisch, S. E. (2017) ‘Epidemiology of preterm birth’, Seminars in Perinatology. W.B. Saunders, 41(7), 
pp. 387–391. doi: 10.1053/J.SEMPERI.2017.07.009. 
RA, B. P. & B. (1995) ‘Scientific basis and therapeutic regimens for use of antenatal glucocorticoids.’, 
American Journal of Obstetrics and Gynecology, 173, pp. 254–262. 
Razaz N., Skoll A., Fahey J., Allen VM., J. K. (2015) ‘Trends in optimal, suboptimal, and questionably 
appropriate receipt of antenatal corticosteroid prophylaxis’, Obstetrics & Gynecology, 125(2), pp. 
288–96. 
Di Renzo, G. C., Tosto, V. and Giardina, I. (2018) ‘The biological basis and prevention of preterm 
birth’, Best Practice & Research Clinical Obstetrics & Gynaecology. Baillière Tindall, 52, pp. 13–22. 
doi: 10.1016/J.BPOBGYN.2018.01.022. 
Reusens, B. and Remacle, C. (2006) ‘Programming of the endocrine pancreas by the early nutritional 
environment.’, The international journal of biochemistry & cell biology, 38(5–6), pp. 913–22. doi: 
 258 
 
258 References 
10.1016/j.biocel.2005.10.012. 
Richardson, D. W. and Dodge, G. R. (2003) ‘Dose-dependent effects of corticosteroids on the 
expression of matrix-related genes in normal and cytokine-treated articular chondrocytes.’, 
Inflammation research : official journal of the European Histamine Research Society ... [et al.], 52(1), 
pp. 39–49. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12608648 (Accessed: 15 August 
2019). 
Roberts D., Brown J., Medley D., D. S. (2017) ‘Antenatal corticosteroids for accelerating fetal lung 
maturation for women at risk of preterm birth’, Cochrane Database of Systematic Reviews, 
CD004454. 
Roberts, D. and Dalziel, S. (2006) ‘Antenatal corticosteroids for accelerating fetal lung maturation for 
women at risk of preterm birth.’, The Cochrane database of systematic reviews, (3), p. CD004454. 
doi: 10.1002/14651858.CD004454.pub2. 
Robillard, J. E. et al. (1992) ‘Mechanisms regulating renal sodium excretion during development.’, 
Pediatric nephrology (Berlin, Germany), 6(2), pp. 205–13. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1533309. 
Robillard, J. E. and Nakamura, K. T. (1988) ‘Neurohormonal regulation of renal function during 
development.’, The American journal of physiology, 254(6 Pt 2), pp. F771-9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3289401. 
Rog-Zielinska, E. A. et al. (2013) ‘Glucocorticoid receptor is required for foetal heart maturation’, 
Human Molecular Genetics, 22(16), pp. 3269–3282. doi: 10.1093/hmg/ddt182. 
Rog-Zielinska, E. A. et al. (2014a) ‘Glucocorticoids and foetal heart maturation; implications for 
prematurity and foetal programming.’, Journal of molecular endocrinology, 52(2), pp. R125-35. doi: 
10.1530/JME-13-0204. 
Rog-Zielinska, E. A. et al. (2014b) ‘Glucocorticoids and foetal heart maturation; implications for 
prematurity and foetal programming’, Journal of Molecular Endocrinology, 52(2), pp. R125–R135. 
doi: 10.1530/JME-13-0204. 
Romejko-Wolniewicz, E., Teliga-Czajkowska, J. and Czajkowski, K. (2014) ‘Antenatal steroids: can we 
optimize the dose?’, Current opinion in obstetrics & gynecology, 26(2), pp. 77–82. doi: 
10.1097/GCO.0000000000000047. 
Romero, R. et al. (2012) ‘Vaginal progesterone in women with an asymptomatic sonographic short 
cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review 
and metaanalysis of individual patient data’, American Journal of Obstetrics and Gynecology. Mosby, 
206(2), pp. 124.e1-124.e19. doi: 10.1016/J.AJOG.2011.12.003. 
Rotmensch, S. et al. (1999) ‘The effect of betamethasone and dexamethasone on fetal heart rate 
patterns and biophysical activities. A prospective randomized trial.’, Acta obstetricia et gynecologica 
Scandinavica, 78(6), pp. 493–500. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10376858. 
Rouhert, P. et al. (1993) ‘Endothelin Receptor Regulation by Endothelin Synthesis in Vascular Smooth 
Muscle Cells: Effects of Dexamethasone and Phosphoramidon’, Journal of Vascular Research, 30(3), 
pp. 139–144. doi: 10.1159/000158988. 
Royal College of Paediatrics and Child Health (2015) ‘National Neonatal Audit Programme, 2015 
Annual Report on 2014 Data’, National Neonatal Audit Programme. 
Rumbold, A. et al. (2015) ‘Vitamin C supplementation in pregnancy.’, The Cochrane database of 
systematic reviews, (9), p. CD004072. doi: 10.1002/14651858.CD004072.pub3. 
 259 
 
259 References 
Ryan, R. M. (2006) ‘A new look at bronchopulmonary dysplasia classification’, Journal of 
Perinatology, 26(4), pp. 207–209. doi: 10.1038/sj.jp.7211449. 
Saccone, G. and Berghella, V. (2016) ‘Antenatal corticosteroids for maturity of term or near term 
fetuses: systematic review and meta-analysis of randomized controlled trials’, BMJ, 355, p. i5044. 
doi: 10.1136/bmj.i5044. 
Sadowska, G. B. and Stonestreet, B. S. (2014) ‘Maternal treatment with glucocorticoids modulates 
gap junction protein expression in the ovine fetal brain.’, Neuroscience, 275, pp. 248–58. doi: 
10.1016/j.neuroscience.2014.05.066. 
Safaeian, L. and Zabolian, H. (2014) ‘Antioxidant Effects of Bovine Lactoferrin on Dexamethasone-
Induced Hypertension in Rat’, ISRN Pharmacology, 2014, pp. 1–6. doi: 10.1155/2014/943523. 
Saigal, S. et al. (2000) ‘School Difficulties at Adolescence in a Regional Cohort of Children Who Were 
Extremely Low Birth Weight’, PEDIATRICS, 105(2), pp. 325–331. doi: 10.1542/peds.105.2.325. 
Salem, I. I. and Najib, N. M. (2012) ‘Pharmacokinetics of Betamethasone After Single-Dose 
Intramuscular Administration of Betamethasone Phosphate and Betamethasone Acetate to Healthy 
Subjects’, Clinical Therapeutics. Elsevier, 34(1), pp. 214–220. doi: 10.1016/J.CLINTHERA.2011.11.022. 
Sales, V. M., Ferguson-Smith, A. C. and Patti, M.-E. (2017) ‘Epigenetic Mechanisms of Transmission of 
Metabolic Disease across Generations’, Cell Metabolism, 25(3), pp. 559–571. doi: 
10.1016/j.cmet.2017.02.016. 
Salomon, L. J., Bernard, J. P. and Ville, Y. (2007) ‘Estimation of fetal weight: reference range at 20–36 
weeks’ gestation and comparison with actual birth-weight reference range’, Ultrasound in Obstetrics 
and Gynecology. John Wiley & Sons, Ltd, 29(5), pp. 550–555. doi: 10.1002/uog.4019. 
Samtani, M. N. et al. (2005) ‘BETAMETHASONE PHARMACOKINETICS AFTER TWO PRODRUG 
FORMULATIONS IN SHEEP: IMPLICATIONS FOR ANTENATAL CORTICOSTEROID USE’, Drug 
Metabolism and Disposition, 33(8), pp. 1124–1130. doi: 10.1124/dmd.105.004309. 
Sapolsky, R. M., Romero, L. M. and Munck, A. U. (2000) ‘How Do Glucocorticoids Influence Stress 
Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions 1’, Endocrine 
Reviews. Oxford University Press, 21(1), pp. 55–89. doi: 10.1210/edrv.21.1.0389. 
Sato, A. et al. (1992) ‘Dexamethasone potentiates production of inositol trisphosphate evoked by 
endothelin-1 in vascular smooth muscle cells.’, Journal of cardiovascular pharmacology, 20(2), pp. 
290–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1381021 (Accessed: 12 July 2017). 
Schachter, M. (2005) ‘Chemical, pharmacokinetic and pharmacodynamic properties of statins: an 
update’, Fundamental and Clinical Pharmacology, 19(1), pp. 117–125. doi: 10.1111/j.1472-
8206.2004.00299.x. 
Schena, F. et al. (2015) ‘Association between Hemodynamically Significant Patent Ductus Arteriosus 
and Bronchopulmonary Dysplasia’, The Journal of Pediatrics, 166(6), pp. 1488–1492. doi: 
10.1016/j.jpeds.2015.03.012. 
Scheschowitsch, K., Leite, J. A. and Assreuy, J. (2017) ‘New Insights in Glucocorticoid Receptor 
Signaling-More Than Just a Ligand-Binding Receptor.’, Frontiers in endocrinology. Frontiers Media 
SA, 8, p. 16. doi: 10.3389/fendo.2017.00016. 
Schittny, J. C. (2017) ‘Development of the lung’, Cell and Tissue Research, 367(3), pp. 427–444. doi: 
10.1007/s00441-016-2545-0. 
Schmidt, A. F. et al. (2016) ‘Antenatal Dexamethasone vs Betamethasone dosing for lung maturation 
in fetal sheep’, Pediatric Research. doi: 10.1038/pr.2016.249. 
 260 
 
260 References 
Schmidt, A. F. et al. (2018) ‘Low-dose betamethasone-acetate for fetal lung maturation in preterm 
sheep’, American Journal of Obstetrics and Gynecology, 218(1), pp. 132.e1-132.e9. doi: 
10.1016/j.ajog.2017.11.560. 
Schmidt, A. F. et al. (2019) ‘Dosing and formulation of antenatal corticosteroids for fetal lung 
maturation and gene expression in rhesus macaques’, Scientific Reports, 9(1), p. 9039. doi: 
10.1038/s41598-019-45171-6. 
Schwab, M. et al. (2006) ‘Kinetics of betamethasone and fetal cardiovascular adverse effects in 
pregnant sheep after different doses.’, Obstetrics and gynecology, 108(3 Pt 1), pp. 617–25. doi: 
10.1097/01.AOG.0000232815.80648.01. 
SCOTT, T. R. et al. (1981) ‘Circulating Levels of Corticosterone in the Serum of Developing Chick 
Embryos and Newly Hatched Chicks’, Poultry Science. Narnia, 60(6), pp. 1314–1320. doi: 
10.3382/ps.0601314. 
Scull, C. M. and Tabas, I. (2011) ‘Mechanisms of ER Stress-Induced Apoptosis in Atherosclerosis’, 
Arteriosclerosis, Thrombosis, and Vascular Biology, 31(12), pp. 2792–2797. doi: 
10.1161/ATVBAHA.111.224881. 
Sedmera, D. and Thompson, R. P. (2011) ‘Myocyte proliferation in the developing heart.’, 
Developmental dynamics : an official publication of the American Association of Anatomists. NIH 
Public Access, 240(6), pp. 1322–34. doi: 10.1002/dvdy.22650. 
Segar, J. L. et al. (1992) ‘Ontogeny of renal response to specific dopamine DA1-receptor stimulation 
in sheep.’, The American journal of physiology, 263(4 Pt 2), pp. R868-73. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1357989. 
Selli, C. and Tosun, M. (2016) ‘Effects of cyclopiazonic acid and dexamethasone on serotonin-
induced calcium responses in vascular smooth muscle cells’, Journal of Physiology and Biochemistry, 
72(2), pp. 245–253. doi: 10.1007/s13105-016-0474-8. 
Severinova, E. et al. (2019) ‘Glucocorticoid Receptor‐Binding and Transcriptome Signature in 
Cardiomyocytes’, Journal of the American Heart Association. Wiley-Blackwell, 8(6), p. e011484. doi: 
10.1161/JAHA.118.011484. 
Shaltout, H. A. et al. (2011) ‘Exaggerated sympathetic mediated responses to behavioral or 
pharmacological challenges following antenatal betamethasone exposure.’, American journal of 
physiology. Endocrinology and metabolism, 300(6), pp. E979-85. doi: 10.1152/ajpendo.00636.2010. 
Shaltout, H. A. et al. (2012) ‘Angiotensin-(1-7) deficiency and baroreflex impairment precede the 
antenatal Betamethasone exposure-induced elevation in blood pressure.’, Hypertension (Dallas, 
Tex. : 1979), 59(2), pp. 453–8. doi: 10.1161/HYPERTENSIONAHA.111.185876. 
Shanmugam, S. and Sandberg, K. (1996) ‘Ontogeny of angiotensin II receptors.’, Cell biology 
international, 20(3), pp. 169–76. doi: 10.1006/cbir.1996.0021. 
Sharma, R. et al. (2007) ‘Neonatal gut barrier and multiple organ failure: role of endotoxin and 
proinflammatory cytokines in sepsis and necrotizing enterocolitis’, Journal of Pediatric Surgery, 
42(3), pp. 454–461. doi: 10.1016/j.jpedsurg.2006.10.038. 
Shi, L. et al. (2014) ‘Chicken Embryos as a Potential New Model for Early Onset Type I Diabetes’, 
Journal of Diabetes Research, 2014, pp. 1–10. doi: 10.1155/2014/354094. 
Shinozuka, N., Yen, A. and Nathanielsz, P. W. (2000) ‘Increased myometrial contracture frequency at 
96-140 days accelerates fetal cardiovascular maturation.’, American journal of physiology. Heart and 
circulatory physiology, 278(1), pp. H41-9. Available at: 
 261 
 
261 References 
http://www.ncbi.nlm.nih.gov/pubmed/10644582. 
Siedner, S. et al. (2003) ‘Developmental changes in contractility and sarcomeric proteins from the 
early embryonic to the adult stage in the mouse heart’, The Journal of Physiology. John Wiley & 
Sons, Ltd (10.1111), 548(2), pp. 493–505. doi: 10.1111/j.1469-7793.2003.00493.x. 
Siegel, H. S. and Gould, N. R. (1976) ‘Chick embryonic plasma proteins and binding capacity for 
corticosterone’, Developmental Biology. Academic Press, 50(2), pp. 510–516. doi: 10.1016/0012-
1606(76)90169-X. 
Silver M, F. AL (1988) The Endocrine Control of the Fetus. Berlin, Heidelberg: Springer. 
Skeffington, K. L. et al. (2018) ‘Isolating the direct effects of adverse developmental conditions on in 
vivo cardiovascular function at adulthood: the avian model’, Journal of Developmental Origins of 
Health and Disease, 9(4), pp. 460–466. doi: 10.1017/S2040174418000247. 
Smith, F. G. and Lumbers, E. R. (1989) ‘Comparison of renal function in term fetal sheep and 
newborn lambs.’, Biology of the neonate, 55(4–5), pp. 309–16. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/2497803. 
Sotiriadis, A. et al. (2009) ‘Corticosteroids for preventing neonatal respiratory morbidity after 
elective caesarean section at term.’, The Cochrane database of systematic reviews, (4), p. CD006614. 
doi: 10.1002/14651858.CD006614.pub2. 
Stahn, C. and Buttgereit, F. (2008) ‘Genomic and nongenomic effects of glucocorticoids’, Nature 
Clinical Practice Rheumatology. Nature Publishing Group, 4(10), pp. 525–533. doi: 
10.1038/ncprheum0898. 
Stevenson, D. K. et al. (2000) ‘Sex differences in outcomes of very low birthweight infants: the 
newborn male disadvantage.’, Archives of disease in childhood. Fetal and neonatal edition. BMJ 
Publishing Group, 83(3), pp. F182-5. doi: 10.1136/fn.83.3.f182. 
Stieb, D. M. et al. (2012) ‘Ambient air pollution, birth weight and preterm birth: A systematic review 
and meta-analysis’, Environmental Research, 117, pp. 100–111. doi: 10.1016/j.envres.2012.05.007. 
Stojanovska, V. et al. (2018) ‘The Effect of Antenatal Betamethasone on White Matter Inflammation 
and Injury in Fetal Sheep and Ventilated Preterm Lambs’, Developmental Neuroscience. Karger 
Publishers, 40(5–6), pp. 497–507. doi: 10.1159/000496466. 
Stutchfield, P. et al. (2005) ‘Antenatal betamethasone and incidence of neonatal respiratory distress 
after elective caesarean section: pragmatic randomised trial’, BMJ, 331(7518), p. 662. doi: 
10.1136/bmj.38547.416493.06. 
Su, B.-H. et al. (2015) ‘Neonatal Outcomes of Extremely Preterm Infants from Taiwan: Comparison 
with Canada, Japan, and the USA’, Pediatrics & Neonatology. Elsevier, 56(1), pp. 46–52. doi: 
10.1016/J.PEDNEO.2014.05.002. 
Sugden, M. C. et al. (2001) ‘Maternal glucocorticoid treatment modulates placental leptin and leptin 
receptor expression and materno-fetal leptin physiology during late pregnancy, and elicits 
hypertension associated with hyperleptinaemia in the early-growth-retarded adult offspring.’, 
European journal of endocrinology, 145(4), pp. 529–39. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11581014. 
Sullivan, L. C. and Orgeig, S. (2001) ‘Dexamethasone and epinephrine stimulate surfactant secretion 
in type II cells of embryonic chickens.’, American journal of physiology. Regulatory, integrative and 
comparative physiology, 281(3), pp. R770-7. doi: 10.1152/ajpregu.2001.281.3.R770. 
Sunny, N. E. and Bequette, B. J. (no date) ‘Gluconeogenesis differs in developing chick embryos 
 262 
 
262 References 
derived from small compared with typical size broiler breeder eggs’. doi: 10.2527/jas.2009-2479. 
Tai, I.-H. et al. (2016) ‘Maternal N-acetylcysteine therapy regulates hydrogen sulfide-generating 
pathway and prevents programmed hypertension in male offspring exposed to prenatal 
dexamethasone and postnatal high-fat diet’, Nitric Oxide, 53, pp. 6–12. doi: 
10.1016/j.niox.2015.12.006. 
Tain, Y. L. et al. (2014) ‘Maternal citrulline supplementation prevents prenatal dexamethasone-
induced programmed hypertension’, Free Radical Research, 48(5), pp. 580–586. doi: 
10.3109/10715762.2014.895341. 
Takahashi, T. et al. (2002) ‘Corticosterone acutely prolonged N-methyl-d-aspartate receptor-
mediated Ca2+ elevation in cultured rat hippocampal neurons.’, Journal of neurochemistry, 83(6), 
pp. 1441–51. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12472898 (Accessed: 13 June 
2019). 
Takeshita, Y. et al. (2015) ‘Blockade of glucocorticoid receptors with RU486 attenuates cardiac 
damage and adipose tissue inflammation in a rat model of metabolic syndrome.’, Hypertension 
research : official journal of the Japanese Society of Hypertension, 38(11), pp. 741–50. doi: 
10.1038/hr.2015.77. 
Tanabe, Y., Saito, N. and Nakamura, T. (1986) ‘Ontogenetic steroidogenesis by testes, ovary, and 
adrenals of embryonic and postembryonic chickens (Gallus domesticus)’, General and Comparative 
Endocrinology. Academic Press, 63(3), pp. 456–463. doi: 10.1016/0016-6480(86)90146-2. 
Tanai, E. and Frantz, S. (2015) ‘Pathophysiology of Heart Failure’, in Comprehensive Physiology. 
Hoboken, NJ, USA: John Wiley & Sons, Inc., pp. 187–214. doi: 10.1002/cphy.c140055. 
Tang, V. M. et al. (2013) ‘Glucocorticoids increase protein carbonylation and mitochondrial 
dysfunction.’, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones 
et metabolisme, 45(10), pp. 709–15. doi: 10.1055/s-0033-1345119. 
Tazawa, H. (1980) ‘Adverse effect of failure to turn the avian egg on the embryo oxygen exchange.’, 
Respiration physiology, 41(2), pp. 137–42. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/6776598 (Accessed: 31 May 2019). 
Tazawa, H. (2004) ‘Embryonic cardiovascular variables during incubation’, World’s Poultry Science 
Journal. Cambridge University Press on behalf of World&#x0027;s Poultry Science Association, 60(4), 
pp. 478–488. doi: 10.1079/WPS200431. 
The Global Action Report on Preterm Birth Born Too Soon (no date). Available at: 
https://www.who.int/pmnch/media/news/2012/201204_borntoosoon-report.pdf (Accessed: 9 July 
2019). 
Thornburg, K. et al. (2011a) ‘Regulation of the cardiomyocyte population in the developing heart.’, 
Progress in biophysics and molecular biology, 106(1), pp. 289–99. doi: 
10.1016/j.pbiomolbio.2010.11.010. 
Thornburg, K. et al. (2011b) ‘Regulation of the cardiomyocyte population in the developing heart’, 
Progress in Biophysics and Molecular Biology, 106(1), pp. 289–299. doi: 
10.1016/j.pbiomolbio.2010.11.010. 
Tijsseling, D. et al. (2013) ‘Statins prevent adverse effects of postnatal glucocorticoid therapy on the 
developing brain in rats.’, Pediatric research, 74(6), pp. 639–45. doi: 10.1038/pr.2013.152. 
Tönnies, E. and Trushina, E. (2017) ‘Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease’, 
Journal of Alzheimer’s Disease, 57(4), pp. 1105–1121. doi: 10.3233/JAD-161088. 
 263 
 
263 References 
Travers, C. P. et al. (2017) ‘Exposure to any antenatal corticosteroids and outcomes in preterm 
infants by gestational age: prospective cohort study.’, BMJ (Clinical research ed.). British Medical 
Journal Publishing Group, 356, p. j1039. doi: 10.1136/BMJ.J1039. 
Ullian, M. (1999) ‘The role of corticosteroids in the regulation of vascular tone’, Cardiovascular 
Research. Narnia, 41(1), pp. 55–64. doi: 10.1016/S0008-6363(98)00230-2. 
Uno, H. et al. (1990) ‘Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus 
macaques. I. Hippocampus.’, Brain research. Developmental brain research, 53(2), pp. 157–67. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/2357788. 
Verhaeghe, J., van Bree, R. and Van Herck, E. (2009) ‘Oxidative stress after antenatal 
betamethasone: acute downregulation of glutathione peroxidase-3.’, Early human development, 
85(12), pp. 767–71. doi: 10.1016/j.earlhumdev.2009.10.005. 
Vinukonda, G. et al. (2010) ‘Effect of Prenatal Glucocorticoids on Cerebral Vasculature of the 
Developing Brain’, Stroke, 41(8), pp. 1766–1773. doi: 10.1161/STROKEAHA.110.588400. 
Vogel, J. P. et al. (2015) ‘Use of Antenatal Corticosteroids and Tocolytic Drugs in Preterm Births in 29 
Countries’, Obstetrical & Gynecological Survey, 70(2), pp. 79–81. doi: 
10.1097/01.ogx.0000461897.24476.fd. 
Volk, K. A. et al. (2010) ‘Coronary endothelial function and vascular smooth muscle proliferation are 
programmed by early-gestation dexamethasone exposure in sheep’, AJP: Regulatory, Integrative and 
Comparative Physiology, 298(6), pp. R1607–R1614. doi: 10.1152/ajpregu.00824.2009. 
van der Voorn, B. et al. (2015) ‘Antenatal glucocorticoid treatment and polymorphisms of the 
glucocorticoid and mineralocorticoid receptors are associated with IQ and behavior in young adults 
born very preterm.’, The Journal of clinical endocrinology and metabolism, 100(2), pp. 500–7. doi: 
10.1210/jc.2014-2843. 
Wadhwa, P. D. et al. (2001) ‘Stress and Preterm Birth: Neuroendocrine, Immune/Inflammatory, and 
Vascular Mechanisms’, Maternal and Child Health Journal. Kluwer Academic Publishers-Plenum 
Publishers, 5(2), pp. 119–125. doi: 10.1023/A:1011353216619. 
Wallwork, C. J., Parks, D. A. and Schmid-Schönbein, G. W. (2003) ‘Xanthine oxidase activity in the 
dexamethasone-induced hypertensive rat.’, Microvascular research, 66(1), pp. 30–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12826072. 
Walsh, M. C. et al. (2006) ‘Changes in the use of postnatal steroids for bronchopulmonary dysplasia 
in 3 large neonatal networks.’, Pediatrics, 118(5), pp. e1328-35. doi: 10.1542/peds.2006-0359. 
Walther, F. J. et al. (1991) ‘Corticosteroids, Thyrotropin-Releasing Hormone, and Antioxidant 
Enzymes in Preterm Lamb Lungs’, Pediatric Research, 30(6), pp. 518–521. doi: 10.1203/00006450-
199112000-00004. 
Walther, F. J., Jobe, A. H. and Ikegami, M. (1998) ‘Repetitive prenatal glucocorticoid therapy reduces 
oxidative stress in the lungs of preterm lambs.’, Journal of applied physiology (Bethesda, Md. : 1985), 
85(1), pp. 273–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9655786. 
Wan, Z. et al. (2016) ‘Sexing chick mRNA: A protocol based on quantitative real-time polymerase 
chain reaction’, Poultry Science, 96(3), p. pew338. doi: 10.3382/ps/pew338. 
WANG, L. et al. (2015) ‘Glucocorticoids induce autophagy in rat bone marrow mesenchymal stem 
cells’, Molecular Medicine Reports, 11(4), pp. 2711–2716. doi: 10.3892/mmr.2014.3099. 
Watts, S. W. (2016) ‘Oh, the places you’ll go! My many colored serotonin (apologies to Dr. Seuss).’, 
American journal of physiology. Heart and circulatory physiology. American Physiological Society, 
 264 
 
264 References 
311(5), pp. H1225–H1233. doi: 10.1152/ajpheart.00538.2016. 
WATTS, S. W. (2005) ‘5-HT in systemic hypertension: foe, friend or fantasy?’, Clinical Science, 108(5), 
pp. 399–412. doi: 10.1042/CS20040364. 
Watts, S. W. and Thompson, J. M. (2004) ‘Characterization of the Contractile 5-Hydroxytryptamine 
Receptor in the Renal Artery of the Normotensive Rat’, Journal of Pharmacology and Experimental 
Therapeutics, 309(1), pp. 165–172. doi: 10.1124/jpet.103.062562. 
Webster, A. C. et al. (2016) ‘Chronic Kidney Disease.’, Lancet (London, England). doi: 10.1016/S0140-
6736(16)32064-5. 
Weibel, E. R. (2017) ‘Lung morphometry: the link between structure and function’, Cell and Tissue 
Research. Springer Berlin Heidelberg, 367(3), pp. 413–426. doi: 10.1007/s00441-016-2541-4. 
WHO recommendations on interventions to improve preterm birth outcomes (no date). Available at: 
www.who.int/reproductivehealth (Accessed: 28 June 2019). 
Willet, K. E. et al. (1999) ‘Lung Morphometry and Collagen and Elastin Content: Changes During 
Normal Development and After Prenatal Hormone Exposure in Sheep’, Pediatric Research, 45(5 Pt 
1), pp. 615–625. doi: 10.1203/00006450-199905010-00002. 
Wilson-Costello, D. et al. (2005) ‘Improved Survival Rates With Increased Neurodevelopmental 
Disability for Extremely Low Birth Weight Infants in the 1990s’, PEDIATRICS, 115(4), pp. 997–1003. 
doi: 10.1542/peds.2004-0221. 
Wlodek, M. E., Harding, R. and Thorburn, G. D. (no date) Fetal-maternal fluid and electrolyte 
relations during chronic fetal urine loss in sheep. Available at: www.physiology.org/journal/ajprenal 
(Accessed: 26 June 2019). 
ter Wolbeek, M. et al. (2013) ‘Early life intervention with glucocorticoids has negative effects on 
motor development and neuropsychological function in 14-17 year-old adolescents.’, 
Psychoneuroendocrinology, 38(7), pp. 975–86. doi: 10.1016/j.psyneuen.2012.10.001. 
Ter Wolbeek, M. et al. (2015) ‘Neonatal glucocorticoid treatment: long-term effects on the 
hypothalamus-pituitary-adrenal axis, immune system, and problem behavior in 14-17 year old 
adolescents.’, Brain, behavior, and immunity, 45, pp. 128–38. doi: 10.1016/j.bbi.2014.10.017. 
Wu, T.-H. et al. (2014) ‘Melatonin prevents neonatal dexamethasone induced programmed 
hypertension: histone deacetylase inhibition.’, The Journal of steroid biochemistry and molecular 
biology, 144 Pt B, pp. 253–9. doi: 10.1016/j.jsbmb.2014.07.008. 
Wyrwoll, C. S. et al. (2016) ‘Pravastatin ameliorates placental vascular defects, fetal growth, and 
cardiac function in a model of glucocorticoid excess’, Proceedings of the National Academy of 
Sciences, 113(22), pp. 6265–6270. doi: 10.1073/pnas.1520356113. 
Wyrwoll, C. S., Holmes, M. C. and Seckl, J. R. (2011) ‘11β-Hydroxysteroid dehydrogenases and the 
brain: From zero to hero, a decade of progress’, Frontiers in Neuroendocrinology, 32(3), pp. 265–286. 
doi: 10.1016/j.yfrne.2010.12.001. 
Yang, K. et al. (1991) ‘Pro-opiomelanocortin messenger RNA levels increase in the fetal sheep 
pituitary during late gestation.’, The Journal of endocrinology, 131(3), pp. 483–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1783891. 
Yao, Y. et al. (2014) ‘Ancestral exposure to stress epigenetically programs preterm birth risk and 
adverse maternal and newborn outcomes’, BMC Medicine, 12(1), p. 121. doi: 10.1186/s12916-014-
0121-6. 
 265 
 
265 References 
Yazıcı, T. et al. (2018) ‘Zoledronic Acid, Bevacizumab and Dexamethasone-Induced Apoptosis, 
Mitochondrial Oxidative Stress, and Calcium Signaling Are Decreased in Human Osteoblast-Like Cell 
Line by Selenium Treatment’, Biological Trace Element Research, 184(2), pp. 358–368. doi: 
10.1007/s12011-017-1187-8. 
Yokoyama, K. et al. (2008) ‘Dose-dependent effects of a glucocorticoid on prolactin production.’, 
Endocrine journal, 55(2), pp. 405–14. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18379123 
(Accessed: 15 August 2019). 
Yu, E. P. K. and Bennett, M. R. (2014) ‘Mitochondrial DNA damage and atherosclerosis.’, Trends in 
endocrinology and metabolism: TEM, 25(9), pp. 481–7. doi: 10.1016/j.tem.2014.06.008. 
Yunis, K. A. et al. (1999) ‘Transient hypertrophic cardiomyopathy in the newborn following multiple 
doses of antenatal corticosteroids.’, American journal of perinatology, 16(1), pp. 17–21. doi: 
10.1055/s-2007-993830. 
Zeitlin, J. et al. (2013) ‘Preterm birth time trends in Europe: a study of 19 countries.’, BJOG : an 
international journal of obstetrics and gynaecology. Wiley-Blackwell, 120(11), pp. 1356–65. doi: 
10.1111/1471-0528.12281. 
Zhang, J. et al. (2010) ‘Differential effects of clinical doses of antenatal betamethasone on nephron 
endowment and glomerular filtration rate in adult sheep.’, Reproductive sciences (Thousand Oaks, 
Calif.), 17(2), pp. 186–95. doi: 10.1177/1933719109351098. 
Zhang, Y. et al. (2004) ‘The antioxidant tempol prevents and partially reverses dexamethasone-
induced hypertension in the rat.’, American journal of hypertension, 17(3), pp. 260–5. doi: 
10.1016/j.amjhyper.2003.11.004. 
Zhang, Y. et al. (2005) ‘Apocynin but not allopurinol prevents and reverses adrenocorticotropic 
hormone-induced hypertension in the rat.’, American journal of hypertension, 18(7), pp. 910–6. doi: 
10.1016/j.amjhyper.2005.02.017. 
Zhao, Y., Vanhoutte, P. M. and Leung, S. W. S. (2015) ‘Vascular nitric oxide: Beyond eNOS’, Journal of 
Pharmacological Sciences. Elsevier, 129(2), pp. 83–94. doi: 10.1016/J.JPHS.2015.09.002. 
 
